



- (51) **International Patent Classification:**
C12N 5/0735 (2010.01) A61K 35/407 (2015.01)
A61K 35/545 (2015.01)
- (21) **International Application Number:**
PCT/US2015/062674
- (22) **International Filing Date:**
25 November 2015 (25.11.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/085,185 26 November 2014 (26.11.2014) US
- (71) **Applicant: ACCELERATED BIOSCIENCES CORP.**
[US/US]; 1769 1st Street, Manhattan Beach, California
90266 (US).
- (72) **Inventors: LEE, Jau-Nan;** No. 1 Nan Shin Chen Street,
Kaohsiung, 830 (TW). **LEE, Tony Tung-Yin;** 7603 Glaci-
er Way, Yakima, Washington 98908 (US). **LEE, Yuta;**
No. 1 Nan Shin Chen Street, Kaohsiung, 830 (TW). **TSAI,
Eing-Mei;** 302 Chengping Street, Kaohsiung, 830 (TW).
- (74) **Agents: LIU, Shan et al.;** Wilson Sonsini Goodrich &
Rosati, 650 Page Mill Road, Palo Alto, California 94304
(US).


- (81) **Designated States** (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

- (54) **Title:** INDUCED HEPATOCYTES AND USES THEREOF

FIG. 12A



(57) **Abstract:** Disclosed herein are induced hepatocytes from a trophoblast stem cell, methods for inducing the cells, and compositions thereof. Also disclosed herein are methods of treating a disease or disorder (e.g., liver-associated) by utilizing an induced hepatocyte disclosed herein.

INDUCED HEPATOCYTES AND USES THEREOF**CROSS-REFERENCE**

[0001] This application claims the benefit of U.S. Provisional Application No. 62/085,185, filed on November 26, 2014, which is incorporated herein by reference in its entirety.

INCORPORATION BY REFERENCE

[0002] All publications, patents, and patent applications disclosed herein are incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. In the event of a conflict between a term disclosed herein and a term in an incorporated reference, the term herein controls.

BRIEF SUMMARY

[0003] In one of many aspects, disclosed herein is a method of inducing a trophoblast stem (TS) cell to differentiate into an induced hepatocyte *in vitro*, comprising: contacting the trophoblast stem cell with a conditioned medium (e.g., for sufficient time) to induce differentiation of the trophoblast stem cell into an induced hepatocyte, wherein the condition medium comprises a fibroblast growth factor (FGF), a steroid, and a cytokine. In some embodiments, disclosed herein is a method of inducing a trophoblast stem (TS) cell to differentiate into an induced hepatocyte *in vitro*, which comprises (a) contacting the trophoblast stem cell in a conditioned medium comprising a fibroblast growth factor (FGF), a steroid, and a cytokine; and (b) incubating the cell for sufficient time to induce differentiation of the trophoblast stem cell into an induced hepatocyte. In some embodiments, the method further comprises contacting the trophoblast stem cell with the FGF prior to addition of the steroid and the cytokine to the conditioned medium. In some embodiments, the trophoblast stem cell is contacted with FGF for at least 2 hours, at least 4 hours, at least 6 hours, 8 hours, at least 12 hours, at least 16 hours, at least 20 hours, or at least 24 hours prior to addition of the steroid and the cytokine to the conditioned medium. In some embodiments, the method further comprises incubating the trophoblast stem cell for at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, or at least 7 days. In some embodiments, the steroid and the cytokine are added simultaneously or sequentially into the conditioned medium.

[0004] In some embodiments, an induced hepatocyte herein is a hepatic progenitor cell. In some embodiments, FGF upregulates miRNA-124a in the TS cell. In some embodiments, elevated level of miRNA-124a initiates definitive endoderm (DE) specification in the TS cell. In some

embodiments, the DE specification is associated with biomarkers comprising forkhead box protein A2 (FOXA2), SRY-box 17 (SOX17), Goosecoid (GSC), or Homeodomain protein MIXL1. In some embodiments, the DE specification is associated with elevated expression levels of SOX17, FOXA2, and GSC. In some embodiments, the elevated expression levels are increased protein expression levels. In some embodiments, the DE specification is associated with a decreased expression level of MIXL1. In some embodiments, the decreased expression level is a decreased protein expression levels. In some embodiments, the elevated protein expression levels of SOX17, FOXA2, and GSC and the decreased protein expression level of MIXL1 are relative to the protein expression levels of SOX17, FOXA2, GSC, and MIXL1 in an equivalent TS cell that has not undergone DE specification. In some embodiments, the DE specification is further associated with elevated expression levels of SOX2, NANOG, and OCT4. In some embodiments, elevated expression levels of SOX2, NANOG, and OCT4 are increased level of protein expressions. In some embodiments, elevated expression levels of SOX2, NANOG, and OCT4 are increased level of gene expressions. In some embodiments, the elevated expression levels of SOX2, NANOG, and OCT4 are relative to the expression levels of SOX2, NANOG, and OCT4 in an equivalent TS cell that has not undergone DE specification. In some embodiments, differentiation induced by a method herein comprises one or more of four stages: primitive streak to definitive endoderm (DE) stage, hepatic specified endoderm stage, hepatoblastic stage, and the fetal and adult hepatocyte cell stage. In some embodiments, one or more biomarkers selected from the group consisting of CXCR4, FOXA2, SOX17, HHEX, TTR, ALB, TAT, CYP7A1, BSEP, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , HNF4 α , and any combination thereof express in one or more of the four stages. In some embodiments, one or more biomarkers selected from the group consisting of CXCR4, FOXA2, SOX17, HHEX, and any combination thereof, express at the primitive streak to DE stage. In some embodiments, an expression level of CXCR4, FOXA2, SOX17, and/or HHEX increases at the primitive streak to DE stage, relative to that before the primitive streak to DE stage. In some embodiments, the increased expression level is an increased level of gene expression. In some embodiments, the expression level of CXCR4, FOXA2, SOX17 and/or HHEX increases by about 1 fold and about 10,000 fold higher than that before the primitive streak to DE stage. In some embodiments, the expression level of CXCR4, FOXA2, SOX17 and/or HHEX increases by about 10 fold and about 1000 fold higher than that before the primitive streak to DE stage. In some embodiments, one or more biomarkers selected from the group consisting of SOX17, TTR, ALB, TAT, SERPINA1, CYP7A1, and any combination thereof express in the hepatic specified endoderm stage. In some embodiments, an expression level of SOX17, TTR, ALB, TAT, SERPINA1,

and/or CYP7A1 increases at the hepatic specified endoderm stage, relative to that before the hepatic specified endoderm stage. In some embodiments, the increased expression level is an increased level of gene expression. In some embodiments, the expression level of SOX17, TTR, ALB, TAT, SERPINA1, and/or CYP7A1 increases by about 1 fold and about 1000 fold higher than that before the hepatic specified endoderm stage. In some embodiments, the expression level of SOX17, TTR, ALB, TAT, SERPINA1, and/or CYP7A1 increases by about 10 fold and about 100 fold higher than that before the hepatic specified endoderm stage. In some embodiments, one or more biomarkers selected from the group consisting of TTR, ALB, TAT, CYP7A1, SERPINA1, BSEP, and any combination thereof express at the hepatoblastic stage. In some embodiments, an expression level of TTR, ALB, TAT, CYP7A1, SERPINA1, and/or BSEP increases at the hepatoblastic stage, relative to that before the hepatoblastic stage. In some embodiments, the increased expression level is an increased level of gene expression. In some embodiments, the expression level of TTR, ALB, TAT, CYP7A1, SERPINA1, and/or BSEP increases by about 1 fold and about 1000 fold higher than that before the hepatoblastic stage. In some embodiments, the expression level of TTR, ALB, TAT, CYP7A1, SERPINA1, and/or BSEP increases by about 10 fold and about 100 fold higher than that before the hepatoblastic stage. In some embodiments, one or more biomarkers selected from the group consisting of HHEX, BSEP, TTR, ALB, TAT, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , HNF4 α , and any combination thereof express at the fetal and adult hepatocyte-like cell stage. In some embodiments, an expression level of HHEX, BSEP, TTR, ALB, TAT, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , and/or HNF4 α increases at the fetal and adult hepatocyte-like cell stage, relative to that before the fetal and adult hepatocyte-like cell stage. In some embodiments, the increased expression level is an increased level of gene expression. In some embodiments, the expression level of HHEX, BSEP, TTR, ALB, TAT, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , and/or HNF4 α increases by about 10 fold and about 1000 fold higher than that before the fetal and adult hepatocyte cell stage. In some embodiments, the expression level of HHEX, BSEP, TTR, ALB, TAT, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , and/or HNF4 α increases by at least 100 fold higher than that before the fetal and adult hepatocyte cell stage.

[0005] In some embodiments, a trophoblast stem cell herein is a human trophoblast stem cell. In some embodiments, the steroid is dexamethasone. In some embodiments, the cytokine is oncostatin M. In some embodiments, the oncostatin M is a human oncostatin M. In some embodiments, the human oncostatin M is a recombinant human oncostatin M. In some embodiments, the conditioned medium further comprises a bone morphogenetic protein (BMP). In some embodiments, the BMP is present in a concentration of about 1-100 ng/ml. In some

embodiments, the BMP is present in a concentration of about 1-50 ng/ml, e.g., about 20 ng/ml. In some embodiments, the BMP is BMP1, BMP2, BMP3, BMP4, BMP5, BMP6, BMP7, BMP8a, BMP8b, BMP10, or BMP15. In some embodiments, the BMP is BMP4. In some embodiments, the conditioned medium further comprises a hepatic growth factor (HGF). In some embodiments, the HGF is present in a concentration of about: 0.1-50 ng/ml or 0.1-25 ng/ml, e.g., about 5 ng/ml.

[0006] In some embodiments, a hepatocyte disclosed herein is immune privileged. In some embodiments, the induced hepatocyte expresses TGF β 1. In some embodiments, the induced hepatocyte expresses TGF β 1, fibronectin, and collagen IV in extracellular matrix (ECM). In some embodiments, the induced hepatocyte expresses HLA-G. In some embodiments, the induced hepatocyte expresses HLA-G and stem-121. In some embodiments, the induced hepatocytes recruit CD4⁺Foxp3⁺ Treg cells. In some embodiments, the induced hepatocytes form tissue of a 3-dimensional structure. In some embodiments, the induced hepatocytes cluster or aggregate. In some embodiments, the induced hepatocytes form a crescent cell mass. In some embodiments, the induced hepatocytes comprise a peripheral compartment and a central compartment. In some embodiments, the induced hepatocytes distribute irregularly along ECM beyond basement membrane in the peripheral compartment. In some embodiments, the induced hepatocytes distribute from basal towards central areas in the central compartment. In some embodiments, the induced hepatocyte expresses one or more markers selected from the group consisting of TGF β 1, HLA-G, stem 121, C-kit, CK19, CK18, ALB, α -AFP, betatrophin, ADH1, APOF, CPS1, GATA4, CYP1A1, CYP2B6, ASGR1, CXCR4, BSEP, MRP2, Cx32, and any combination thereof. In some embodiments, the induced hepatocyte expresses one or more markers selected from the group consisting of TGF β 1, HLA-G, stem 121, C-kit, betatrophin, ADH1, APOF, CPS1, CYP2B6, ASGR1, CXCR4, Cx32, and any combination thereof. In some embodiments, the induced hepatocyte expresses one or more markers selected from the group consisting of CPS1, CYP2B6, and a combination thereof.

[0007] In one aspect, provided herein is an induced hepatocyte produced by any method disclosed herein. In another aspect, provided herein is an isolated induced hepatocyte derived from a trophoblast stem cell. In another aspect, provided herein is an isolated hepatocyte induced from a trophoblast stem cell. In some embodiments, the hepatocyte expresses one or more biomarkers selected from the group consisting of transforming growth factor beta 1 (TGF β 1), human leukocyte antigen G (HLA-G), cluster of differentiation 4 (CD4), forkhead box P3 (Foxp3), human cytoplasmic marker stem 121 (stem 121), mast/stem cell growth factor receptor C-kit (C-kit), betatrophin, apolipoprotein F (APOF), alcohol dehydrogenase-1 (ADH1),

carbamoyl-phosphate synthase 1 (CPS1), GATA transcription factor 4 (GATA4), cytochrome P450 family 1 subfamily A polypeptide 1 (CYP1A1), cytochrome P450 2B6 (CYP2B6), asialoglycoprotein receptor 1 (ASGR1), C-X-C chemokine receptor type 4 (CXCR4), bile salt export pump (BSEP), multi-drug resistance protein-2 (MRP2), connexin 32 (CX32), forkhead box protein A2 (FOXA2), SRY-box 17 (SOX17), hexosaminidase A alpha polypeptide (HEXA), hematopoietically expressed homeobox (HHEX), transthyretin (TTR), albumin (ALB), tyrosine aminotransferase (TAT), cytochrome P450 7A1 (CYP7A1), glucose-6-phosphatase (G6PC), serpin peptidase inhibitor clade A (alpha-1 antiproteinase, antitrypsin) member 1 (SERPINA1), ATP-binding cassette sub-family C (ABCC2), CCAAT-enhancer-binding protein beta (C/EBP β), hepatocyte nuclear factor 1-alpha (HNF1 α), hepatocyte nuclear factor 4-alpha (HNF4 α), alpha-1-fetoprotein (AFP), cytokeratin 8 (CK8), phosphoenolpyruvate carboxykinase 2 mitochondrial (PCK2), glycogen synthase 2 (GYS2), hepatocyte nuclear factor 6 (HNF6), alcohol dehydrogenase 1C (class I) gamma polypeptide (ADH1C), cytochrome P450 3A4 (CYP3A4), prospero homeobox 1 (PROX1), tryptophan 2,3-dioxygenase (TDO2), cytokeratin 18 (CK18), and cytokeratin 19 (CK19).

[0008] In some embodiments, a hepatocyte herein is a hepatic progenitor cell. In some embodiments, FGF upregulates miRNA-124a in the TS cell. In some embodiments, elevated level of miRNA-124a initiates definitive endoderm (DE) specification in the TS cell. In some embodiments, the DE specification is associated with biomarkers comprising forkhead box protein A2 (FOXA2), SRY-box 17 (SOX17), Goosecoid (GSC), or Homeodomain protein MIXL1. In some embodiments, the DE specification is associated with elevated expression levels of SOX17, FOXA2, and GSC. In some embodiments, the elevated expression levels are increased protein expression levels. In some embodiments, the DE specification is associated with a decreased expression level of MIXL1. In some embodiments, the decreased expression level is a decreased protein expression levels. In some embodiments, the elevated protein expression levels of SOX17, FOXA2, and GSC and the decreased protein expression level of MIXL1 are relative to the protein expression levels of SOX17, FOXA2, GSC, and MIXL1 in an equivalent TS cell that has not undergone DE specification. In some embodiments, the DE specification is further associated with elevated expression levels of SOX2, NANOG, and OCT4. In some embodiments, elevated expression levels of SOX2, NANOG, and OCT4 are increased level of protein expressions. In some embodiments, elevated expression levels of SOX2, NANOG, and OCT4 are increased level of gene expressions. In some embodiments, the elevated expression levels of SOX2, NANOG, and OCT4 are relative to the expression levels of SOX2, NANOG, and OCT4 in an equivalent TS cell that has not undergone DE specification. In

some embodiments, a hepatocyte disclosed herein is at one of four stages: primitive streak to definitive endoderm (DE) stage, hepatic specified endoderm stage, hepatoblastic stage, and the fetal and adult hepatocyte cell stage. In some embodiments, one or more biomarkers selected from the group consisting of CXCR4, FOXA2, SOX17, HHEX, TTR, ALB, TAT, CYP7A1, BSEP, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , HNF4 α , and any combination thereof express in one or more of the four stages. In some embodiments, one or more biomarkers selected from the group consisting of CXCR4, FOXA2, SOX17, HHEX, and any combination thereof, express at the primitive streak to DE stage. In some embodiments, an expression level of CXCR4, FOXA2, SOX17, and/or HHEX increases at the primitive streak to DE stage, relative to that before the primitive streak to DE stage. In some embodiments, the increased expression level is an increased level of gene expression. In some embodiments, the expression level of CXCR4, FOXA2, SOX17 and/or HHEX increases by about 1 fold and about 10,000 fold higher than that before the primitive streak to DE stage. In some embodiments, the expression level of CXCR4, FOXA2, SOX17 and/or HHEX increases by about 10 fold and about 1000 fold higher than that before the primitive streak to DE stage. In some embodiments, one or more biomarkers selected from the group consisting of SOX17, TTR, ALB, TAT, SERPINA1, CYP7A1, and any combination thereof express in the hepatic specified endoderm stage. In some embodiments, an expression level of SOX17, TTR, ALB, TAT, SERPINA1, and/or CYP7A1 increases at the hepatic specified endoderm stage, relative to that before the hepatic specified endoderm stage. In some embodiments, the increased expression level is an increased level of gene expression. In some embodiments, the expression level of SOX17, TTR, ALB, TAT, SERPINA1, and/or CYP7A1 increases by about 1 fold and about 1000 fold higher than that before the hepatic specified endoderm stage. In some embodiments, the expression level of SOX17, TTR, ALB, TAT, SERPINA1, and/or CYP7A1 increases by about 10 fold and about 100 fold higher than that before the hepatic specified endoderm stage. In some embodiments, one or more biomarkers selected from the group consisting of TTR, ALB, TAT, CYP7A1, SERPINA1, bile salts excretion pump (BSEP), and any combination thereof express at the hepatoblastic stage. In some embodiments, an expression level of TTR, ALB, TAT, CYP7A1, SERPINA1, and/or BSEP increases at the hepatoblastic stage, relative to that before the hepatoblastic stage. In some embodiments, the increased expression level is an increased level of gene expression. In some embodiments, the expression level of TTR, ALB, TAT, CYP7A1, SERPINA1, and/or BSEP increases by about 1 fold and about 1000 fold higher than that before the hepatoblastic stage. In some embodiments, the expression level of TTR, ALB, TAT, CYP7A1, SERPINA1, and/or BSEP increases by about 10 fold and about 100 fold higher than that before the hepatoblastic

stage. In some embodiments, one or more biomarkers selected from the group consisting of HHEX, BSEP, TTR, ALB, TAT, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , HNF4 α , and any combination thereof express at the fetal and adult hepatocyte-like cell stage. In some embodiments, an expression level of HHEX, BSEP, TTR, ALB, TAT, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , and/or HNF4 α increases at the fetal and adult hepatocyte-like cell stage, relative to that before the fetal and adult hepatocyte-like cell stage. In some embodiments, the increased expression level is an increased level of gene expression. In some embodiments, the expression level of HHEX, BSEP, TTR, ALB, TAT, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , and/or HNF4 α increases by about 10 fold and about 1000 fold higher than that before the fetal and adult hepatocyte cell stage. In some embodiments, the expression level of HHEX, BSEP, TTR, ALB, TAT, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , and/or HNF4 α increases by at least 100 fold higher than that before the fetal and adult hepatocyte cell stage. In some embodiments, the trophoblast stem cell is a human trophoblast stem cell.

[0009] In some embodiments, a hepatocyte herein is immune privileged. In some embodiments, the hepatocyte expresses TGF β 1. In some embodiments, the hepatocyte expresses TGF β 1, fibronectin, and collagen IV in extracellular matrix (ECM). In some embodiments, the hepatocyte expresses HLA-G. In some embodiments, the hepatocyte expresses HLA-G and stem-121. In some embodiments, the hepatocyte recruits CD4⁺Foxp3⁺ Treg cells. In some embodiments, the hepatocytes form tissue of a 3-dimensional structure. In some embodiments, the hepatocytes cluster or aggregate. In some embodiments, the hepatocytes form a crescent cell mass. In some embodiments, the hepatocytes comprise a peripheral compartment and a central compartment. In some embodiments, the hepatocytes distribute irregularly along ECM beyond basement membrane in the peripheral compartment. In some embodiments, the hepatocytes distribute from basal towards central areas in the central compartment. In some embodiments, the hepatocyte expresses one or more markers selected from the group consisting of TGF β 1, HLA-G, stem 121, C-kit, CK19, CK18, ALB, α -AFP, betatrophin, ADH1, APOF, CPS1, GATA4, CYP1A1, CYP2B6, ASGR1, CXCR4, BSEP, MRP2, Cx32, and any combination thereof. In some embodiments, the hepatocyte expresses one or more markers selected from the group consisting of TGF β 1, HLA-G, stem 121, C-kit, betatrophin, ADH1, APOF, CPS1, CYP2B6, ASGR1, CXCR4, Cx32, and any combination thereof. In some embodiments, the hepatocyte expresses one or more markers selected from the group consisting of CPS1, CYP2B6, and a combination thereof. In some embodiments, the hepatocyte expresses one or more markers selected from the group consisting of stem 121, C-kit, CK19, CK18, and any combination thereof. In some embodiments, the hepatocyte expresses one or more markers selected from the

group consisting of ALB, AFP, betatrophin, ADH1, APOF, CPS1, GATA4, CYP1A1, CYP2B6, and any combination thereof. In some embodiments, the hepatocyte expresses one or more markers selected from the group consisting of ASGR1, CXCR4, BSEP, MRP2, Cx32, and any combination thereof.

[0010] Also disclosed herein is a method of screening a therapeutic compound for use in treatment or prevention of a condition, comprising: contacting an isolated hepatocyte disclosed herein with the therapeutic compound; and detecting an expression level of a biomarker in the isolated hepatocyte. In some embodiments, the expression level of a biomarker in the isolated hepatocyte increases as compared to an equivalent isolated hepatocyte not contacted with the therapeutic compound. In some embodiments, the expression level of a biomarker in the isolated hepatocyte decreases as compared to an equivalent isolated hepatocyte not contacted with the therapeutic compound. In some embodiments, the expression level is a gene expression level. In some embodiments, the biomarker comprises CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4, or CYP7A1. In some embodiments, the therapeutic compound is a small molecule drug, a peptide, or a protein. In some embodiments, the therapeutic compound is a synthetic chemical drug. In some embodiments, the condition is a liver failure. In some embodiments, the condition is a liver-associated disease or disorder. In some embodiments, the liver-associated disease or disorder comprises alagille syndrome, alpha 1 anti-trypsin deficiency, autoimmune hepatitis, benign liver tumors, biliary atresia, cirrhosis, cystic disease of the liver, fatty liver disease including alcohol-related liver disease and non-alcohol fatty liver disease (NAFLD), galactosemia, gallstones, Gilbert's Syndrome, hemochromatosis, liver cysts, liver cancer, liver disease in pregnancy (optionally acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, preeclampsia, or HELLP Syndrome (hemolysis, elevated liver tests, low platelets)), neonatal hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, porphyria, Reye's Syndrome, sarcoidosis, toxic hepatitis, type 1 glycogen storage disease, tyrosinemia, viral hepatitis, Wilson disease, or any combination thereof.

[0011] In one aspect, disclosed herein is a composition (e.g., pharmaceutical composition) comprising any hepatocyte disclosed herein.

[0012] In another aspect, disclosed herein is a method of treating a condition in a subject, comprising administering to a subject a pharmaceutical composition that comprises an isolated hepatocyte herein, in an amount effective for the hepatocytes to engraft to the subject (e.g., to the subject's liver). In some embodiments, the hepatocytes are administered in a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutically acceptable carrier comprises a phosphate buffer saline. In some embodiments, the hepatocytes are administered in a suspension

containing about 1×10^6 to about 100×10^6 cells per ml, about 1×10^6 to about 250×10^6 cells per ml, about 1×10^6 to about 500×10^6 cells per ml, or about 10×10^6 to about 40×10^6 cells per ml. In some embodiments, the hepatocytes are administered in a volume of about: 1-5 ml, 1-10 ml, 1-50 ml, 1-100 ml, or 10-150 ml. In some embodiments, the subject is a human. In some embodiments, the administering comprises an injection, e.g., intravenous injection. In some embodiments, the injection is administered at a hepatic vein. In some embodiments, the injection is administered at a hepatic artery. In some embodiments, the condition is a liver-associated disease or disorder. In some embodiments, the condition is a liver failure. In some embodiments, the liver-associated disease or disorder comprises alagille syndrome, alpha 1 anti-trypsin deficiency, autoimmune hepatitis, benign liver tumors, biliary atresia, cirrhosis, cystic disease of the liver, fatty liver disease including alcohol-related liver disease and non-alcohol fatty liver disease (NAFLD), galactosemia, gallstones, Gilbert's Syndrome, hemochromatosis, liver cysts, liver cancer, liver disease in pregnancy (optionally, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, preeclampsia, or HELLP Syndrome (hemolysis, elevated liver tests, low platelets)), neonatal hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, porphyria, Reye's Syndrome, sarcoidosis, toxic hepatitis, type 1 glycogen storage disease, tyrosinemia, viral hepatitis, Wilson disease, or any combination thereof.

[0013] In another aspect, disclosed herein is a use of a composition comprising a hepatocyte herein for the production of therapeutic proteins. In some embodiments, the therapeutic proteins comprise major plasma proteins such as human serum albumin, soluble plasma fibronectin, α -fetoprotein, C-reactive protein, and several globulins; proteins involved in hemostasis and fibrinolysis such as coagulation factors involved in the coagulation cascade, α 2-macroglobulin, α 1-antitrypsin, antithrombin III, protein S, protein C, plasminogen, α 2-antiplasmin, and complement component 3; carrier proteins such as albumin, ceruloplasmin, transcortin, haptoglobin, hemopexin, IGF binding protein, major urinary proteins, retinol binding protein, sex hormone-binding globulin, transthyretin, transferrin, and Vitamin D-binding protein; hormones such as insulin-like growth factor 1, thrombopoietin, hepcidin, and betatrophin; prohormones such as angiotensinogen; or apolipoproteins.

[0014] Also disclosed herein is a use of a composition comprising a hepatocyte herein for liver regeneration. In some embodiments, the liver regeneration is an *ex vivo* liver regeneration. In some embodiments, the *ex vivo* liver regeneration is a bioprinting method. In some embodiments, the bioprinting method is a 3 dimensional bioprinting method.

[0015] In one aspect, disclosed herein is a use of a composition comprising a hepatocyte herein for bioprinting. In some embodiments, the bioprinting is a 3 dimensional bioprinting.

[0016] Also disclosed herein is a use of the hepatocyte herein for tissue scaffold generation. In some embodiments, the tissue scaffold is a 3 dimensional tissue scaffold.

[0017] In one aspect, disclosed herein is a use of a composition comprising a hepatocyte herein for gene therapy. In some embodiments, the gene therapy is an *ex vivo* gene therapy.

[0018] In another aspect, disclosed herein is an artificial tissue generated from hepatocytes herein. In some embodiments, the tissue is three-dimensional. In some embodiments, the tissue is vascularized.

[0019] Also disclosed herein is an artificial organ generated from hepatocytes herein.

[0020] In some embodiments, a hepatocyte, tissue, or organ disclosed herein produces AFP, ALB, alpha-1-antitrypsin, glucose, or glycogen. In some embodiments, the hepatocyte, tissue, or organ metabolizes a lipid, cholesterol, or carbohydrate. In some embodiments, the hepatocyte, tissue, or organ metabolizes a pharmaceutical drug or toxic substance. In some embodiments, the hepatocyte, tissue, or organ uptakes ammonia or bile acid.

[0021] In some embodiments, a hepatocyte herein has comparable phenotypic (e.g., immunophenotypic) properties as a primary hepatocyte. In some embodiments, a hepatocyte herein has comparable morphologic properties as a primary hepatocyte. In some embodiments, a hepatocyte herein has comparable functional properties as a primary hepatocyte.

[0022] In some embodiments, a hepatocyte, tissue, or organ disclosed herein has one or more functions of: synthesis of fatty acids, triglycerides, cholesterol, bile salts, or phospholipids; detoxification, modification, and excretion of exogenous or endogenous compounds (e.g., drug, insecticide, steroid, ammonia, heavy metal, or toxin); carbohydrate metabolism; synthesis of proteins (e.g., serum albumin, fibrinogen, lipoprotein, apoprotein, ceruloplasmin, transferrin, complement, or glycoprotein); protein storage; or formation or secretion of bile. In some instances, a hepatocyte can be a hepatic progenitor cell (e.g., hepatocyte-like cell) or a hepatocyte derived from a stem cell; a hepatic stem cell; or a primary hepatocyte (e.g., are or comparable to freshly isolated or uncultured, cryopreserved hepatocytes obtained from a liver).

[0023] In some embodiments, a trophoblast stem cell disclosed herein is derived from an ectopic pregnancy mass (e.g., tubal). In some embodiments, the method of isolating a trophoblast stem cell herein comprises the steps of: obtaining trophoblastic villi from an ectopic pregnancy mass (e.g., tubal); collecting cells from the trophoblastic villi; and culturing the collected cells in a culture medium to obtain the isolated trophoblast stem cell. In some embodiments, the method further comprises cutting the trophoblastic villi into pieces. In some embodiments, the method further comprises treating the trophoblastic villi with an enzyme. In some embodiments, the human trophoblast stem cell is genetically modified to introduce a mutation into the cell. In some

embodiments, the pregnant mass is obtained in an unruptured manner. In some embodiments, the pregnant mass is at a gestational age of no older than 7 or 8 weeks. In some embodiments, the culture medium is free of a feeder layer. In some embodiments, the method further comprises the steps of: forming embryonic bodies (EBs) in the culture medium; treating the EBs with an enzyme; and collecting cells from the enzyme-treated EBs to obtain the isolated human trophoblast stem cell.

BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figures 1A-1F illustrate immunoreactive markers of DE lineages. Figures 1A-1D show immunocytochemistry to detect FOXA2 and SOX17 (Figure 1A), GSC (Figure 1B), and MIXL1 (Figure 1C) at 4 hr of bFGF induction compared to the control in hTS cells. Figure 1D shows western blots in time course of DE-related transcription factors including GSC, Brachyury, MIXL1, SOX17, and FOXA2 at initial 8 hr of bFGF induction. Error bars indicate standard deviation (SD) of mean. N = 3, *: p < 0.05 as statistic significant. Figure 1E shows colocalization of hepatocyte-associated markers showing AFP and albumin (upper panel) and ABCC2 and BSEP (lower panel) at day-4 after induction. Figure 1F shows a two-step regimen for hepatocyte-like cell differentiation showing various hepatocyte-specific markers by Western blotting assay in hTS cells. α -tubulin as loading control.

[0025] Figures 2A-2M illustrates regulatory Molecular Mechanisms for DE Specification. Figure 2A indicates miR-124a analysis (ChIP-qPCR) which identifies that CREB1 targets at three sites of promoter of miR-124a mRNA. A schematic drawing of the consensus miR-124a binding sites (upper panel). C: as no-antibody control. Error bars indicate SD of 3 replicates. Figure 2B illustrates that knockdown of CREB1 reduces the bFGF-induced miR-124a expression by immunoblotting assay. Error bars indicate SD of 3 replicates. *: p < 0.05. Figure 2C shows bFGF induced expression of phosphor(p)-CREB1 and miRNA-124a during 8 hr induction by qPCR assay. Error bars indicate SD of 4 replicates. Figure 2D shows ChIP-qPCR of Smad4 which identifies that miR-124a represses Smad4 expression via targeting two sites of the promoter by luciferase reporter assay. The schematic drawing of the consensus miR-124a binding sites (upper panel). Empty vector as control; pSmad4 indicating Smad4 plasmid, Error bars indicate SD of 3 replicates. *: p < 0.05. Figure 2E shows the effects of bFGF, miR-124a, and anti-miR-124a antibody on the expression of DE-related transcription factors by Western blots. β -actin was used as loading control. Figure 2F shows the knockdown of Smad4 using shRNAs represses expression of Smad4 and MIXL1 by Western blots. β -actin was used as loading control. Figure 2G and Figure 2H show ChIP-qPCR assays which identify the inhibitory GSK3 β by miR-124a by luciferase report assays at 4 hr induction (Figure 2G); while qPCR assay

showed an inhibitory FOXA2 by β -catenin (Figure 2H). A schematic drawing of the consensus miR-124a binding sites (G, upper panel). Empty vector as control; pGSK3 β indicating GSK3 β plasmid, Error bars indicate SD of 3 replicates. *: $p < 0.05$. Figure 2I shows ChIP-qPCR assay which identifies the inhibitory CDX2 by miR-124a by luciferase reporter assay. A schematic drawing of the consensus miR-124a binding sites (upper panel). Empty vector as control; pCDX2 indicating CDX2 plasmid, Error bars indicate SD of 3 replicates. *: $p < 0.05$. Figure 2J shows imaging which revealed a reciprocal inhibitory mechanism between CDX2 and OCT4 at 4 hr bFGF induction in hTS cells. Figure 2K shows western blots in timeline of pluripotent transcription factors CDX2 and OCT4 (upper panel) as well as NANOG, and SOX2 (lower panel) during DE differentiation. Error bars indicate SD of 3 replicates. *: $p < 0.05$. Figure 2L shows ChIP-qPCR assay which identifies binding of OCT4 at the two sites of the promoter of *SOX17* gene. Error bars indicate SD of 3 replicates. Figure 2M shows a schematic illustration of bFGF induction in the differentiation of hTS cells towards DE lineages.

[0026] Figures 3A-3C illustrate morphogenesis of hepatocyte-like cells. Figure 3A shows morphological changes of cells the differentiation, forming a plate-like tissue structure at day 6-8 day of induction. Figure 3B shows electron micrographs revealed the infrastructure: large cytoplasm/nucleus ratio, plenty of mitochondria (m), Golgi apparatus (Gi), well-organized endoplasmic reticulum (RER), the junctional complexes (white arrow) to form bile canaliculus lumen (Cn), and the junctional complexes (double arrows) seal off the space from the remaining extracellular space, lamelleted incursion at cytoplasm, and desmosome junction (arrow). Figure 3C shows immunohistochemistry of the hepatic plate-like tissue showing immunoreactive cell membrane markers of hepatocytes: CXCR4, CX32, BSEP, and MRP2 (ABCC2) and cytoplasmic markers: Betatrophin, HNF4 α , Albumin, AFP, CYP2B6, APOF, CPS1, and ADH1.

[0027] Figures 4A-4D illustrate liver functions of the differentiated hepatocyte-like cells. Figure 4A shows differentiated hepatocyte-like cells (4 days) exhibiting protein secreting capacity in the medium such as albumin and urea measured by an automatic analyzer (Hitachi 7080; Tokyo, Japan). Error bars indicate SD of 3 replicates. **: $p < 0.01$. Figure 4B and Figure 4C show a LDL uptake assay which illustrates immunoreactive LDL receptor (LDLR, middle panel) and LDL staining (left panel) (Figure 4B) and Oil-O-Red test showing fat droplets (Figure 4C) in the differentiated hepatocyte-like cells. Figure 4D shows glycogen storage test identifies the presence of glycogen in the cells by periodic acid-Schiff (PAS) staining evidenced by diastase to digest glycogen (upper pane) and confirmed by fluorescent PAS staining (lower panel) in the hepatocyte-like cells (left 3 panel) and the hepatic plate-like tissue (right panel).

[0028] Figures 5A-5I illustrate a variety of CYP 450 enzyme activities in the differentiated hepatocyte-like cells. Phase I-II CYP450 enzyme activity is estimated by drug-drug interaction and detoxification tests (inducer, inhibitor), including CYP1A2 (Figure 5A), CYP2B6 (Figure 5B), CYP2C8 (Figure 5C), CYP2C9 (Figure 5D), CYP2C19 (Figure 5E), CYP2D6 (Figure 5F), CYP2E1 (Figure 5G), CYP3A4 (Figure 5H), and CYP 7A1 (Figure 5I). Inducer and inhibitor used as (rifampin, Rif and ciprofloxacin, Cip), (phenobarbital, phen and Cip), (Rif and gemfibrozil, Gem), (Rif and Gem), (Rif and ticlopidine, Tico), (Rif as inducer only), (Rif as inducer only), (Rif, and itraconazole, Itra), and (THA, 2,4,6-trihydroxyacetophenone and CDCA, chenodeoxycholic acid), respectively. hTS indicating hTS cells, hTHL indicating human trophoblast-derived hepatocyte-like cells; and Huh7 indicating human hepatoma Huh7 cells.

[0029] Figure 6 illustrates a table showing biomarker expression (e.g. mRNAs) during the different stages of a hepatocyte differentiation.

[0030] Figure 7 illustrates the cellular processes of DE formation by TissueFAX analysis. bFGF (10 ng/mL) was used to induce differentiation of hTS cells to mesendoderm indicated by upregulation of MIXL1 (black). Subsequently, the mesendoderm differentiated into DE lineage at about 4 hours induction, expressing a downregulation of MIXL1 (grey). n indicates the total number of cells counted.

[0031] Figure 8 illustrates expression level analysis of biomarkers described herein. Figure 8A illustrates that FGFR inhibitor (PD166866) blocks bFGF-induced PI3K with β -actin as a loading control. Figure 8B illustrates that PI3K siRNA inhibits the expression of PI3K and p-AKT. Cells transfected with non-specific shRNA were used as control. β -actin was used as a loading control. Figure 8C shows that siRNAs against AKT subunits inhibits the bFGF-induced expression of p-AKT and p-CREB1. Cells transfected with non-specific shRNA were used as control. β -actin was used as a loading control. Figure 8D shows that AKT interacts directly to CREB1 by IP assay.

[0032] Figure 9 illustrates the genetic fluctuation profiles of hepatic development-associated 31 genes after induction by qPCR analysis in hTS cells.

[0033] Figures 10A-10D and 10AS-10FS illustrate immunoreactive markers during DE formation. (10A) Western blot analysis in time course of representative markers of primitive streak and DE markers at the initial induction (8 hr). Data indicating mean \pm SD, n = 3, *: p < 0.05 as statistic significant. (10B) immunocytochemistry of Foxa2 and Sox17 (left panel), Gsc (middle panel), and Mixl1 (right panel) at 4 hr of bFGF induction. (10C) Identification of CREB1 in targeting at three sites of promoter (upper panel) in miR-124a to increase its levels by ChIP-qPCR. C: as control. Data representing mean \pm SD, n = 3, *: p < 0.05 as statistic significant.

(10D) bFGF induces a parallel expression between phosph(p)-CREB1 and miRNA-124a by qPCR assay. Data indicating mean \pm SD, n = 4, *: p < 0.05 as statistic significant. (10AS) A shifting mean Mix11 intensity in cells within 4 hr induction by TissueFAX analysis. Blank area as control, blue area as mesendoderm stage, red area as DE stage. (10BS). FGFR inhibitor (PD 166866) blocks the bFGF-induced PI3K by Western blotting. β -actin was used as loading control. (10CS) PI3K siRNA inhibits expression of PI3K and p-Akt. Cells transfected with non-specific shRNA are used as control. β -actin was used as loading control. (10DS) siRNAs against Akt subunits inhibits the bFGF-induced expressions of p-Akt and p-CREB1. Cells transfected with non-specific shRNA are used as control. β -actin was used as loading control. (10ES) Akt interacts directly to CREB1 by IP assay. (10FS) bFGF-induced miR-124a is inhibited by using CREB1 shRNAs. Data representing mean \pm SD, n = 3, *: p < 0.05 as statistic significant.

[0034] Figures 11A-11I and 11AS-11CS illustrate molecular mechanisms for DE specification. (11A, 11B, 11C) Luciferase reporter assays of miR-124a repressing the expressions of Smad4 plasmid (pSmad4) (A), pGSK3 β (B), and pCdx2 (C) via targeting the promoter(s) of gene (upper panel). Empty vector: control, Data indicating mean \pm SD, n = 3, *: p < 0.05 as statistic significant. (11D) β -catenin binds to the region (-2.1 kb) of promoter in *Foxa2* gene over time by CHIP-qPCR assay. Error bars indicate SD of 3 replicates. (11E) *Foxa2* targets the promoter of *Betatrophin* by CHIP assay, showing production of betatrophin at 12 hr induction (arrow). Input: whole cells as positive control. IgG as negative control. (11F) Expression of various transcription factors in response to miR-124a and anti-miR-124a antibody at 4 hr of bFGF induction by Western blot analysis. β -actin: loading control. (11G) A reciprocal inhibitory function between Cdx2 (green) and Oct4 (red) at 4 hr of bFGF induction immunocytochemically. (11H) Oct4 binds to two regions (-1 and -1.8 kb) of promoter in *Sox17* gene at 2 hr of bFGF induction by CHIP-qPCR assay. Error bars indicate SD of 3 replicates. (11I) Schematic illustration of molecular regulation in DE differentiation of hTS cells. (11AS) Smad4 shRNAs inhibit expression of Mix11 by immunoblotting assay. (11BS) Expression of Oct4, Cdx2, Nanog, and Sox2 in time course during DE formation. Data indicating mean \pm SD, n = 3, *: p < 0.05. (11CS) Immunoreactive Albumin (ABL) and AFP express in the hepatocyte-like cells.

[0035] Figures 12A- 12D and 12AS illustrate biological characteristics of hepatocyte-like cells. (12A) H&E staining of the crescent cell mass (left panel, insert). Numerous clustered cells distributed irregularly at the outer peripheral layer containing abundant small embryonic progenitor-like cells with condensed nuclei (right lower). Columnar tree-like ECMs along with hepatocyte-like cell linings radiating from the peripheral layer to the central areas (right upper). (12B) Hepatocyte-like cells in the CC14-damaged liver tissues, showing immunoreactive stem-

121-positive cells (left upper), *C-kit* positive cells (right upper, arrow), CK19 (left lower, arrow), and CK18 (right lower, arrow). (12C) A variety of specific immunoreactive markers during liver development observed in the crescent cell mass histologically. Cellular surface markers make up polygonal shape of hepatocyte seen in small insert. (12D) Representative electron micrographs showing: a large cytoplasm/nucleus ratio, plenty of mitochondria (m), endoplasmic reticulum (rer), lipid droplets, space of Disse (SD), extracellular matrix (ecm), nucleus (n), and sinusoid in upper micrograph, glycogen (gly) storage with rosette formation (red circle) in lower left micrograph, and lower right micrographs showing bile canaliculus lumen (bc) and junctional complex (upper) and tight junction (lower). (12AS) Morphological changes during hTS cells differentiation to hepatocyte-like cells in time course.

[0036] Figures 13A-13B and 13AS illustrate secretomics in hepatocyte-like cell culture medium. (13A) Proteomic analysis of culture medium before cell culture (as control, left panel) and after 5-day cell culture (right panel) revealing a new formation of protein (designated as No. 413, circle). (13B) No immunoreactive TGF β 1, collagen IV (COL4), and fibronectin (FN) expressed in hTS cells before induction (upper panels) and after induction for 5-days, coexpression of them distribute as columnar ECMs between hepatocyte-like cells in 3-D structure (lower panels). (13AS) Mascot MS/MS ions search system analysis 20151001_LiP_413, transforming growth factor-beta-induced protein ig-h3 precursor [Homo sapiens].

[0037] Figures 14A-14E illustrate functional Characteristics of Hepatocyte-Like Cells. (14A) HepatoHepatocyte-like cells secrete albumin (left) and urea (right; by stimulation of 5 mM ammonium chloride for 1-day) into the cultured medium by automatic analyzer (Hitachi 7080; Tokyo, Japan). Error bars indicate SD of 3 replicates. **: $p < 0.01$. (14B) LDL uptake assay shows immunoreactive LDL (red, left), LDL receptor (LDLR, green, middle), and their emerged image (right) in the cells. (14C) Oil-O-Red test shows fat droplets (red) in the cells. (14D) Glycogen storage test identifies the presence of glycogen (pink and red) by periodic acid-Schiff (PAS) staining using diastase treatment (upper panel) and also by fluorescent PAS staining (lower panel). (14E) A variety of phase I-II CYP 450 enzyme activity in response to inducer (green) and inhibitor (pink) at 24 hr treatment in hepatocyte-like cells by qPCR analysis. Abbreviations: Rif, rifampin; Cip, ciprofloxacin; Itra, itraconazole; Phen, phenobarbital; Gem, gemfibrozil; THA, 2,4,6-trihydroxyacetophenone; CDCA, chenodeoxycholic acid; and Tico, ticlopidine.

[0038] Figures 15A-15F illustrate responsiveness of intravenous transplantation by hepatocyte-like cells (15A) Serum levels of AST and ALT are higher in cell therapy group (CCl₄ + cells; n =

8) than control group (CCl₄ only; n = 8) over time. Data represent mean ± s.e.m., n = , Student test: *: p < 0.01. (15B) Expression of immunoreactive stem-121 in hTS cells (upper) and in hepatocyte-like cells resided in liver tissues (lower). (15C) Stem-121-positive hepatocytes in the CCl₄-damaged liver tissues expressing characteristics of cellular degeneration (insert). PT indicating portal triad. (15D) Coexpression of immunoreactive Stem-121 and HLA-G in the implanted hepatocyte-like cells. Bar scale: 20 μm. (15E, 15F) Distribution of immunoreactive CD4⁺Foxp3⁺ Treg cells among the CCl₄-damaged hepatocytes immunocytochemistry (15E) and immunoreactive CD4⁺ cells (red) around a central vein immunohistochemistry (15F).

DETAILED DESCRIPTION

[0039] Disclosed herein are methods, compositions, cells, manufacture process, and kits for generating an induced hepatocyte from a trophoblast stem cell. In some embodiments, described herein is a method of inducing a trophoblast stem (TS) cell to differentiate into an induced hepatocyte *in vitro*, that comprises (a) contacting the trophoblast stem cell in a conditioned medium comprising a fibroblast growth factor (FGF), a steroid, and a cytokine; and (b) incubating the cell for sufficient time to induce differentiation of the trophoblast stem cell into an induced hepatocyte.

[0040] Also described herein is an isolated induced hepatocyte derived from a trophoblast stem cell, wherein the isolated induced hepatocyte comprises an elevated level of expression of one or more biomarkers comprising C-X-C chemokine receptor type 4 (CXCR4), Forkhead box protein A2 (FOXA2), SRY-box 17 (SOX17), hexosaminidase A (alpha polypeptide) (HHEX), bile salt export pump (BSEP), transthyretin (TTR), albumin (ALB), tyrosine aminotransferase (TAT), cytochrome P450 7A1 (CYP7A1), glucose-6-phosphatase (G6PC), serpin peptidase inhibitor clade A (alpha-1 antiproteinase, antitrypsin) member 1 (SERPINA1), ATP-binding cassette sub-family C (ABCC2), CCAAT-enhancer-binding protein beta (C/EBPβ), hepatocyte nuclear factor 1-alpha (HNF1α), hepatocyte nuclear factor 4-alpha (HNF4α), alpha-1-fetoprotein (AFP), keratin 8 (KRT8), phosphoenolpyruvate carboxykinase 2 mitochondrial (PCK2), cytochrome P450 2B6 (CYP2B6), glycogen synthase 2 (GYS2), hepatocyte nuclear factor 6 (HNF6), carbamoyl-phosphate synthase 1 mitochondrial (CPS1), alcohol dehydrogenase 1C (class I) gamma polypeptide (ADH1C), connexin 32 (CX32), cytochrome P450 3A4 (CYP3A4), prospero homeobox 1 (PROX1), tryptophan 2,3-dioxygenase (TDO2), apolipoprotein F (APOF), keratin 18 (KRT18), keratin 19 (KRT19), or chromosome 19 open reading frame 80 (angiopoietin-like protein 8, hepatocellular carcinoma-associated gene TD26, lipasin) (Betatrophin).

[0041] Further described herein is a method of screening a compound for use in treatment or prevention of a disease or disorder, which comprises (a) contacting an isolated induced

hepatocyte herein with the compound; and (b) detecting the expression level of a biomarker in the isolated induced hepatocyte.

[0042] Described herein, in addition, are compositions (e.g. pharmaceutical compositions) that comprises an isolated induced hepatocyte disclosed herein, manufacture process for generating a composition (e.g. pharmaceutical composition) that comprises an isolated induced hepatocyte disclosed herein, and methods of treating a disease or disorder (e.g. a liver-associated disease or disorder) with an isolated induced hepatocyte disclosed herein or a composition that comprises an isolated induced hepatocyte disclosed herein.

[0043] In some aspects, disclosed herein is a highly efficient generation of hepatocyte-like cells from ectopic pregnancy-derived human trophoblast (hTS) stem cells, exhibiting molecular, genetic, and biological characteristics resemblance to primary hepatocytes in liver development. In some embodiments, disclosed herein is a mechanism of microRNA-124a controlling definitive endoderm formation during differentiation. In some embodiments, hepatocyte-like cells can construct a 3-D liver plate-like structure in cell culture, expressing HLA-G and secreting TGF β 1 to maintain CD4⁺Foxp3⁺ Treg cells in liver tissues for immune tolerance after intravenous implantation. In some embodiments, the cells herein assist and promote liver regeneration in rat model of CCl₄-induced acute liver failure. In some embodiments, hTS cell-derived hepatocyte-like cells herein can be applied in the urgent management of liver failure or in regenerative medicine. In some embodiments, disclosed herein is efficient two-step differentiation of hTS cells to functional hepatocytes within a week (e.g., 4-6 days). In some embodiments, miR-124a controls DE formation during hepatogenesis. In some embodiments, disclosed herein are hepatocyte-like cells construct 3-D tissue structure with biological functions mimicking primary hepatocytes.

[0044] In some aspects, disclosed herein is intravenous infusion of hepatocyte-like cells can homed to the CCl₄-damaged liver tissues to promote liver regeneration in rat animal model. In some embodiments, disclosed herein are both hTS cells and its derivative hepatocyte-like cells express HLA-G to obtain immune tolerance after transplantation. In some embodiments, disclosed herein are homing hepatocyte-like cells secret TGF β 1 to assist the construction of new ECMs after injury via the formation of fibronectin and collagen. In some embodiments, Hepatocyte-like cell-secreted TGF β 1 resulting in the bone marrow's fibrocytes migration to liver, activates hepatic stellate cells for liver regeneration and maintains CD4⁺Foxp3⁺ Treg cells in liver tissues for immune tolerance. In some embodiments, basic fibroblast growth factor (bFGF) alone induces activation of microRNA (miRNA)-124a to consequently control the DE specification in early differentiation. In some embodiments, with certain conditions, DE gives

rise to hepatic endoderm followed by hepatoblasts and eventually differentiates to fetal/adult hepatocyte-like cells, bearing similar genetic, molecular and biological characteristics to primary human hepatocytes.

[0045] In some aspects, hepatocyte-like cells enable to build a three-dimensional (3-D) tissue structure in vitro and intravenous infusion of such cells results in hepatic homing and protects the liver from damage. In some embodiments, a tissue-culture media composition used herein comprises about serum and culture medium. In some embodiments, the culture medium is Synthetic Oviductal Fluid (SOF), Modified Eagle's Medium (MEM), Dulbecco's Modified Eagle's Medium (DMEM), RPMI 1640, F-12, IMDM, Alpha Medium, or McCoy's Medium. In some embodiments, the serum is allogeneic serum, autologous serum, or xenogeneic serum. In some embodiments, hTS cells are cultured with a combination of fibroblast growth factor (e.g., bFGF), steroid (e.g., dexamethasone), cytokine (e.g., oncostatin M), bone morphogenetic protein (e.g., BMP4), and hepatic growth factor (HGF) after DE formation (e.g., 8 hr). In some embodiments, the resulting cells form dispersed fibroblast-like cells. In some embodiments, the resulting cells gradually aggregate to form a crescent cell mass. In some embodiments, two distinct peripheral and central compartments construct a 3-dimensional (3D) tissue structure. In some embodiments, in the peripheral part, numerous clustered small cells distribute irregularly among the extracellular matrix (ECM) beyond the basement membrane. In some embodiments, cells have condensed nuclei, frequently eccentric located, and abundant granular and vacuoles in the eosinophilic cytoplasm similar to the embryonic stem/progenitor cells. In some embodiments, in the central part, many independent columnar ECMS, by cell linings at both sides, distribute from the basal towards the central areas. These cells contain abundant eosinophilic cytoplasm and disperse chromatin in the single round nucleus with one or two prominent nucleoli mimicking the phenotypic hepatocytes. In some embodiments, several binucleate cells can form, similar to hepatic plates in human liver.

[0046] In some embodiments, the hepatocyte or hepatocyte-like cells herein exhibit specific marker(s) of: i) human cytoplasmic marker stem 121TM for human cells, mast/stem cell growth factor receptor *C-kit* for liver intrinsic stem cells, CK19 for cholangiocytes, and CK18 for hepatocytes; and ii) albumin (ALB), α -fetoprotein (AFP), Betatrophin, ADH1, APOF, CPS1, GATA4, CYP1A1, and CYP2B6 in the cytoplasm for hepatocytes immunohistochemically. In some embodiments, a subset of surface markers including ASGR1, CXCR4, BSEP, MRP2, and Cx32 construct a polygonal cell shape similar to the primary human hepatocyte, e.g., a similar ultrastructure to primary hepatocyte, including a large cytoplasm to nucleus ratio, plenty of mitochondria, well-organized endoplasmic reticulum, tight junction, numerous lipid

vacuoles, glycogen storage, enlarged lumen of the bile canaliculus with junctional complexes, and multiplex ECMs.

[0047] Among 9 newly upregulated, secreted proteins in the cell-cultured medium, protein (no. 413) significantly predicts, by 46% of peptide sequences matched, to be the transforming growth factor- β (TGF- β)-induced protein ig-h3 precursor (TGF β 1) by Mascot MS/MS ions search system (ESI-QUAD-TOF, Bruker Impact HD, Matrix Science, USA). TGF β 1 is a major fibrogenic, multifunctional cytokine, acting as both autocrine and paracrine manner to enhance fibronectin and collagen formation in hepatic stellate cells (HSCs). In some embodiments, TGF β 1 is expressed in ECM. In some embodiments, TGF β 1, fibronectin, and collagen IV are co-expressed in the ECMs. In some embodiments, TGF β 1, fibronectin, and collagen IV constitute, at least partly, the scaffold of ECMs in the 3-D tissue structure of hepatocyte-like cells that may support proliferation and differentiation of hepatocytes in the hepatic plates.

[0048] In some aspects, hepatocyte-like cells can be efficiently generated from pluripotent hTS cells through a series of cellular processes, including the primitive streak, DE formation, hepatic endoderm, hepatoblasts, and ultimately hepatocyte-like cells. The onset of primitive streak differentiation can be verified at the initial induction (e.g., 30 min) by upregulation of GSC, Brachyury, and Mix11. The immediately decreased Mix11 can perform an impact on the endoderm potential of the mesendoderm progenitors. Moreover, Sox7-expressing cells can be originally present at the extra-embryonic endoderm but not at the DE lineages. As development progresses, the apparent upregulation of Sox17 and Foxa2 as well as downregulation of Mix11 can define the formation of DE, in which Oct4 play a main role in the maintenance of pluripotency distinct from Nanog in the hES cell- or iPS cell-derived DE.

[0049] In some aspects, a transient elevation of miR-124a can negatively modulate multiple gene expressions post-transcriptionally via binding to the targeted mRNAs, typically in the 3'UTR to control DE specification. There can be presence of functionally silenced miR-124a in the early hepatic differentiation. Wherein, the downregulated miR-124a after peaking at 4 hr induction bears a resemblance to the scenario when cell migration begins in gastrulation to form three embryonic germ layers in hES cells.

[0050] In some aspects, the initiation of hepatic lineage differentiation following DE specification can be achieved by a combination of bFGF, dexamethasone, oncostatin M, BMP4, and HGF. The stage-specific gene profiles can indicate a committed step in the hepatic specified endoderm (Table 3, second column). For example, expression of α -fetoprotein (AFP) expression suggests the initial differentiation of hepatic endoderm and both C/EBP β and Hnf4 α control

initial liver-specific activity in the urea cycle. Expression of α -1-antitrypsin (SERPINA1) can protect cells from damage and promotes metabolic activity of enzymes such as CYP7A1, CYP3A4, and CYP2B6. These facts represent that hepatic endoderm is capable of metabolism of cholesterol, drug, and toxin at the early differentiation. Since Sox17 directly induces zinc finger protein 202 (ZFP202) to suppress the master hepatic gene regulator Hnf4 α , thereby, withdrawal of Sox17 facilitated the initiation of Hnf4 α expression after DE stage, which, in turn, to characterize the specification of hepatic progenitor cells, controlling hepatocyte cell fate. A sustained Foxa2 can be responsible for the consequent expressions of albumin, AFP, mitochondrial protein TAT, and betatrophin; while betatrophin expression reflects the early capacity in the promotion of β cell proliferation and lipid metabolism at the early hepatic differentiation.

[0051] In some aspects, as differentiation proceeds, numerous hepatic markers begin to emerge, including PROX1, G6PC, Hnf1 α , ABCC2, and TDO2 as well as cytokeratins such as CK8, CK18, and CK19. PROX1, for example, is required for hepatoblastic migration and its ablation in hepatoblasts causes defective hepatocyte specification and promotes biliary cell commitment. CK8 is an intermediate filament protein to polymerize with CK18 forming a component of the epithelial cytoskeleton and acts as a plasminogen receptor. Hepatoblasts in between 2 and 4 days differentiation can express cholangiocyte marker CK19 and hepatic progenitor markers CK8 and CK18 (Table 3), mimicking the bipotential capacity in differentiation to biliary epithelial cells and hepatocytes, respectively. Expression of the hepatocyte-enriched transcription factor cluster, including Foxa2, Hnf1 α , Hnf4 α , and Hnf6, can represent a milestone of the hepatoblastic differentiation, directing the parenchymal hepatoblasts into hepatocytes and promoting hepatocyte maturation. For metabolism, expression of hepatobiliary excretion transporter MRP2 (ABCC2) and hepatic gap junction protein Cx32 can facilitate the transport of various molecules across cellular membranes. An upregulation of HHEX, however, can implicate the presence of hematopoietic capacity in the hepatoblasts.

[0052] In some aspects, implanted hTS cell-derived hepatocyte-like cells can survive to reach a subject's liver after intravenous transplantation. In some embodiments, the cells herein have a homing instinct. In some embodiments, these cells can express HLA-G, a nonclassical HLA class I molecule, which, membrane-bound or soluble, strongly acts on different immune cell types (NK, T, B, monocytes/dendritic cells) to inhibit both innate and adaptive immunity through the interaction with the inhibitory receptors that are expressed at the surface of immune cells. Additionally, these hepatocyte-like cells can enable to recruit CD4⁺Foxp3⁺ regulatory T (Treg) cell population postimplantation, contributing to the generation of an immunosuppressive

environment by the inhibition of proinflammatory T cells and the induction of T cells with a regulatory. In some embodiments, hTS cell-derived hepatocyte-like cells possess immune privilege.

[0053] In some aspects, provided herein are compositions and methods for transplanting hepatocyte or hepatocyte-like cells to subjects. In some embodiments, the subject is injected by hTS cell-derived hepatocytes (e.g., intravenously, intramuscularly, transdermally, endoscopic retrograde injection, or intraperitoneally). In some embodiments, the subject is not treated with an immunosuppressive agent prior to the transplanting. In some embodiments, the method further comprises treating the patient with an immunosuppressive agent, e.g., FK-506, cyclosporin, or GAD65 antibodies.

Certain Terminology

[0054] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the claimed subject matter belongs. It is to be understood that the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of any subject matter claimed. In this application, the use of the singular includes the plural unless specifically stated otherwise. It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. In this application, the use of “or” means “and/or” unless stated otherwise. Furthermore, use of the term “including” as well as other forms, such as “include,” “includes,” and “included,” is not limiting.

[0055] As used herein, ranges and amounts can be expressed as “about” a particular value or range, e.g., $\pm 15\%$ of a referenced numeral value. About also includes the exact amount. Hence “about 5 μL ” means “about 5 μL ” and also “5 μL .” Generally, the term “about” includes an amount that would be expected to be within experimental error.

[0056] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

Overview

[0057] Liver possesses a dynamic range of functions including detoxification, protein synthesis, protein storage, and production of biochemical components necessary for digestion. It comprises two major types of cells, parenchymal and non-parenchymal cells. Parenchymal cells make up about 80% of the liver volume and are also referred to as hepatocytes. Non-

parenchymal cells contribute to about 6.5% of liver volume, but constitute to about 40% of the total number of liver cells. In some instances, non-parenchymal cells comprise sinusoidal hepatic endothelial cells, Kupffer cells, and hepatic stellate cells.

Hepatocytes

[0058] Hepatocytes, or parenchymal cells, are responsible for the function of the liver. In some instances, hepatocytes are involved in protein synthesis, protein storage, synthesis of cholesterol, bile salts and phospholipids, formation and secretion of bile, carbohydrate metabolism, and detoxification, modification, and excretion of exogenous and endogenous substances.

[0059] In some instances, proteins synthesized from the hepatocytes include major plasma proteins such as human serum albumin, soluble plasma fibronectin, α -fetoprotein, C-reactive protein, and several globulins; proteins involved in hemostasis and fibrinolysis such as coagulation factors involved in the coagulation cascade, α 2-macroglobulin, α 1-antitrypsin, antithrombin III, protein S, protein C, plasminogen, α 2-antiplasmin, and complement component 3; carrier proteins such as albumin, ceruloplasmin, transcortin, haptoglobin, hemopexin, IGF binding rotein, major urinary proteins, retinol binding protein, sex hormone-binding globulin, transthyretin, transferrin, and Vitamin D-binding protein; hormones such as insulin-like growth factor 1, thrombopoietin, hepcidin, and betatrophin; prohormones such as angiotensinogen; and apolipoproteins.

[0060] In addition to formation, breakdown, and interconversion of carbohydrates, in some instances, carbohydrate metabolism also involves gluconeogenesis, glycogenolysis, and glycogenesis. Gluconeogenesis is the synthesis of glucose from certain amino acids, lactate or glycerol. Glycogenolysis is the breakdown of glycogen into glucose. Glycogenesis is the formation of glycogen from glucose.

[0061] In some instances, lipid metabolism within hepatocytes includes cholesterol synthesis and lipogenesis, the production of triglycerides or fats.

[0062] In some cases, after injuries such as tissue damage or tissue loss, hepatocytes can re-enter the cell cycle leading to proliferation and subsequent regeneration of the injured portion, such as the damaged or lost tissue. In some instances after the removal of liver tissue, the remaining hepatocytes undergo at least one, two, three, or more rounds of DNA synthesis leading to regeneration of the lost tissue mass.

[0063] In some embodiments, hepatocytes are utilized for pharmaceutical research. In some embodiments, these researches include drug metabolism, enzyme induction, hepatotoxicity, hepatocyte regeneration, and transplantation.

[0064] The term hepatocyte refers to a hepatic cell or hepatic progenitor cell that has one or more functions of: synthesis of fatty acids, triglycerides, cholesterol, bile salts, or phospholipids; detoxification, modification, and excretion of exogenous or endogenous compounds (e.g., drug, insecticide, steroid, ammonia, heavy metal, or toxin); carbohydrate metabolism; synthesis of proteins (e.g., serum albumin, fibrinogen, lipoprotein, apoprotein, ceruloplasmin, transferrin, complement, or glycoprotein); protein storage; or formation or secretion of bile. In some instances, a hepatocyte can be a hepatic progenitor cell (e.g., hepatocyte-like cell) or a hepatocyte derived from a stem cell; a hepatic stem cell; or a primary hepatocyte (e.g., are or comparable to freshly isolated or uncultured, cryopreserved hepatocytes obtained from a liver).

[0065] In some embodiments, a hepatic stem cell is a small epithelial cell adhesion molecule-expressing (EpCAM-expressing) cell that constitutes about 0.5%-2.5% of the liver parenchyma. In some embodiments, the stem cell includes, but is not limited to, embryonic stem cell, adult stem cell, inducible pluripotent stem (iPS) cell, parthenogenetic stem cells, or trophoblast stem cell. In some embodiments, the stem cell is a human stem cell. In some embodiments, the stem cell is a trophoblast stem cell. In some embodiments, the trophoblast stem cell is a human trophoblast stem cell. In some embodiments, the human trophoblast stem cell is an ectopic pregnancy-derived human trophoblast stem cell. In some instances, a hepatocyte derived from a stem cell is also referred to as an induced hepatocyte. In some embodiments, an induced hepatocyte is derived from a human trophoblast stem cell. In some embodiments, an induced hepatocyte is derived from an ectopic pregnancy-derived human trophoblast stem cell. In some embodiments, an induced hepatocyte comprises a trophoblast stem cell undergoing the process of differentiation into a hepatocyte, and a differentiated trophoblast stem cell. In some embodiments, a trophoblast stem cell undergoing the process of differentiation into a hepatocyte is also referred to as an immature induced hepatocyte. In some embodiments, a differentiated trophoblast stem cell is also referred to as a mature induced hepatocyte.

[0066] In some embodiments, an induced hepatocyte functions similarly to a primary hepatocyte. In some embodiments, an induced hepatocyte comprises cellular functions exhibited by a primary hepatocyte. In some embodiments, an induced hepatocyte participates in cellular functions such as for example protein synthesis, protein storage, synthesis of cholesterol, bile salts and phospholipids, formation and secretion of bile, carbohydrate metabolism, and detoxification, modification, and excretion of exogenous and endogenous substances, which are observed in a primary hepatocyte. In some embodiments, hepatocytes herein express a subset of surface markers including ASGR1, CXCR4, BSEP, MRP2, and Cx32 and construct a polygonal cell shape similar to the primary human hepatocyte, e.g., a similar ultrastructure to primary

hepatocyte, including a large cytoplasm to nucleus ratio, plenty of mitochondria, well-organized endoplasmic reticulum, tight junction, numerous lipid vacuoles, glycogen storage, enlarged lumen of the bile canaliculus with junctional complexes, and multiplex ECMs.

[0067] In some instances, proteins synthesized from an induced hepatocyte include major plasma proteins such as human serum albumin, soluble plasma fibronectin, α -fetoprotein, C-reactive protein, and several globulins; proteins involved in hemostasis and fibrinolysis such as coagulation factors involved in the coagulation cascade, α 2-macroglobulin, α 1-antitrypsin, antithrombin III, protein S, protein C, plasminogen, α 2-antiplasmin, and complement component 3; carrier proteins such as albumin, ceruloplasmin, transcortin, haptoglobin, hemopexin, IGF binding protein, major urinary proteins, retinol binding protein, sex hormone-binding globulin, transthyretin, transferrin, and Vitamin D-binding protein; hormones such as insulin-like growth factor 1, thrombopoietin, hepcidin, and betatrophin; prohormones such as angiotensinogen; and apolipoproteins.

[0068] In some embodiments, carbohydrate metabolism such as the formation, breakdown, and interconversion of carbohydrates, gluconeogenesis, glycogenolysis, glycogenesis, lipid metabolism including cholesterol synthesis, and lipogenesis, the production of triglycerides or fats, are observed in an induced hepatocyte.

[0069] In some embodiments, an induced hepatocyte comprises similar ultrastructure, or the cellular makeup, as a primary hepatocyte. In some instances, this is achieved through comparison based on transmission electron microscopy images.

[0070] In some embodiments, an induced hepatocyte is utilized for pharmaceutical research, such as drug metabolism, enzyme induction, hepatotoxicity, hepatocyte regeneration, and transplantation.

Trophoblast Stem Cells (hTS Cells)

[0071] Trophoblast stem cells (TS cells) are precursors of differentiated placenta cells. In some instances, a TS cell is derived from a blastocyst polar trophoderm (TE) or an extraembryonic ectoderm (ExE) cell. In some cases, TS is capable of indefinite proliferation *in vitro* in an undifferentiated state, and is capable of maintaining the potential multilineage differentiation capabilities *in vitro*. In some instances, a TS cell is a mammalian TS cell. Exemplary mammals include mouse, rat, rabbit, sheep, cow, cat, dog, monkey, ferret, bat, kangaroo, seals, dolphin, and human. In some embodiments, a TS cell is a human TS (hTS) cell.

[0072] In some instances, TS cells are obtained from fallopian tubes. Fallopian tubes are the site of fertilization and the common site of ectopic pregnancies, in which biological events such

as the distinction between inner cell mass (ICM) and trophectoderm and the switch from totipotency to pluripotency with major epigenetic changes take place. In some instances, these observations provide support for fallopian tubes as a niche reservoir for harvesting blastocyst-associated stem cells at the preimplantation stage. Blastocyst is an early-stage preimplantation embryo, and comprises ICM which subsequently forms into the embryo, and an outer layer termed trophoblast which gives rise to the placenta.

[0073] In some embodiments, a TS cell is a stem cell used for generation of a progenitor cell such as for example a hepatocyte. In some embodiments, a TS cell is derived from ectopic pregnancy. In some embodiments, the TS cell is a human TS cell. In one embodiment, the human TS cell derived from ectopic pregnancies does not involve the destruction of a human embryo. In another embodiment, the human TS cell derived from ectopic pregnancies does not involve the destruction of a viable human embryo. In another embodiment, the human TS cell is derived from trophoblast tissue associated with non-viable ectopic pregnancies. In another embodiment, the ectopic pregnancy cannot be saved. In another embodiment, the ectopic pregnancy would not lead to a viable human embryo. In another embodiment, the ectopic pregnancy threatens the life of the mother. In another embodiment, the ectopic pregnancy is tubal, abdominal, ovarian or cervical.

[0074] During normal blastocyst development, ICM contact per se or its derived diffusible 'inducer' triggers a high rate of cell proliferation in the polar trophectoderm, leading to cell movement toward the mural region throughout the blastocyst stage and can continue even after the distinction of the trophectoderm from the ICM. The mural trophectoderm cells overlaying the ICM are able to retain a 'cell memory' of ICM. At the beginning of the implantation, the mural cells opposite the ICM cease division because of the mechanical constraints from the uterine endometrium. However, in an ectopic pregnancy in which the embryo is located within the fallopian tube, constraints do not exist in the fallopian tubes which result in continuing division of polar trophectoderm cells to form extraembryonic ectoderm (ExE) in the stagnated blastocyst. In some instances, the ExE-derived TS cells exist for up to 20 days in a proliferation state. As such, until clinical intervention occurs, the cellular processes can yield an indefinite number of hTS cells in the preimplantation embryos and such cells can retain cell memory from ICM.

[0075] In some instances, TS cells possess specific genes of ICM (e.g. OCT4, NANOG, SOX2, FGF4) and trophectoderm (e.g. CDX2, Fgfr-2, Eomes, BMP4), and express components of the three primary germ layers, mesoderm, ectoderm, and endoderm. In some instances, TS cells express embryonic stem (e.g. human embryonic stem) cell-related surface markers such as specific stage embryonic antigen (SSEA)-1, -3 and -4 and mesenchymal stem cell-related

markers (CD 44, CD90, CK7 and Vimentin). In other instances, hematopoietic stem cell markers (CD34, CD45, α 6-integrin, E-cadherin, and L-selectin) are not expressed.

Methods of Preparation of Induced Hepatocytes

[0076] Disclosed herein, in certain embodiments, is a method of inducing a trophoblast stem (TS) cell to differentiate into an induced hepatocyte *in vitro*, which comprises contacting the trophoblast stem cell in a conditioned medium comprising a fibroblast growth factor (FGF), a steroid, and a cytokine; and incubating the cell for a sufficient time to induce differentiation of the trophoblast stem cell into an induced hepatocyte. In some embodiments, the TS cell is a human TS (hTS) cell. In some embodiments, the FGF, the steroid, and the cytokine are human FGF, human steroid, and human cytokine.

[0077] In some embodiments, fibroblast growth factors (FGFs) are a family of growth factors involved in angiogenesis, wound healing, embryonic development, and cellular proliferation and differentiation processes. In some instances, FGFs are heparin-binding proteins and interact with heparin sulfate proteoglycans. In some instances, there are 22 members of the FGF family. Exemplary FGFs include: FGF1, FGF2 (also known as basic FGF or bFGF or FGF- β), FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9, FGF10, FGF11, FGF12, FGF13, FGF14, FGF16, FGF17, FGF18, FGF15/19, FGF20, FGF21, FGF22, and FGF23. In some embodiments, the fibroblast growth factor is basic fibroblast growth factor (bFGF, also known as FGF2 or FGF- β). In some embodiments, the bFGF is a human bFGF. In some embodiments, the human bFGF is a recombinant human bFGF, or a fragment thereof.

[0078] In some embodiments, FGF is introduced into the cultured medium at a concentration of between about 0.001 and about 5000 ng/mL, about 0.01 and about 500 ng/mL, about 0.1 and about 100 ng/mL, or about 1 and about 50 ng/mL.

[0079] In some instances, FGF is introduced into the cultured medium at a concentration of at least 0.001, 0.01, 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 100, 200, 300, 400, 500, 1000 ng/mL or more. In some embodiments, FGF is introduced into the cultured medium at a concentration of at most 0.001, 0.01, 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 100, 200, 300, 400, 500, 1000 ng/mL or less.

[0080] In some embodiments, bFGF is introduced into the cultured medium at a concentration of between about 0.001 and about 5000 ng/mL, about 0.01 and about 500 ng/mL, about 0.1 and about 100 ng/mL, or about 1 and about 50 ng/mL.

[0081] In some instances, FGF is introduced into the cultured medium at a concentration of at least 0.001, 0.01, 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 100, 200, 300, 400, 500, 1000 ng/mL or more. In some embodiments, bFGF is introduced into the cultured medium at a concentration of at most 0.001, 0.01, 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 100, 200, 300, 400, 500, 1000 ng/mL or less.

[0082] In some embodiments, a fibroblast growth factor is introduced into the cultured medium comprising hTS cells to initiate hTS cell differentiation event. In some embodiments, the fibroblast growth factor is bFGF. In some embodiments, a steroid and a cytokine are introduced into the cultured medium after the addition of FGF (e.g. bFGF).

[0083] In some embodiments, a steroid is a chemical involved in a wide range of physiological processes such as stress response, immune response, regulation of inflammation, carbohydrate metabolism, protein catabolism, blood electrolyte levels, and behaviors. In some instances, steroids also include steroid hormones, such as glucocorticoids, mineralocorticoids, androgens, estrogens, and progestogens. In some embodiments, steroids include, but are not limited to, hydrocortisone types such as hydrocortisone, hydrocortisone acetate, cortisone acetate, tixocortol pivalate, prednisolone, methylprednisolone, and prednisone; acetonides such as triamcinolone acetonide, triamcinolone alcohol, mometasone, amcinonide, budesonide, desonide, fluocinonide, fluocinolone acetonide, and halcinonide; betamethasone types such as betamethasone, betamethasone sodium phosphate, dexamethasone, dexamethasone sodium phosphate, and fluocortolone; halogenated such as hydrocortisone-17-valerate, halometasone, alclometasone dipropionate, betamethasone valerate, betamethasone dipropionate, prednicarbate, clobetasone-17-butyrate, clobetasol-17-propionate, fluocortolone caproate, fluocortolone pivalate, and fluprednidene acetate; labile prodrug esters such as hydrocortisone-17-butyrate, hydrocortisone-17-aceponate, hydrocortisone-17-buteprate, ciclesonide, and prednicarbate. In some embodiments, a steroid is a naturally derived or chemically modified steroid. In some embodiments, a steroid is dexamethasone, betamethasone, prednisolone, methylprednisolone, triamcinolone acetonide, triamcinolone alcohol, or hydrocortisone. In some embodiments, a steroid is dexamethasone. As used herein, the term “dexamethasone” refers to dexamethasone and its derivatives. In some embodiments, dexamethasone is utilized for directing an hTS cell to differentiate into hepatic lineage. In some embodiments, dexamethasone is utilized in combination with another agent for directing an hTS cell to differentiate into hepatic lineage. In some embodiments, the another agent is a cytokine.

[0084] In some embodiments, a steroid is introduced into the cultured medium at a concentration of between about 0.001 and about 100 μM , about 0.005 and about 5 μM , about 0.01 and about 1 μM , or about 0.05 and about 0.5 μM .

[0085] In some instances, a steroid is introduced into the cultured medium at a concentration of at least 0.001, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.25, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10 μM , or more. In some embodiments, a steroid is introduced into the cultured medium at a concentration of at most 0.001, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.25, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10 μM , or less.

[0086] In some embodiments, dexamethasone is introduced into the cultured medium at a concentration of between about 0.001 and about 100 μM , about 0.005 and about 5 μM , about 0.01 and about 1 μM , or about 0.05 and about 0.5 μM .

[0087] In some embodiments, dexamethasone is introduced into the cultured medium at a concentration of at least 0.001, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.25, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10 μM , or more. In some embodiments, dexamethasone is introduced into the cultured medium at a concentration of at most 0.001, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.25, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10 μM , or less.

[0088] In some embodiments, a cytokine is a category of small proteins between about 5-20kDa that are involved in cell signaling. In some instances, cytokines include chemokines, interferons, interleukins, and tumor necrosis factors. Chemokines can play a role as a chemoattractant to guide the migration of cells, and can be classified into four subfamilies: CXC, CC, CX3C, and XC. Exemplary chemokines include chemokines from the CC subfamily: CCL1, CCL2 (MCP-1), CCL3, CCL4, CCL5 (RANTES), CCL6, CCL7, CCL8, CCL9 (or CCL10), CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, and CCL28; the CXC subfamily: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, and CXCL17; the XC subfamily: XCL1 and XCL2; and the CX3C subfamily CX3CL1.

[0089] Interferons (IFNs) comprise interferon type I (e.g. IFN- α , IFN- β , IFN- ϵ , IFN- κ , and IFN- ω), interferon type II (e.g. IFN- γ), and interferon type III. In some embodiments, IFN- α is

further classified into about 13 subtypes including IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, and IFNA21.

[0090] Interleukins are expressed by leukocytes or white blood cells and they promote the development and differentiation of T and B lymphocytes and hematopoietic cells. Exemplary interleukins include IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IL-35, and IL-36.

[0091] Tumor necrosis factors (TNFs) are a group of cytokines that modulate apoptosis. In some instances, there are about 19 members within the TNF family, including, not limited to, TNF α , lymphotoxin-alpha (LT-alpha), lymphotoxin-beta (LT-beta), T cell antigen gp39 (CD40L), CD27L, CD30L, FASL, 4-1BBL, OX40L, and TNF-related apoptosis inducing ligand (TRAIL).

[0092] In some embodiments, dexamethasone is utilized in combination with a cytokine for directing an hTS cell to differentiate into hepatic lineage. In some instances, the cytokine is a chemokine, an interferon, an interleukin, or a tumor necrosis factor. In some instances, the cytokine is an interleukin. In some embodiments, dexamethasone is utilized in combination with an interleukin for directing an hTS cell to differentiate into hepatic lineage. In some embodiments, the interleukin is IL-6. In some instances, IL-6 is further grouped with additional cytokines based on its interaction through the Gp130 receptor sub-unit. In some instances, additional members of the IL-6 group include oncostatin M (OSM), IL-11, Ciliary neurotropic factor (CNTF), Cardiotrophin-1 (CT-1), Cardiotrophin-like cytokine (CLC), and Leukaemia inhibitory factor (LIF). In some embodiments, dexamethasone is utilized in combination with IL-6 for directing an hTS cell to differentiate into hepatic lineage. In some embodiments, dexamethasone is utilized in combination with a member of the IL-6 group for directing an hTS cell to differentiate into hepatic lineage. In some embodiments, dexamethasone is utilized in combination with OSM, IL-11, CNTF, CT-1, CLC, or LIF for directing an hTS cell to differentiate into hepatic lineage. In some embodiments, dexamethasone is utilized in combination with OSM for directing an hTS cell to differentiate into hepatic lineage. In some embodiments, the IL-6 group of cytokines is human IL-6 cytokines or their fragments thereof. In some embodiments, OSM is a human OSM. In some embodiments, the human OSM is a recombinant human OSM, or its fragments thereof.

[0093] In some embodiments, a cytokine is introduced into the cultured medium at a concentration of between about 0.001 and about 5000 ng/mL, about 0.01 and about 500 ng/mL, about 0.1 and about 100 ng/mL, or about 1 and about 50 ng/mL.

[0094] In some embodiments, a cytokine is introduced into the cultured medium at a concentration of at least 0.01, 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 100, 200, 300, 400, 500, 1000 ng/mL or more. In some embodiments, a cytokine is introduced into the cultured medium at a concentration of at most 0.01, 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 100, 200, 300, 400, 500, 1000 ng/mL or less.

[0095] In some embodiments, OSM is introduced into the cultured medium at a concentration of between about 0.001 and about 5000 ng/mL, about 0.01 and about 500 ng/mL, about 0.1 and about 100 ng/mL, or about 1 and about 50 ng/mL.

[0096] In some embodiments, OSM is introduced into the cultured medium at a concentration of at least 0.01, 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 100, 200, 300, 400, 500, 1000 ng/mL or more. In some embodiments, OSM is introduced into the cultured medium at a concentration of at most 0.01, 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 100, 200, 300, 400, 500, 1000 ng/mL or less.

[0097] In some embodiments, a fibroblast growth factor (e.g. bFGF) modulates the expression of a biomarker within an hTS cell. In some embodiments, the biomarker is a microRNA (miR). In some embodiments, the biomarker is miRNA-124a. In some embodiments, the fibroblast growth factor is bFGF. In some embodiments, bFGF upregulates or activates miRNA-124a. In some embodiments, bFGF downregulates miRNA-124a.

[0098] In some embodiments, the expression level of miRNA-124a in a bFGF treated trophoblast stem cell is compared to the expression level of miRNA-124a in an untreated trophoblast stem cell. In some embodiments, the expression level of miRNA-124a is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 1000 fold, or more in a bFGF treated trophoblast stem cell relative to the expression level of miRNA-124a in an untreated trophoblast stem cell. In some embodiments, the expression level of miRNA-124a is at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 1000 fold, or less in a bFGF treated trophoblast stem cell relative to the expression level of miRNA-124a in an untreated trophoblast stem cell.

[0099] In some embodiments, activation or upregulation of miRNA-124a initiates definitive endoderm (DE) specification in the trophoblast stem cell. In some embodiments, the DE specification occurs between about 0.1 and about 96 hours, about 0.5 and about 36 hours, about 1 and about 24 hours, about 2 and about 18 hours, about 4 and about 12 hours, or about 6 and about 10 hours.

[00100] In some embodiments, the DE specification occurs at least 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 36, 48, 72 hours, or more after induction with bFGF. In some embodiments, the DE specification occurs at most 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 36, 48, 72 hours, or less after induction with bFGF. In some embodiments, the DE specification occurs about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 hours post induction with bFGF. In some embodiments, the DE specification occurs about 6, 7, 8, 9, or 10 hours post induction with bFGF.

[00101] In some embodiments, the DE specification is associated with a set of biomarkers. In some embodiments, the biomarkers include forkhead box protein A2 (FOXA2), SRY-box 17 (SOX17), Goosecoid (GSC), Homeodomain protein MIXL1, SRY-box 2 (SOX2), transcription factor NANOG, and OCT4. In some embodiments, the DE specification is characterized by an elevated expression of biomarkers selected from forkhead box protein A2 (FOXA2), SRY-box 17 (SOX17), Goosecoid (GSC), Homeodomain protein MIXL1, SRY-box 2 (SOX2), transcription factor NANOG, and OCT4. In some embodiments, the DE specification is characterized by an elevated expression of biomarkers selected from forkhead box protein A2 (FOXA2), SRY-box 17 (SOX17), Goosecoid (GSC), SRY-box 2 (SOX2), transcription factor NANOG, and OCT4. In some embodiments, the DE specification is characterized by a decreased expression of biomarkers selected from forkhead box protein A2 (FOXA2), SRY-box 17 (SOX17), Goosecoid (GSC), Homeodomain protein MIXL1, SRY-box 2 (SOX2), transcription factor NANOG, and OCT4. In some embodiments, the DE specification is characterized by a decreased expression of Homeodomain protein MIXL1.

[00102] In some embodiments, the expression levels of FOXA2, SOX17, GSC, MIXL1, SOX2, NANOG, and OCT4 in a bFGF induced trophoblast stem cell are compared to the expression levels of FOXA2, SOX17, GSC, MIXL1, SOX2, NANOG, and OCT4 in an uninduced trophoblast stem cell. In some embodiments, the elevated expression level is an increased protein expression level. In some embodiments, the protein expression levels of FOXA2, SOX17, GSC, MIXL1, SOX2, NANOG, and OCT4 are between about 1 and about 20,000 fold, about 2 and about 1000 fold, or about 10 and about 100 fold higher than the protein expression levels of FOXA2, SOX17, GSC, MIXL1, SOX2, NANOG, and OCT4 in an untreated trophoblast stem cell. In some embodiments, the protein expression levels of FOXA2, SOX17, GSC, MIXL1, SOX2, NANOG, and OCT4 are at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 1000, 10,000 fold, or more in a bFGF treated trophoblast stem cell relative to the protein expression levels of FOXA2, SOX17, GSC, MIXL1, SOX2, NANOG, and OCT4 in an untreated

trophoblast stem cell. In some embodiments, the protein expression levels of FOXA2, SOX17, GSC, MIXL1, SOX2, NANOG, and OCT4 are at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 1000, 10,000 fold, or less in a bFGF treated trophoblast stem cell relative to the protein expression levels of FOXA2, SOX17, GSC, MIXL1, SOX2, NANOG, and OCT4 in an untreated trophoblast stem cell.

[00103] In some embodiments, the elevated expression level is an increased gene expression level. In some embodiments, the gene expression levels of FOXA2, SOX17, GSC, MIXL1, SOX2, NANOG, and OCT4 are between about 1 and about 20,000 fold, about 2 and about 1000 fold, or about 10 and about 100 fold higher than the gene expression levels of FOXA2, SOX17, GSC, MIXL1, SOX2, NANOG, and OCT4 in an untreated trophoblast stem cell. In some embodiments, the gene expression levels of FOXA2, SOX17, GSC, MIXL1, SOX2, NANOG, and OCT4 are at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 1000, 10,000 fold, or more in a bFGF treated trophoblast stem cell relative to the gene expression levels of FOXA2, SOX17, GSC, MIXL1, SOX2, NANOG, and OCT4 in an untreated trophoblast stem cell. In some embodiments, the gene expression levels of FOXA2, SOX17, GSC, MIXL1, SOX2, NANOG, and OCT4 are at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 1000, 10,000 fold, or less in a bFGF treated trophoblast stem cell relative to the gene expression levels of FOXA2, SOX17, GSC, MIXL1, SOX2, NANOG, and OCT4 in an untreated trophoblast stem cell.

[00104] In some embodiments, a cocktail of a steroid and a cytokine is utilized to direct DE differentiation into hepatic lineage. In some embodiments, the cocktail comprise dexamethasone and oncostatin M is utilized to direct DE differentiation into hepatic lineage. In some embodiments, the cocktail is introduced into a cultured medium comprising hTS cells before, after, or simultaneously with the addition of bFGF. In some embodiments, the cocktail is introduced into a cultured medium comprising hTS cells between about 0.5 and about 96 hours, about 1 and about 48 hours, about 2 and about 36 hours, about 3 and about 24 hours, about 4 and about 12 hours, or about 6 and about 10 hours.

[00105] In some embodiments, the cocktail is introduced into a cultured medium comprising hTS cells at least 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 36, 48, 60, 72 hours, or more after addition of bFGF. In some embodiments, the cocktail is introduced into a cultured medium comprising hTS cells at most 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 36, 48, 60, 72 hours, or less after addition of bFGF. In some embodiments, the cocktail is introduced into a cultured medium comprising hTS cells about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 hours after addition of bFGF. In

some embodiments, the cocktail is introduced into a cultured medium comprising hTS cells about 6, 7, 8, 9, 10, 11, or 12 hours after addition of bFGF.

[00106] In some embodiment, a hTS cell is incubated in a cultured medium comprising bFGF, dexamethasone and oncostatin M for between about 0.5 and about 100 days, about 1 and about 50 days, about 2 and about 30 days, about 3 and about 15 days, or about 4 and about 12 days.

[00107] In some embodiment, an hTS cell is incubated in a cultured medium comprising bFGF, dexamethasone and oncostatin M for at least 0.5 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 days or more. In some embodiment, an hTS cell is incubated in a cultured medium comprising bFGF, dexamethasone and oncostatin M for at most 0.5 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 days or less.

[00108] In some embodiments, the trophoblast stem cell is classified into four stages of hepatocyte-like cell development. In some embodiments, the four stages include primitive streak to DE stage, hepatic specified endoderm, hepatoblastic stage, and the fetal and adult hepatocyte-like cell stage. In some embodiments, each of the four stages are associated with a set of biomarkers comprising C-X-C chemokine receptor type 4 (CXCR4), Forkhead box protein A2 (FOXA2), SRY-box 17 (SOX17), hexosaminidase A (alpha polypeptide) (HHEX), bile salt export pump (BSEP), transthyretin (TTR), albumin (ALB), tyrosine aminotransferase (TAT), cytochrome P450 7A1 (CYP7A1), glucose-6-phosphatase (G6PC), serpin peptidase inhibitor clade A (alpha-1 antiproteinase, antitrypsin) member 1 (SERPINA1), ATP-binding cassette sub-family C (ABCC2), CCAAT-enhancer-binding protein beta (C/EBP β), hepatocyte nuclear factor 1-alpha (HNF1 α), hepatocyte nuclear factor 4-alpha (HNF4 α), alpha-1-fetoprotein (AFP), keratin 8 (KRT8), phosphoenolpyruvate carboxykinase 2 mitochondrial (PCK2), cytochrome P450 2B6 (CYP2B6), glycogen synthase 2 (GYS2), hepatocyte nuclear factor 6 (HNF6), carbamoyl-phosphate synthase 1 mitochondrial (CPS1), alcohol dehydrogenase 1C (class I) gamma polypeptide (ADH1C), connexin 32 (CX32), cytochrome P450 3A4 (CYP3A4), prospero homeobox 1 (PROX1), tryptophan 2,3-dioxygenase (TDO2), apolipoprotein F (APOF), keratin 18 (KRT18), keratin 19 (KRT19), or chromosome 19 open reading frame 80 (angiopoietin-like protein 8, hepatocellular carcinoma-associated gene TD26, lipasin) (Betatrophin). In some embodiments, each of the four stages are associated with a set of biomarkers comprising CXCR4, FOXA2, SOX17, HHEX, TTR, ALB, TAT, CYP7A1, BSEP, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , or HNF4 α .

[00109] In some instances, the primitive streak to DE stage is a stage in which an hTS cell that has not entered a hepatic differentiation stage or is about to enter a hepatic differentiation stage. In some embodiments, an hTS cell at the primitive streak to DE stage undergoes DE

specification. In some instances after induction with a FGF (e.g. bFGF), a hTS cell remains in the primitive streak to DE stage for between about 0.1 and about 24 hours, about 0.5 and about 18 hours, or about 1 and about 12 hours. In some instances after induction with a FGF (e.g. bFGF), a hTS cell remains in the primitive streak to DE stage for at most 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 hours or less. In some instances after induction with a FGF (e.g. bFGF), an hTS cell remains in the primitive streak to DE stage for at least 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 hours or more.

[00110] In some instances, a hTS cell in the primitive streak to DE stage is characterized with a set of biomarkers selected from CXCR4, FOXA2, SOX17, HHEX, BSEP, TTR, ALB, TAT, CYP7A1, G6PC, SERPINA1, ABCC2, C/EBP β , HNF1 α , HNF4 α , AFP, KRT8, PCK2, CYP2B6, GYS2, HNF6, CPS1, ADH1C, CX32, CYP3A4, PROX1, TDO2, APOF, KRT18, KRT19, and Betatrophin. In some embodiments, the primitive streak to DE stage is associated with a set of biomarkers selected from CXCR4, FOXA2, SOX17 and HHEX.

[00111] In some embodiments, the primitive streak to DE stage is associated with elevated expression levels of CXCR4, FOXA2, SOX17 and HHEX. In some embodiments, the elevated expression level is an increased protein expression level or an increased gene expression level. In some embodiments, the elevated expression level is an increased gene expression level. In some embodiments, the elevated gene expression levels of CXCR4, FOXA2, SOX17 and HHEX are relative to the gene expression levels of CXCR4, FOXA2, SOX17 and HHEX in an equivalent trophoblast stem cell which has not entered the primitive streak to DE stage. In some embodiments, the elevated gene expression levels of CXCR4, FOXA2, SOX17 and HHEX are between about 0.1 and about 10,000, about 1 and about 5000, or about 2 and about 1000. In some embodiments, the elevated gene expression levels of CXCR4, FOXA2, SOX17 and HHEX are at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 1000, 5000 fold, or more relative to the gene expression levels of CXCR4, FOXA2, SOX17 and HHEX in an equivalent hTS cell which has not entered the primitive streak to DE stage. In some embodiments, the gene expression levels of CXCR4, FOXA2, SOX17 and HHEX are at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 1000, 5000 fold, or less relative to the gene expression levels of CXCR4, FOXA2, SOX17 and HHEX in an equivalent hTS cell which has not entered the primitive streak to DE stage.

[00112] In some instances, the hepatic specified endoderm characterizes the first appearance of epithelium cells after hepatic specification. In some embodiments, the hepatic specified endoderm stage is initiated with the addition of a cocktail of steroid (e.g. dexamethasone) and cytokine (e.g. oncostatin M). In some instances, the cocktail of steroid (e.g. dexamethasone) and

cytokine (e.g. oncostatin M) is added to the cultured medium at between about 1 and about 48 hours, about 2 and about 24 hours, about 3 and about 18 hours, or about 4 and about 12 hours. In some instances, the cocktail of steroid (e.g. dexamethasone) and cytokine (e.g. oncostatin M) is added to the cultured medium at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 hours, or more post induction of a FGF (e.g. bFGF). In some instances, the cocktail of steroid (e.g. dexamethasone) and cytokine (e.g. oncostatin M) is added to the cultured medium at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 hours, or less post induction of a FGF (e.g. bFGF).

[00113] In some cases after induction with the cocktail of steroid (e.g. dexamethasone) and cytokine (e.g. oncostatin M), a hTS cell remains in the hepatic specified endoderm stage for between about 1 and about 72 hours, about 2 and about 36 hours, about 3 and about 24 hours, or about 4 and about 12 hours. In some cases after induction with the cocktail of steroid (e.g. dexamethasone) and cytokine (e.g. oncostatin M), a hTS cell remains in the hepatic specified endoderm stage for at least 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 hours, or more. In some cases after induction with the cocktail of steroid (e.g. dexamethasone) and cytokine (e.g. oncostatin M), a hTS cell remains in the hepatic specified endoderm stage for at most 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 hours, or less.

[00114] In some instances, a hTS cell in the hepatic specified endoderm stage is characterized with a set of biomarkers selected from CXCR4, FOXA2, SOX17, HHEX, BSEP, TTR, ALB, TAT, CYP7A1, G6PC, SERPINA1, ABCC2, C/EBP β , HNF1 α , HNF4 α , AFP, KRT8, PCK2, CYP2B6, GYS2, HNF6, CPS1, ADH1C, CX32, CYP3A4, PROX1, TDO2, APOF, KRT18, KRT19, and Betatrophin. In some embodiments, the hepatic specified endoderm is associated with a set of biomarkers selected from SOX17, TTR, ALB, TAT, and CYP7A1.

[00115] In some embodiments, the hepatic specified endoderm is associated with elevated expression levels of SOX17, TTR, ALB, TAT, and CYP7A1. In some embodiments, the elevated expression level is an increased protein expression level or an increased gene expression level. In some embodiments, the elevated expression level is an increased gene expression level. In some embodiments, the elevated gene expression levels of SOX17, TTR, ALB, TAT, and CYP7A1 are relative to the gene expression levels of SOX17, TTR, ALB, TAT, and CYP7A1 in an equivalent trophoblast stem cell which has not entered the hepatic specified endoderm stage. In some embodiments, the gene expression levels of SOX17, TTR, ALB, TAT, and CYP7A1 are between about 1 and about 10,000 fold, about 2 and about 1000 fold, or about 2 and about 100 fold. In some embodiments, the gene expression levels of SOX17, TTR, ALB, TAT, and CYP7A1 are at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 1000, 5000 fold, or more

relative to the gene expression levels of SOX17, TTR, ALB, TAT, and CYP7A1 in an equivalent trophoblast stem cell which has not entered the hepatic specified endoderm stage. In some embodiments, the gene expression levels of SOX17, TTR, ALB, TAT, and CYP7A1 are at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 1000, 5000 fold, or less relative to the gene expression levels of SOX17, TTR, ALB, TAT, and CYP7A1 in an equivalent trophoblast stem cell which has not entered the hepatic specified endoderm stage.

[00116] In some embodiments, a hTS cell enters the hepatoblastic stage after between about 1 and about 36 hours, about 3 and about 24 hours, or about 6 and about 12 hours post addition of a cocktail of steroid (e.g. dexamethasone) and cytokine (e.g. oncostatin M). In some embodiments, a hTS cell enters the hepatoblastic stage after about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours post addition of a cocktail of steroid (e.g. dexamethasone) and cytokine (e.g. oncostatin M).

[00117] In some embodiments, an hTS cell remains in the hepatoblastic stage for between about 1 and about 30 days, about 2 and about 12 days, or about 3 and about 7 days. In some embodiments, an hTS cell remains in the hepatoblastic stage for at most 1, 2, 3, 4, 5, 6, 7, 8 days or less. In some embodiments, an hTS cell remains in the hepatoblastic stage for at least 1, 2, 3, 4, 5, 6, 7, 8 days or more.

[00118] In some instances, a hTS cell in the hepatoblastic stage is characterized with a set of biomarkers selected from CXCR4, FOXA2, SOX17, HHEX, BSEP, TTR, ALB, TAT, CYP7A1, G6PC, SERPINA1, ABCC2, C/EBP β , HNF1 α , HNF4 α , AFP, KRT8, PCK2, CYP2B6, GYS2, HNF6, CPS1, ADH1C, CX32, CYP3A4, PROX1, TDO2, APOF, KRT18, KRT19, and Betatrophin. In some embodiments, the hepatoblastic stage is associated with a set of biomarkers selected from TTR, ALB, TAT, CYP7A1, and BSEP.

[00119] In some embodiments, the hepatoblastic stage is associated with elevated expression levels of TTR, ALB, TAT, CYP7A1, and BSEP. In some embodiments, the elevated expression level is an increased protein expression level or an increased gene expression level. In some embodiments, the elevated expression level is an increased gene expression level. In some embodiments, the elevated gene expression levels of TTR, ALB, TAT, CYP7A1, and BSEP are relative to the gene expression levels of TTR, ALB, TAT, CYP7A1, and BSEP in an equivalent hTS cell which has not entered the hepatoblastic stage. In some embodiments, the gene expression levels of TTR, ALB, TAT, CYP7A1, and BSEP are between about 1 and about 10,000 fold, about 2 and about 1000 fold, or about 2 and about 100 fold.

[00120] In some embodiments, the gene expression levels of TTR, ALB, TAT, CYP7A1, and BSEP are at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 200, 300, 400, 500, 1000, 5000

fold, or more relative to the gene expression levels of TTR, ALB, TAT, CYP7A1, and BSEP in an equivalent hTS cell which has not entered the hepatoblastic stage. In some embodiments, the gene expression levels of TTR, ALB, TAT, CYP7A1, and BSEP are at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 200, 300, 400, 500, 1000, 5000 fold, or less relative to the gene expression levels of TTR, ALB, TAT, CYP7A1, and BSEP in an equivalent hTS cell which has not entered the hepatoblastic stage.

[00121] In some instances, a hTS cell enters the fetal and adult hepatocyte-like stage between about 1 and about 20 days, about 2 and about 10 days, or about 3 and about 6 days post addition of a cocktail of steroid (e.g. dexamethasone) and cytokine (e.g. oncostatin M). In some instances, an hTS cell enters the fetal and adult hepatocyte-like stage after about 1, 2, 3, 4, 5, or 6 days after post addition of a cocktail of steroid (e.g. dexamethasone) and cytokine (e.g. oncostatin M).

[00122] In some embodiments, an hTS cell remains in the fetal and adult hepatocyte-like stage for between about 1 and about 100 days, about 2 and about 50 days, about 3 and about 30 days, about 4 and about 12 days, or about 6 and about 10 days. In some embodiments, an hTS cell remains in the fetal and adult hepatocyte-like stage for at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 60 days or less. In some embodiments, an hTS cell remains in the fetal and adult hepatocyte-like stage for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 60 days or more.

[00123] In some instances, a hTS cell in the fetal and adult hepatocyte-like stage is characterized with a set of biomarkers selected from CXCR4, FOXA2, SOX17, HHEX, BSEP, TTR, ALB, TAT, CYP7A1, G6PC, SERPINA1, ABCC2, C/EBP β , HNF1 α , HNF4 α , AFP, KRT8, PCK2, CYP2B6, GYS2, HNF6, CPS1, ADH1C, CX32, CYP3A4, PROX1, TDO2, APOF, KRT18, KRT19, and Betatrophin. In some embodiments, the fetal and adult hepatocyte-like cell stage is associated with a set of biomarkers selected from HHEX, BSEP, TTR, ALB, TAT, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , and HNF4 α .

[00124] In some embodiments, the fetal and adult hepatocyte-like cell stage is associated with elevated expression levels of HHEX, BSEP, TTR, ALB, TAT, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , and HNF4 α . In some embodiments, the elevated expression level is an increased protein expression level or an increased gene expression level. In some embodiments, the elevated expression level is an increased gene expression level. In some embodiments, the elevated gene expression levels of HHEX, BSEP, TTR, ALB, TAT, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , and HNF4 α are relative to the gene expression level of HHEX, BSEP, TTR, ALB, TAT, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , and HNF4 α in an equivalent hTS cell which has not entered the fetal and adult hepatocyte-like cell stage. In some

embodiments, the gene expression levels of HHEX, BSEP, TTR, ALB, TAT, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , and HNF4 α are between about 1 and about 10,000 fold, about 2 and about 5000 fold, or about 2 and about 1000 fold.

[00125] In some embodiments, the gene expression levels of HHEX, BSEP, TTR, ALB, TAT, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , and HNF4 α are at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 1000, 5000 fold, or more relative to the gene expression levels of HHEX, BSEP, TTR, ALB, TAT, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , and HNF4 α in an equivalent hTS cell which has not entered the fetal and adult hepatocyte-like cell stage. In some embodiments, the gene expression levels of HHEX, BSEP, TTR, ALB, TAT, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , and HNF4 α are at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 1000, 5000 fold, or less relative to the gene expression levels of HHEX, BSEP, TTR, ALB, TAT, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , and HNF4 α in an equivalent hTS cell which has not entered the fetal and adult hepatocyte-like cell stage.

[00126] In some embodiments, a cell in the fetal and adult hepatocyte-like cell stage matures into an induced hepatocyte. In some embodiments, a cell in the fetal and adult hepatocyte-like cell stage is an induced hepatocyte. In some embodiments, the induced hepatocyte does not differentiate further. In some embodiments, the induced hepatocyte reaches a terminally differentiated stage. In some embodiments, the induced hepatocyte remains as a stable cell for up to 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100 generations or more. In some embodiments, the induced hepatocyte remains as a stable cell for up to 7 days, 10 days, 14 days, 21 days, 30 days, 60 days, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 years, 2 years, or more.

Methods of Use

[00127] Described herein, in certain embodiments, are methods of utilizing induced hepatocytes for one or more uses. In some embodiments, induced hepatocytes are utilized for screening a compound for use in treatment or prevention of a disease or disorder. In some embodiments, the screening process involves one or more of studies of the compound, enzyme induction, and toxicity studies. In some embodiments, induced hepatocytes are administered for the treatment of a liver injury, such as a damage or loss of liver tissue due to a liver-associated disease or disorder. In other embodiments, induced hepatocytes are utilized for the production of therapeutic proteins (e.g. hormones), cytokines, cholesterol, carbohydrates, bile, or a combination thereof. In other embodiments, induced hepatocytes are utilized for liver

regeneration. In additional embodiments, induced hepatocytes are utilized as a source for gene therapy.

Induced hepatocytes for screening a compound

[00128] In some embodiments, induced hepatocytes are utilized for screening a compound for use in treatment or prevention of a disease or disorder. In some embodiments, the method comprises contacting an isolated induced hepatocyte with a compound. In some embodiments, the method comprises contacting an isolated primary hepatocyte with the compound. In other embodiments, the method further comprises detecting a change in the activity of at least one biomarker (e.g. gene, transcript or protein) in the induced hepatocytes. In other embodiments, the method further comprises detecting a change in the level of at least one biomarker (e.g. gene, transcript or protein) in primary hepatocytes. In some embodiments, a change in the level of at least one biomarker is a change in the gene expression level of at least one biomarker. In some embodiments, the biomarker comprises a member of the cytochrome P450 superfamily. In some embodiments, the biomarker comprises cytochrome P450 families: CYP1, CYP2, CYP3, CYP4, CYP5, CYP7, CYP8, CYP11, CYP17, CYP19, CYP20, CYP21, CYP24, CYP26, CYP27, CYP39, CYP46, CYP51, and their respective subfamily members. In some embodiments, the biomarker comprises CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4, or CYP7A1.

[00129] In some embodiments, a compound (e.g. a drug) is metabolized through the liver. In some instances, the liver's primary mechanism for metabolizing the compound (e.g. drug) is the P450 cytochrome system of enzymes. In some instances, the rate of metabolizing the compound is too quickly, it may decrease the compound's efficacy. Alternatively, if the rate of metabolizing the compound is too slow, it may allow toxicity to build up in the host cell. Therefore in some instances, the metabolism of a compound is evaluated, such as for example, its toxicity.

[00130] In some instances, the compound acts as an inducer or an inhibitor toward a member of the cytochrome P450 family of enzymes. In some cases, the compound is an inducer toward a member of the cytochrome P450 family of enzymes. In some instances, an inducer initiates or enhances the expression level of an enzyme, such as a member of the cytochrome P450 family of enzymes. In some instances, an inducer initiates or enhances the gene expression level of a member of the cytochrome P450 family of enzymes. In some instances, an inducer initiates or enhances the protein expression level of a member of the cytochrome P450 family of enzymes. In some cases, the compound is an inhibitor toward a member of the cytochrome P450 family of enzymes. In some instances, an inhibitor inhibits, decreases, or interferes with the expression level of an enzyme, such as a member of the cytochrome P450 family of enzymes. In some

instances, an inhibitor inhibits, decreases, or interferes with the gene expression level of a member of the cytochrome P450 family of enzymes. In some instances, an inhibitor inhibits, decreases, or interferes with the protein expression level of a member of the cytochrome P450 family of enzymes. In some instances, the expression level of the enzyme, such as a member of the cytochrome P450 family of enzymes, is compared to a control expression level of the enzyme. In some embodiments, the control expression level of the enzyme is the expression level of the enzyme uninduced by the compound.

[00131] In some instances after contacting an isolated induced hepatocyte with a compound, a change in the gene expression of a member of the cytochrome P450 superfamily is detected. In some cases, the gene expression level of a biomarker from a member of the cytochrome P450 superfamily from an isolated induced hepatocyte that have been contacted with a compound is compared to the gene expression level of a biomarker from the cytochrome P450 superfamily of an equivalent isolated induced hepatocyte not contacted with the compound or compared with a primary hepatocyte.

[00132] In some instances after contacting an isolated induced hepatocyte with a compound, a change in the gene expression level of a biomarker selected from cytochrome P450 families: CYP1, CYP2, CYP3, CYP4, CYP5, CYP7, CYP8, CYP11, CYP17, CYP19, CYP20, CYP21, CYP24, CYP26, CYP27, CYP39, CYP46, CYP51, and their respective subfamily members is detected. In some cases, the gene expression level of a biomarker from the cytochrome P450 families : CYP1, CYP2, CYP3, CYP4, CYP5, CYP7, CYP8, CYP11, CYP17, CYP19, CYP20, CYP21, CYP24, CYP26, CYP27, CYP39, CYP46, CYP51, and their respective subfamily members from an isolated induced hepatocyte that have been contacted with a compound is compared to the gene expression level of a biomarker from the cytochrome P450 families : CYP1, CYP2, CYP3, CYP4, CYP5, CYP7, CYP8, CYP11, CYP17, CYP19, CYP20, CYP21, CYP24, CYP26, CYP27, CYP39, CYP46, CYP51, and their respective subfamily members of an equivalent isolated induced hepatocyte not contacted with the compound or compared with a primary hepatocyte.

[00133] In some instances after contacting an isolated induced hepatocyte with a compound, a change in the gene expression level of a biomarker selected from CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4, and CYP7A1 is detected. In some cases, the gene expression level of a biomarker selected from CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4, and CYP7A1 from an isolated induced hepatocyte that have been contacted with a compound is compared to the gene expression level of a biomarker selected from CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4, and CYP7A1 of an

equivalent isolated induced hepatocyte not contacted with the compound or compared with a primary hepatocyte.

[00134] In one embodiment, provided herein describes a method of screening a compound for the ability to induce changes in a cell. In one embodiment, the method comprises contacting an isolated induced hepatocyte with the compound. In another embodiment, the method comprises contacting an isolated primary hepatocyte with the compound. In another embodiment, the method further comprises detecting an induction of change (e.g. proliferation) of the induced hepatocyte such as during regeneration. In another embodiment, the method further comprises detecting an induction of change (e.g. proliferation) of the primary hepatocyte such as during regeneration.

[00135] Also provided herein a method of screening a compound for cellular toxicity or modulation of the cell, the method comprising contacting an induced hepatocyte with the compound. In another embodiment, the method further comprises determining any phenotypic or metabolic changes in the cell that result from contact with the compound, and correlating the change with cellular toxicity or any other change in cell function or biochemistry. In another embodiment, screening of pharmaceuticals, toxins, or potential modulators of differentiation is facilitated. These substances (e.g., pharmaceuticals, toxins, or potential modulators) can be added to the culture medium.

[00136] One embodiment provided herein described a method of screening proliferation factors, differentiation factors, and pharmaceuticals. In one embodiment, induced hepatocytes or primary hepatocytes are used to screen for factors (such as small molecule drugs, peptides, polynucleotides, and the like) or conditions (such as culture conditions or manipulation) that affect the characteristics of induced hepatocytes or primary hepatocytes in culture. In one embodiment, this system has the advantage of not being complicated by a secondary effect caused by perturbation of the feeder cells by the test compound. In another embodiment, growth affecting substances are tested. In another embodiment, the conditioned medium is withdrawn from the culture and a simpler medium is substituted. In another embodiment, different wells are then treated with different cocktails of soluble factors that are candidates for replacing the components of the conditioned medium. Efficacy of each mixture is determined if the treated cells are maintained and proliferate in a satisfactory manner, optimally as well as in conditioned medium. Potential differentiation factors or conditions can be tested by treating the cell according to the test protocol, and then determining whether the treated cell develops functional or phenotypic characteristics of a differentiated cell of a particular lineage.

[00137] In one embodiment, the induced hepatocyte or primary hepatocyte are used to screen potential modulators of cellular differentiation. For example, in one assay for screening modulators of cellular differentiation, the induced hepatocyte or primary hepatocyte can be cultured under serum free, or in the present of a modulator, as the situation requires, and the effect on differentiation can be detected. In another embodiment, the screening methods described herein can be used to study conditions associated with cellular development and screen for potential therapeutic or corrective drugs or modulators of the condition. For example, in one embodiment, the development of the induced hepatocyte or primary hepatocyte is compared with the development with cells having a disease or condition.

[00138] In one embodiment, biomarker such as gene and protein expression can be compared between different cell populations obtained from induced hepatocyte or primary hepatocyte, and used to identify and characterize factors upregulated or downregulated in the course of proliferation, and produce nucleotide copies of the affected genes.

[00139] In one embodiment, feeder-free induced hepatocyte or primary hepatocyte cultures can also be used for the testing of pharmaceutical compounds in drug research. Assessment of the activity of candidate pharmaceutical compounds generally involves combining the induced hepatocyte or primary hepatocyte with the candidate compound, determining any resulting change, and then correlating the effect of the compound with the observed change. In another embodiment, the screening is done, for example, either because the compound is designed to have a pharmacological effect on certain cell types, or because a compound designed to have effects elsewhere have unintended side effects. In another embodiment, two or more drugs are be tested in combination (by combining with the cells either simultaneously or sequentially), to detect possible drug-drug interaction effects. In another embodiment, compounds are screened initially for potential toxicity. In another embodiment, cytotoxicity is be determined by the effect on cell viability, survival, morphology, on the expression or release of certain markers, receptors or enzymes, on DNA synthesis or repair.

[00140] The terms “treating,” “treatment,” and the like are used herein to mean obtaining a desired pharmacologic and/or physiologic effect. In some embodiments, an individual (e.g., an individual suspected to be suffering from and/or genetically pre-disposed to a liver-associated disease or disorder is treated prophylactically with a preparation of induced hepatocyte described herein and such prophylactic treatment completely or partially prevents a liver-associated disease or disorder or sign or symptom thereof. In some embodiments, an individual is treated therapeutically (e.g., when an individual is suffering from a liver-associated disease or disorder), such therapeutic treatment causes a partial or complete cure for the disease or disorder and/or

reverses an adverse effect attributable to the disease or disorder and/or stabilizes the disease or disorder and/or delays progression of the disease or disorder and/or causes regression of the disease or disorder.

[00141] Administration (e.g., transplantation) of induced hepatocyte to the area in need of treatment is achieved by, for example and not by way of limitation, local infusion during surgery, by injection, by means of a catheter, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers.

[00142] “Transplanting” a composition into a mammal refers to introducing the composition into the body of the mammal by any method established in the art. The composition being introduced is the “transplant”, and the mammal is the “recipient”. The transplant and the recipient can be syngeneic, allogeneic or xenogeneic. Further, the transplantation can be an autologous transplantation.

[00143] An “effective amount” is an amount of a therapeutic agent sufficient to achieve the intended purpose. For example, an effective amount of induced hepatocytes is an amount sufficient, as the case can be, to result in an increase in primary hepatocyte number. An effective amount of a composition to treat or ameliorate a liver-associated disease or disorder is an amount of the composition sufficient to reduce or remove the symptoms of the liver-associated disease or disorder. The effective amount of a given therapeutic agent will vary with factors such as the nature of the agent, the route of administration, the size and species of the animal to receive the therapeutic agent, and the purpose of the administration.

[00144] Further provided herein in one embodiment are genetically modified induced hepatocytes. Manipulations modify various properties of the cell, e.g., render it more adapted or resistant to certain environmental conditions, and/or induce a production of one or more certain substances therefrom, which substances can, e.g., improve the viability of the cell. Such genetic alterations can be performed in order to make the cell more suitable for use in transplantation, for example, in order to avoid rejection thereof from the recipient (for reviews of gene therapy procedures, see Anderson, *Science*, 256:808; Mulligan, *Science*, 926; Miller, *Nature*, 357:455; Van Brunt, *Biotechnology*, 6(10):1149; and Yu et al., *Gene Therapy*, 1:13).

[00145] A “vector” refers to a recombinant DNA or RNA construct, such as a plasmid, a phage, recombinant virus, or other vector that, upon introduction into an appropriate host cell, results in a modification of a progenitor cell described herein. Appropriate expression vectors are well known to those with ordinary skill in the art and include those that are replicable in eukaryotic and/or prokaryotic cells and those that remain episomal or those that integrate into the host cell genome.

[00146] Construction of vectors is achieved using techniques described in, for example, as described in Sambrook et al., 1989. In one embodiment isolated plasmids or DNA fragments are cleaved, tailored, and relegated in the form desired to generate the plasmids. If desired, analysis to confirm correct sequences in the constructed plasmids is performed using any suitable method. Suitable methods for constructing expression vectors, preparing in vitro transcripts, introducing DNA into host cells, and performing analyses for assessing gene expression and function are known. Gene presence, amplification, and/or expression are measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA, dot blotting (DNA or RNA analysis), or in situ hybridization, using an appropriately labeled probe which can be based on a sequence provided herein.

[00147] As used herein, terms such as “transfection”, “transformation”, and the like are intended to indicate the transfer of nucleic acid to a cell or organism in functional form. Such terms include various means of transferring nucleic acids to cells, including transfection with CaP04, electroporation, viral transduction, lipofection, delivery using liposomes, and/or other delivery vehicles.

Induced hepatocytes for treatment of a disease or disorder

[00148] In some embodiments, induced hepatocytes are administered for the treatment of a liver injury. In some embodiments, liver injury includes damaged or loss of liver tissue due to external factors, such as injury to the host, e.g. injury to an individual, or due to surgery. In some embodiments, liver injury includes damage or loss of liver tissue due to a liver-associated disease or disorder. In some embodiments, the liver-associated disease or disorder is an acute liver disease or disorder such as acute liver failure, or is a chronic liver disease or disorder such as cirrhosis. In some embodiments, the liver-associated disease or disorder is resulted from genetic factors, chemicals or pathogenic infections.

[00149] Exemplary liver-associated diseases or disorders include, but are not limited to, alagille syndrome, alpha 1 anti-trypsin deficiency, autoimmune hepatitis, benign liver tumors, biliary atresia, cirrhosis, cystic disease of the liver, fatty liver disease including alcohol-related liver disease and non-alcohol fatty liver disease (NAFLD), galactosemia, gallstones, Gilbert's Syndrome, hemochromatosis, liver cysts, liver cancer, liver disease in pregnancy (e.g. acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, preeclampsia, or HELLP Syndrome (hemolysis, elevated liver tests, low platelets)), neonatal hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, porphyria, Reye's Syndrome, sarcoidosis, toxic hepatitis, type 1 glycogen storage disease, tyrosinemia, viral hepatitis A, B, C, and Wilson disease.

[00150] In some embodiments, induced hepatocytes are administered for the treatment of an acute liver disease or disorder. In other embodiments, induced hepatocytes are administered for the treatment of a chronic liver disease or disorder. In some embodiments, induced hepatocytes are administered for the treatment of alagille syndrome, alpha 1 anti-trypsin deficiency, autoimmune hepatitis, benign liver tumors, biliary atresia, cirrhosis, cystic disease of the liver, fatty liver disease including alcohol-related liver disease and non-alcohol fatty liver disease (NAFLD), galactosemia, gallstones, Gilbert's Syndrome, hemochromatosis, liver cysts, liver cancer, liver disease in pregnancy (e.g. acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, preeclampsia, or HELLP Syndrome (hemolysis, elevated liver tests, low platelets)), neonatal hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, porphyria, Reye's Syndrome, sarcoidosis, toxic hepatitis, type 1 glycogen storage disease, tyrosinemia, viral hepatitis A, B, C, Wilson disease, or a combination thereof.

[00151] In some embodiments, induced hepatocytes are administered in combination with an additional therapeutic agent for the treatment of a liver-associated disease or disorder. In some embodiments, the additional therapeutic agent includes, but is not limited to, curcumin, resveratrol, thalidomide, cholestyramine (Questran), tacrolimus (PROGRAF), ursodiol (Actigall), interferons, diuretics such as loop diuretics, and liver transplantation.

[00152] In some embodiments, chemicals that are toxic to the liver results in chemical-induced liver disease. In some embodiments, chemicals that are toxic to the liver include drugs; consumables such as alcohols, food additives, or preservatives; and chemical and environmental toxins. In some instances, drugs that cause liver injury include, but are not limited to, acetaminophen, allopurinol, anabolic steroids, danazol, dantrolene, imipramine, isoniazid, methotrexate, methyl dopa, nicotinic acid, nitrofurantoin, phenothiazines, phenytoin, salicylates, statins, terbinafine HCl, thiabendazole, thorotrast, tolbutamide, chlorpromazine/valproic acid, and chlorpropamide/erythro-mycin.

[00153] In some embodiments, pathogenic infections induce liver-associated diseases or disorders. In some embodiments, a pathogen is a virus, a bacterium, a fungus, or a parasite. In some embodiments, the pathogen is a virus. In some embodiments, a viral infection induces liver-associated diseases or disorders.

[00154] In some embodiments, a virus is a DNA virus or an RNA virus. In some instances, a DNA virus is a single-stranded (ss) DNA virus, a double-stranded (ds) DNA virus, or a DNA virus that contains both ss and ds DNA regions. In some cases, an RNA virus is a single-stranded (ss) RNA virus or a double-stranded (ds) RNA virus. Sometimes, a ssRNA virus is further classified into a positive-sense RNA virus or a negative-sense RNA virus.

[00155] In some instances, a dsDNA virus is from the family: Myoviridae, Podoviridae, Siphoviridae, Alloherpesviridae, Herpesviridae, Malacoherpesviridae, Lipothrixviridae, Rudiviridae, Adenoviridae, Ampullaviridae, Ascoviridae, Asfaviridae, Baculoviridae, Bicaudaviridae, Clavaviridae, Corticoviridae, Fuselloviridae, Globuloviridae, Guttaviridae, Hytrosaviridae, Iridoviridae, Marseilleviridae, Mimiviridae, Nimaviridae, Pandoraviridae, Papillomaviridae, Phycodnaviridae, Plasmaviridae, Polydnaviruses, Polyomaviridae, Poxviridae, Sphaerolipoviridae, and Tectiviridae.

[00156] In some instances, an ssDNA virus is from the family: Anelloviridae, Bacillariodnaviridae, Bidnaviridae, Circoviridae, Geminiviridae, Inoviridae, Microviridae, Nanoviridae, Parvoviridae, and Spiraviridae.

[00157] In some instances, a DNA virus that contains both ss and ds DNA regions is from the group of pleolipoviruses. In some cases, the pleolipoviruses include Haloarcula hispanica pleomorphic virus 1, Halogeometricum pleomorphic virus 1, Halorubrum pleomorphic virus 1, Halorubrum pleomorphic virus 2, Halorubrum pleomorphic virus 3, and Halorubrum pleomorphic virus 6.

[00158] In some instances, a dsRNA virus is from the family: Birnaviridae, Chrysoviridae, Cystoviridae, Endornaviridae, Hypoviridae, Megavirnaviridae, Partitiviridae, Picobirnaviridae, Reoviridae, Rotavirus and Totiviridae.

[00159] In some cases, a positive-sense ssRNA virus is from the family: Alphaflexiviridae, Alphanteriviridae, Alvernaviridae, Arteriviridae, Astroviridae, Barnaviridae, Betaflexiviridae, Bromoviridae, Caliciviridae, Carmotetraviridae, Closteroviridae, Coronaviridae, Dicistroviridae, Flaviviridae, Gammaflexiviridae, Iflaviridae, Leviviridae, Luteoviridae, Marnaviridae, Mesoniviridae, Narnaviridae, Nodaviridae, Permutotetraviridae, Picornaviridae, Potyviridae, Roniviridae, Secoviridae, Togaviridae, Tombusviridae, Tymoviridae, and Virgaviridae.

[00160] Sometimes, a negative-sense ssRNA virus is from the family: Bornaviridae, Filoviridae, Paramyxoviridae, Rhabdoviridae, Nyamiviridae, Arenaviridae, Bunyaviridae, Ophioviridae, and Orthomyxoviridae.

[00161] Exemplary virus includes, but is not limited to: Abelson leukemia virus, Abelson murine leukemia virus, Abelson's virus, Acute laryngotracheobronchitis virus, Adelaide River virus, Adeno associated virus group, Adenovirus, African horse sickness virus, African swine fever virus, AIDS virus, Aleutian mink disease parvovirus, Alpharetrovirus, Alphavirus, ALV related virus, Amapari virus, Aphthovirus, Aquareovirus, Arbovirus, Arbovirus C, arbovirus group A, arbovirus group B, Arenavirus group, Argentine hemorrhagic fever virus, Argentine hemorrhagic fever virus, Arterivirus, Astrovirus, Ateline herpesvirus group, Aujeszky's disease

virus, Aura virus, Ausduk disease virus, Australian bat lyssavirus, Aviadenovirus, avian erythroblastosis virus, avian infectious bronchitis virus, avian leukemia virus, avian leukosis virus, avian lymphomatosis virus, avian myeloblastosis virus, avian paramyxovirus, avian pneumoencephalitis virus, avian reticuloendotheliosis virus, avian sarcoma virus, avian type C retrovirus group, Avihepadnavirus, Avipoxvirus, B virus, B19 virus, Babanki virus, baboon herpesvirus, baculovirus, Barmah Forest virus, Bebaru virus, Berrimah virus, Betaretrovirus, Birnavirus, Bittner virus, BK virus, Black Creek Canal virus, bluetongue virus, Bolivian hemorrhagic fever virus, Boma disease virus, border disease of sheep virus, borna virus, bovine alphaherpesvirus 1, bovine alphaherpesvirus 2, bovine coronavirus, bovine ephemeral fever virus, bovine immunodeficiency virus, bovine leukemia virus, bovine leukosis virus, bovine mammillitis virus, bovine papillomavirus, bovine papular stomatitis virus, bovine parvovirus, bovine syncytial virus, bovine type C oncovirus, bovine viral diarrhea virus, Buggy Creek virus, bullet shaped virus group, Bunyamwera virus supergroup, Bunyavirus, Burkitt's lymphoma virus, Bwamba Fever, CA virus, Calicivirus, California encephalitis virus, camelpox virus, canarypox virus, canid herpesvirus, canine coronavirus, canine distemper virus, canine herpesvirus, canine minute virus, canine parvovirus, Cano Delgadito virus, caprine arthritis virus, caprine encephalitis virus, Caprine Herpes Virus, Capripox virus, Cardiovirus, caviid herpesvirus 1, Cercopithecoid herpesvirus 1, cercopithecine herpesvirus 1, Cercopithecine herpesvirus 2, Chandipura virus, Changuinola virus, channel catfish virus, Charleville virus, chickenpox virus, Chikungunya virus, chimpanzee herpesvirus, chub reovirus, chum salmon virus, Cocal virus, Coho salmon reovirus, coital exanthema virus, Colorado tick fever virus, Coltivirus, Columbia SK virus, common cold virus, contagious eethyma virus, contagious pustular dermatitis virus, Coronavirus, Corriparta virus, coryza virus, cowpox virus, coxsackie virus, CPV (cytoplasmic polyhedrosis virus), cricket paralysis virus, Crimean-Congo hemorrhagic fever virus, croup associated virus, Cryptovirus, Cypovirus, Cytomegalovirus, cytomegalovirus group, cytoplasmic polyhedrosis virus, deer papillomavirus, deltaretrovirus, dengue virus, Densovirus, Dependovirus, Dhori virus, diploma virus, *Drosophila* C virus, duck hepatitis B virus, duck hepatitis virus 1, duck hepatitis virus 2, duovirus, Duvenhage virus, Deformed wing virus DWV, eastern equine encephalitis virus, eastern equine encephalomyelitis virus, EB virus, Ebola virus, Ebola-like virus, echo virus, echovirus, echovirus 10, echovirus 28, echovirus 9, ectromelia virus, EEE virus, EIA virus, EIA virus, encephalitis virus, encephalomyocarditis group virus, encephalomyocarditis virus, Enterovirus, enzyme elevating virus, enzyme elevating virus (LDH), epidemic hemorrhagic fever virus, epizootic hemorrhagic disease virus, Epstein-Barr virus, equid alphaherpesvirus 1, equid alphaherpesvirus 4, equid

herpesvirus 2, equine abortion virus, equine arteritis virus, equine encephalosis virus, equine infectious anemia virus, equine morbillivirus, equine rhinopneumonitis virus, equine rhinovirus, Eubenangu virus, European elk papillomavirus, European swine fever virus, Everglades virus, Eyach virus, felid herpesvirus 1, feline calicivirus, feline fibrosarcoma virus, feline herpesvirus, feline immunodeficiency virus, feline infectious peritonitis virus, feline leukemia/sarcoma virus, feline leukemia virus, feline panleukopenia virus, feline parvovirus, feline sarcoma virus, feline syncytial virus, Filovirus, Flanders virus, Flavivirus, foot and mouth disease virus, Fort Morgan virus, Four Corners hantavirus, fowl adenovirus 1, fowlpox virus, Friend virus, Gammaretrovirus, GB hepatitis virus, GB virus, German measles virus, Getah virus, gibbon ape leukemia virus, glandular fever virus, goatpox virus, golden shinner virus, Gonometa virus, goose parvovirus, granulosis virus, Gross' virus, ground squirrel hepatitis B virus, group A arbovirus, Guanarito virus, guinea pig cytomegalovirus, guinea pig type C virus, Hantaan virus, Hantavirus, hard clam reovirus, hare fibroma virus, HCMV (human cytomegalovirus), hemadsorption virus 2, hemagglutinating virus of Japan, hemorrhagic fever virus, hendra virus, Henipaviruses, Hepadnavirus, hepatitis A virus, hepatitis B virus group, hepatitis C virus, hepatitis D virus, hepatitis delta virus, hepatitis E virus, hepatitis F virus, hepatitis G virus, hepatitis nonA nonB virus, hepatitis virus, hepatitis virus (nonhuman), hepatoencephalomyelitis reovirus 3, Hepatovirus, heron hepatitis B virus, herpes B virus, herpes simplex virus, herpes simplex virus 1, herpes simplex virus 2, herpesvirus, herpesvirus 7, Herpesvirus ateles, Herpesvirus hominis, Herpesvirus infection, Herpesvirus saimiri, Herpesvirus suis, Herpesvirus varicellae, Highlands J virus, Hirame rhabdovirus, hog cholera virus, human adenovirus 2, human alphaherpesvirus 1, human alphaherpesvirus 2, human alphaherpesvirus 3, human B lymphotropic virus, human betaherpesvirus 5, human coronavirus, human cytomegalovirus group, human foamy virus, human gammaherpesvirus 4, human gammaherpesvirus 6, human hepatitis A virus, human herpesvirus 1 group, human herpesvirus 2 group, human herpesvirus 3 group, human herpesvirus 4 group, human herpesvirus 6, human herpesvirus 8, human immunodeficiency virus, human immunodeficiency virus 1, human immunodeficiency virus 2, human papillomavirus, human T cell leukemia virus, human T cell leukemia virus I, human T cell leukemia virus II, human T cell leukemia virus III, human T cell lymphoma virus I, human T cell lymphoma virus II, human T cell lymphotropic virus type 1, human T cell lymphotropic virus type 2, human T lymphotropic virus I, human T lymphotropic virus II, human T lymphotropic virus III, Ichnovirus, infantile gastroenteritis virus, infectious bovine rhinotracheitis virus, infectious haematopoietic necrosis virus, infectious pancreatic necrosis virus, influenza virus A, influenza virus B, influenza virus C, influenza virus D, influenza virus

pr8, insect iridescent virus, insect virus, iridovirus, Japanese B virus, Japanese encephalitis virus, JC virus, Junin virus, Kaposi's sarcoma-associated herpesvirus, Kemerovo virus, Kilham's rat virus, Klamath virus, Kolongo virus, Korean hemorrhagic fever virus, kumba virus, Kysanur forest disease virus, Kyzylagach virus, La Crosse virus, lactic dehydrogenase elevating virus, lactic dehydrogenase virus, Lagos bat virus, Langur virus, lapine parvovirus, Lassa fever virus, Lassa virus, latent rat virus, LCM virus, Leaky virus, Lentivirus, Leporipoxvirus, leukemia virus, leukovirus, lumpy skin disease virus, lymphadenopathy associated virus, Lymphocryptovirus, lymphocytic choriomeningitis virus, lymphoproliferative virus group, Machupo virus, mad itch virus, mammalian type B oncovirus group, mammalian type B retroviruses, mammalian type C retrovirus group, mammalian type D retroviruses, mammary tumor virus, Mapuera virus, Marburg virus, Marburg-like virus, Mason Pfizer monkey virus, Mastadenovirus, Mayaro virus, ME virus, measles virus, Menangle virus, Mengo virus, Mengovirus, Middelburg virus, milkers nodule virus, mink enteritis virus, minute virus of mice, MLV related virus, MM virus, Mokola virus, Molluscipoxvirus, Molluscum contagiosum virus, monkey B virus, monkeypox virus, Mononegavirales, Morbillivirus, Mount Elgon bat virus, mouse cytomegalovirus, mouse encephalomyelitis virus, mouse hepatitis virus, mouse K virus, mouse leukemia virus, mouse mammary tumor virus, mouse minute virus, mouse pneumonia virus, mouse poliomyelitis virus, mouse polyomavirus, mouse sarcoma virus, mousepox virus, Mozambique virus, Mucambo virus, mucosal disease virus, mumps virus, murid betaherpesvirus 1, murid cytomegalovirus 2, murine cytomegalovirus group, murine encephalomyelitis virus, murine hepatitis virus, murine leukemia virus, murine nodule inducing virus, murine polyomavirus, murine sarcoma virus, Muromegalovirus, Murray Valley encephalitis virus, myxoma virus, Myxovirus, Myxovirus multiforme, Myxovirus parotitidis, Nairobi sheep disease virus, Nairovirus, Nanirnavirus, Nariva virus, Ndumo virus, Neethling virus, Nelson Bay virus, neurotropic virus, New World Arenavirus, newborn pneumonitis virus, Newcastle disease virus, Nipah virus, noncytopathogenic virus, Norwalk virus, nuclear polyhedrosis virus (NPV), nipple neck virus, O'nyong'nyong virus, Ockelbo virus, oncogenic virus, oncogenic viruslike particle, oncornavirus, Orbivirus, Orf virus, Oropouche virus, Orthohepadnavirus, Orthomyxovirus, Orthopoxvirus, Orthoreovirus, Orungo, ovine papillomavirus, ovine catarrhal fever virus, owl monkey herpesvirus, Palyam virus, Papillomavirus, Papillomavirus sylvilagi, Papovavirus, parainfluenza virus, parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, parainfluenza virus type 4, Paramyxovirus, Parapoxvirus, paravaccinia virus, Parvovirus, Parvovirus B19, parvovirus group, Pestivirus, Phlebovirus, phocine distemper virus, Picodnavirus, Picornavirus, pig cytomegalovirus-pigeonpox virus, Piry virus, Pixuna virus,

pneumonia virus of mice, Pneumovirus, poliomyelitis virus, poliovirus, Polydnavirus, polyhedral virus, polyoma virus, Polyomavirus, Polyomavirus bovis, Polyomavirus cercopithecii, Polyomavirus hominis 2, Polyomavirus maccacae 1, Polyomavirus muris 1, Polyomavirus muris 2, Polyomavirus papionis 1, Polyomavirus papionis 2, Polyomavirus sylvilagi, Pongine herpesvirus 1, porcine epidemic diarrhea virus, porcine hemagglutinating encephalomyelitis virus, porcine parvovirus, porcine transmissible gastroenteritis virus, porcine type C virus, pox virus, poxvirus, poxvirus variolae, Prospect Hill virus, Provirus, pseudocowpox virus, pseudorabies virus, psittacinepox virus, quailpox virus, rabbit fibroma virus, rabbit kidney vacuolating virus, rabbit papillomavirus, rabies virus, raccoon parvovirus, raccoonpox virus, Ranikhet virus, rat cytomegalovirus, rat parvovirus, rat virus, Rauscher's virus, recombinant vaccinia virus, recombinant virus, reovirus, reovirus 1, reovirus 2, reovirus 3, reptilian type C virus, respiratory infection virus, respiratory syncytial virus, respiratory virus, reticuloendotheliosis virus, Rhabdovirus, Rhabdovirus carpia, Rhadinovirus, Rhinovirus, Rhizidiovirus, Rift Valley fever virus, Riley's virus, rinderpest virus, RNA tumor virus, Ross River virus, Rotavirus, rougeole virus, Rous sarcoma virus, rubella virus, rubeola virus, Rubivirus, Russian autumn encephalitis virus, SA 11 simian virus, SA2 virus, Sabia virus, Sagiyama virus, Saimirine herpesvirus 1, salivary gland virus, sandfly fever virus group, Sandjimba virus, SARS virus, SDAV (sialodacryoadenitis virus), sealpox virus, Semliki Forest Virus, Seoul virus, sheeppox virus, Shope fibroma virus, Shope papilloma virus, simian foamy virus, simian hepatitis A virus, simian human immunodeficiency virus, simian immunodeficiency virus, simian parainfluenza virus, simian T cell lymphotropic virus, simian virus, simian virus 40, Simplexvirus, Sin Nombre virus, Sindbis virus, smallpox virus, South American hemorrhagic fever viruses, sparrowpox virus, Spumavirus, squirrel fibroma virus, squirrel monkey retrovirus, SSV 1 virus group, STLV (simian T lymphotropic virus) type I, STLV (simian T lymphotropic virus) type II, STLV (simian T lymphotropic virus) type III, stomatitis papulosa virus, submaxillary virus, suid alphaherpesvirus 1, suid herpesvirus 2, Suipoxvirus, swamp fever virus, swinepox virus, Swiss mouse leukemia virus, TAC virus, Tacaribe complex virus, Tacaribe virus, Tanapox virus, Taterapox virus, Tench reovirus, Theiler's encephalomyelitis virus, Theiler's virus, Thogoto virus, Thottapalayam virus, Tick borne encephalitis virus, Tioman virus, Togavirus, Torovirus, tumor virus, Tupaia virus, turkey rhinotracheitis virus, turkeypox virus, type C retroviruses, type D oncovirus, type D retrovirus group, ulcerative disease rhabdovirus, Una virus, Uukuniemi virus group, vaccinia virus, vacuolating virus, varicella zoster virus, Varicellovirus, Varicola virus, variola major virus, variola virus, Vasin Gishu disease virus, VEE virus, Venezuelan equine encephalitis virus,

Venezuelan equine encephalomyelitis virus, Venezuelan hemorrhagic fever virus, vesicular stomatitis virus, Vesiculovirus, Vilyuisk virus, viper retrovirus, viral haemorrhagic septicemia virus, Visna Maedi virus, Visna virus, volepox virus, VSV (vesicular stomatitis virus), Wallal virus, Warrego virus, wart virus, WEE virus, West Nile virus, western equine encephalitis virus, western equine encephalomyelitis virus, Whataroa virus, Winter Vomiting Virus, woodchuck hepatitis B virus, woolly monkey sarcoma virus, wound tumor virus, WRSV virus, Yaba monkey tumor virus, Yaba virus, Yatapoxvirus, yellow fever virus, and the Yug Bogdanovac virus.

[00162] In some embodiments, a viral infection induces a liver-associated disease or disorder. In some embodiments, the viral infection is a hepatitis infection. In some embodiments, the virus is a hepatitis A virus, a hepatitis B virus, a hepatitis C virus, a hepatitis D virus, a hepatitis E virus, a hepatitis F virus, or a hepatitis G virus. In some embodiments, a viral infection that induces a liver-associated disease or disorder is caused by a hepatitis A virus, a hepatitis B virus, a hepatitis C virus, a hepatitis D virus, a hepatitis E virus, a hepatitis F virus, or a hepatitis G virus.

[00163] In some embodiments, liver injury arises as a consequence of an immune response to virus within the liver. In some instances, liver injury arises as part of a generalized host infection in which viruses target tissues other than the liver. Exemplary viruses whose primary target is not liver include herpes viruses such as Epstein-Barr virus, cytomegalovirus (CMV) or herpes simplex virus; parvovirus; adenovirus; influenza viruses; lentivirus such as human immunodeficiency virus (HIV); and severe acute respiratory syndrome (SARS)-associated coronavirus. In some instances, viral infections described herein result in hepatitis.

[00164] In some embodiments, the pathogen is a bacterium. In some embodiments, a bacterial infection induces liver-associated diseases or disorders. Examples of bacteria include: *Helicobacter pyloris*, *Borelia burgdorferi*, *Legionella pneumophilia*, *Mycobacteria* spp. (e.g., *M. tuberculosis*, *M. avium*, *M. intracellulare*, *M. kansasii*, *M. goodii*), *Staphylococcus aureus*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Listeria monocytogenes*, *Streptococcus pyogenes* (Group A *Streptococcus*), *Streptococcus agalactiae* (Group B *Streptococcus*), *Streptococcus* (viridans group), *Streptococcus faecalis*, *Streptococcus bovis*, *Streptococcus* (anaerobic spp.), *Streptococcus pneumoniae*, pathogenic *Campylobacter* sp., *Enterococcus* sp., *Haemophilus influenzae*, *Bacillus anthracis*, *Corynebacterium diphtheriae*, *Corynebacterium* sp., *Erysipelothrix rhusiopathiae*, *Clostridium perfringens*, *Clostridium tetani*, *Enterobacter aerogenes*, *Klebsiella pneumoniae*, *Pasturella multocida*, *Bacteroides* sp., *Fusobacterium nucleatum*, *Streptobacillus moniliformis*, *Treponema pallidum*, *Treponema pertenue*, *Leptospira*, and *Actinomyces israelii*.

[00165] In some embodiments, the pathogen is a fungus. In some embodiments, a fungal infection induces liver-associated diseases or disorders. Examples of fungi include:

Cryptococcus neoformans, *Histoplasma capsulatum*, *Coccidioides immitis*, *Blastomyces dermatitidis*, *Chlamydia trachomatis*, *Candida albicans*. Other infectious organisms (i.e., protists) include: *Plasmodium falciparum* and *Toxoplasma gondii*.

[00166] In some embodiments, the pathogen is a parasite. In some embodiments, a parasitic infection induces liver-associated diseases or disorders. Examples of parasite include: sarcodina (e.g. *Entamoeba*), mastigophora (e.g. *Giardia*, *Leishmania*), ciliophora (e.g. *Balantidium*), and sporozoa (e.g. *Plasmodium*, *Cryptosporidium*).

[00167] In some embodiments, induced hepatocytes are utilized for regeneration of a defect liver. In some instances, induced hepatocytes are introduced at the site of liver injury. In some cases, induced hepatocytes are introduced or transplanted as a cell suspension to the site of liver injury. In other cases, induced hepatocytes are introduced or transplanted as a tissue mass to the site of liver injury. In other instances, induced hepatocytes are utilized for regeneration of a defect liver *ex vivo*. In other instances, induced hepatocytes are utilized for *ex vivo* liver generation prior to transplantation into a site of liver injury.

[00168] In some embodiments, induced hepatocytes are formulated as a composition, such as a pharmaceutical composition, for treating a liver injury due to external factors, such as injury to the host, e.g. injury to an individual, or due to surgery.

[00169] In some embodiments, induced hepatocytes are formulated as a composition, such as a pharmaceutical composition, for treating a liver injury due to a liver-associated disease or disorder. In some embodiments, induced hepatocytes are formulated as a composition, such as a pharmaceutical composition, for treating alagille syndrome, alpha 1 anti-trypsin deficiency, autoimmune hepatitis, benign liver tumors, biliary atresia, cirrhosis, cystic disease of the liver, fatty liver disease including alcohol-related liver disease and non-alcohol fatty liver disease (NAFLD), galactosemia, gallstones, Gilbert's Syndrome, hemochromatosis, liver cysts, liver cancer, liver disease in pregnancy (e.g. acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, preeclampsia, or HELLP Syndrome (hemolysis, elevated liver tests, low platelets)), neonatal hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, porphyria, Reye's Syndrome, sarcoidosis, toxic hepatitis, type 1 glycogen storage disease, tyrosinemia, viral hepatitis A, B, C, Wilson disease, or a combination thereof.

[00170] In some embodiments, the composition comprising induced hepatocytes further comprises an additional therapeutic agent. In some embodiment, the additional therapeutic agent is a therapeutic agent for the treatment of a liver-associated disease or disorder. In some

embodiments, the additional therapeutic agent includes, but is not limited to, curcumin, resveratrol, thalidomide, cholestyramine (Questran), tacrolimus (PROGRAF), ursodiol (Actigall), interferons, diuretics such as loop diuretics, and liver transplantation.

[00171] In some embodiments, the composition comprising induced hepatocytes are utilized at the site of liver injury for regeneration of the liver. In some embodiments, the composition comprising induced hepatocytes are introduced or transplanted as a cell suspension to the site of liver injury. In some embodiments, the composition comprising induced hepatocytes are introduced or transplanted as a tissue mass to the site of liver injury. In other embodiments, the composition comprising induced hepatocytes are utilized for regeneration of a defect liver *ex vivo*. In other embodiments, the composition comprising induced hepatocytes are utilized for *ex vivo* liver generation prior to transplantation into a site of liver injury.

[00172] Modes of administration of an isolated induced hepatocyte include, but are not limited to, systemic intravenous injection and injection directly to the intended site of activity (e.g., endoscopic retrograde injection). The preparation can be administered by any convenient route, for example, by infusion or bolus injection, and can be administered together with other biologically active agents. In some embodiments, the administration is systemic localized administration.

[00173] In some embodiments, a composition comprising induced hepatocytes is formulated as a pharmaceutical composition for intravenous administration to a mammal, including a human. In some embodiments, compositions for intravenous administration are solutions in sterile tonic aqueous buffer. Where necessary, the composition also includes a local anesthetic to ameliorate any pain at the site of the injection. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients are mixed prior to administration.

[00174] In some embodiments, suitable pharmaceutical compositions comprise a therapeutically effective amount of the induced hepatocytes and a pharmaceutically acceptable carrier or excipient. Such a carrier includes, but is not limited to, saline, buffered saline, dextrose, water, and combinations thereof.

[00175] In some embodiments, the induced hepatocytes described herein are delivered to a targeted site (e.g., a defect section of the liver) by a delivery system suitable for targeting cells to a particular tissue. For example, the cells are encapsulated in a delivery vehicle that allows for the slow release of the cell(s) at the targeted site. The delivery vehicle is modified such that it is specifically targeted to a particular tissue. The surface of the targeted delivery system is modified

in a variety of ways. In the case of a liposomal-targeted delivery system, lipid groups are incorporated into the lipid bilayer of the liposome in order to maintain the targeting ligand in stable association with the liposomal bilayer.

[00176] In other examples, a colloidal dispersion system is used. Colloidal dispersion systems include macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles, and liposomes.

[00177] The administration of induced hepatocytes described herein is optionally tailored to an individual, by: (1) increasing or decreasing the amount cells injected; (2) varying the number of injections; or (3) varying the method of delivery of the cells.

[00178] The induced hepatocyte preparation is used in an amount effective to promote engraftment of cells in the recipient. At the physician's discretion, the administration is adjusted to meet optimal efficacy and pharmacological dosing.

Induced hepatocytes for production of therapeutic proteins

[00179] In some embodiments, induced hepatocytes are utilized for the production of therapeutic proteins (e.g. hormones), cytokines, cholesterol, carbohydrates, bile, or a combination thereof. In some instances, induced hepatocytes are utilized for the production of therapeutic proteins. In some instances, the therapeutic proteins include full length proteins, domains or fragments thereof, or peptides. In some instances, the proteins, domains or fragments thereof, or peptides containing natural and/or unnatural amino acid residues. In some cases, the therapeutic proteins, their fragments thereof, or peptides, include, but are not limited to, major plasma proteins such as human serum albumin, soluble plasma fibronectin, α -fetoprotein, C-reactive protein, and several globulins; proteins involved in hemostasis and fibrinolysis such as coagulation factors involved in the coagulation cascade, α 2-macroglobulin, α 1-antitrypsin, antithrombin III, protein S, protein C, plasminogen, α 2-antiplasmin, and complement component 3; carrier proteins such as albumin, ceruloplasmin, transcortin, haptoglobin, hemopexin, IGF binding protein, major urinary proteins, retinol binding protein, sex hormone-binding globulin, transthyretin, transferrin, and Vitamin D-binding protein; hormones such as insulin-like growth factor 1, thrombopoietin, hepcidin, and betatrophin; prohormones such as angiotensinogen; and apolipoproteins. In some embodiments, induced hepatocytes are utilized for the production of hormones or its fragments thereof. In some embodiments, induced hepatocytes are utilized for the production of insulin-like growth factor 1, thrombopoietin, hepcidin, betatrophin, angiotensinogen, or their fragments thereof.

[00180] In some instances, induced hepatocytes are utilized for the production of cytokines. As described elsewhere herein, cytokines include chemokines, interferons, interleukins, and tumor necrosis factors. In some embodiments, cytokines are proinflammatory cytokines. In some embodiments, the cytokines include C-X-C and C-C subfamilies of chemokines: CCL1, CCL2 (MCP-1), CCL3, CCL4, CCL5 (RANTES), CCL6, CCL7, CCL8, CCL9 (or CCL10), CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, and CXCL17. In some embodiments, the cytokines include growth related (GRO)-alpha, GRO-beta, GRO-gamma, epithelial neutrophil activating peptide-78 (ENA-78), RANTES, TNF-alpha, IL-1 β , IL-6, IL-8, MCP-1, M-CSF, IFN- α , IFN- β , and cytokine-induced neutrophil chemoattractant (CINC). In some instances, induced hepatocytes are utilized for the production of one or more cytokines described herein. In some embodiments, induced hepatocytes are utilized for the production of cytokines including, but not limiting to: CCL1, CCL2 (MCP-1), CCL3, CCL4, CCL5 (RANTES), CCL6, CCL7, CCL8, CCL9 (or CCL10), CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, CXCL17, growth related (GRO)-alpha, GRO-beta, GRO-gamma, epithelial neutrophil activating peptide-78 (ENA-78), RANTES, TNF-alpha, IL-1 β , IL-6, IL-8, MCP-1, M-CSF, IFN- α , IFN- β , and cytokine-induced neutrophil chemoattractant (CINC).

[00181] In some instances, induced hepatocytes are utilized for the production or process of cholesterol. As used herein, the term "cholesterol" includes cholesterol, its stereoisomers (e.g. *nat*-cholesterol, or *ent*-cholesterol), naturally occurring cholesterols, genetically modified cholesterol, or their fragments thereof. In some embodiments, induced hepatocytes are utilized for the production or process of *nat*-cholesterol or its fragments thereof. In some embodiments, induced hepatocytes are utilized for the production or process of *ent*-cholesterol or its fragments thereof.

[00182] In some instances, induced hepatocytes are utilized for the production or process of carbohydrates. In some instances, induced hepatocytes are utilized for the formation, breakdown or interconversion of carbohydrates, gluconeogenesis, glycogenolysis, glycogenesis, lipid metabolism including cholesterol synthesis as disclosed above, and lipogenesis.

[00183] In some instances, induced hepatocytes are utilized for the production of bile.

[00184] As used herein, an amino acid residue can refer to a molecule containing both an amino group and a carboxyl group. Suitable amino acids include, without limitation, both the D- and L-isomers of the naturally-occurring amino acids, as well as non-naturally occurring amino acids prepared by other metabolic routes. The term amino acid, as used herein, includes, without limitation, α -amino acids, natural amino acids, non-natural amino acids, and amino acid analogs.

[00185] The term “ α -amino acid” can refer to a molecule containing both an amino group and a carboxyl group bound to a carbon which is designated the α -carbon.

[00186] The term “ β -amino acid” can refer to a molecule containing both an amino group and a carboxyl group in a β configuration.

[00187] “Naturally occurring amino acid” can refer to any one of the twenty amino acids commonly found in peptides synthesized in nature, and known by the one letter abbreviations A, R, N, C, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y and V.

[00188] The term “amino acid analog” refers to a molecule which is structurally similar to an amino acid and which can be substituted for an amino acid in the formation of a peptidomimetic macrocycle. Amino acid analogs include, without limitation, β -amino acids and amino acids where the amino or carboxy group is substituted by a similarly reactive group (e.g., substitution of the primary amine with a secondary or tertiary amine, or substitution of the carboxy group with an ester).

[00189] The term “non-natural amino acid” refers to an amino acid which is not one of the twenty amino acids commonly found in peptides synthesized in nature, and known by the one letter abbreviations A, R, N, C, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y and V. Non-natural amino acids include, without limitation, p-acetylphenylalanine, m-acetylphenylalanine, p-(3-oxobutanoyl)-l-phenylalanine, p-(2-amino-3-hydroxyethyl)phenylalanine, p-isopropylthiocarbonyl-phenylalanine, p-ethylthiocarbonyl-phenylalanine, o-propargyloxyphenylalanine, p-azidophenylalanine, phenylselenidylalanine, p-benzoyl-l-phenylalanine, or p-boronophenylalanine.

Induced hepatocytes for liver regeneration

[00190] In other embodiments, induced hepatocytes are utilized for liver regeneration. In other embodiments, induced hepatocytes are utilized for *ex-vivo* liver regeneration. In some cases, the *ex-vivo* liver regeneration utilizes an *ex vivo* perfusion system. In some instances, the *ex vivo* perfusion system include *ex vivo* perfusion bioreactor system (e.g. a 3D perfusion bioreactor system). In some cases, the *ex-vivo* liver regeneration utilizes a bioprinting system. In some instances, the bioprinting system is a 3 dimensional (3D) bioprinting system. In some cases, the

ex-vivo liver regeneration utilizes a 3D bioprinting system. In some embodiments, a 3D bioprinting system includes Organovo's NovoGEN MMX Bioprinter, EnvisionTEC's BioPlotter®, GeSims BioScaffolder 2.1, or regenHu's BioFactory®. In some embodiments, a 3D bioprinting system includes the 3D printing technology from OxSyBio.

[00191] In some embodiments, a 3D bioprinting system includes the system described in: US8691974, US8691274, US20140052285, US20140012407, US20140099709, US20140093932, US20130304233, US20130004469, US20130017564, US20130164339, US20120089238, US20110250688, US20090208466, EP2679669, WO2014039427, WO2013181375, WO2013040087, and WO2012122105.

[00192] In some embodiments, induced hepatocytes are utilized for liver regeneration using a perfusion system (e.g. an *ex vivo* perfusion system). In some embodiments, induced hepatocytes are utilized for liver regeneration using an *ex vivo* perfusion bioreactor system (e.g. a 3D perfusion bioreactor system). In some instances, induced hepatocytes are utilized for liver regeneration using a bioprinting system (e.g. a 3D bioprinting system). In some instances, induced hepatocytes are utilized for liver regeneration using Organovo's NovoGEN MMX Bioprinter, EnvisionTEC's BioPlotter®, GeSims BioScaffolder 2.1, or regenHu's BioFactory®. In some instances, induced hepatocytes are utilized for liver regeneration using the 3D printing technology from OxSyBio.

[00193] In some cases, induced hepatocytes are utilized for liver regeneration using a 3D bioprinting system described in: US8691974, US8691274, US20140052285, US20140012407, US20140099709, US20140093932, US20130304233, US20130004469, US20130017564, US20130164339, US20120089238, US20110250688, US20090208466, EP2679669, WO2014039427, WO2013181375, WO2013040087, or WO2012122105.

[00194] In some instances, induced hepatocytes are utilized for generation of tissue scaffolds through one or more of the methods described above. In some instances, the tissue scaffold is a 2 dimensional (2D) tissue scaffold or a 3 dimensional (3D) tissue scaffold. In some instances, the tissue scaffold is a 3D tissue scaffold. In some instances, induced hepatocytes are utilized for generation of 3D tissue scaffolds. In some embodiments, the 3D-scaffold is pre-coated with one or more extracellular matrix components, e.g., gelatin, laminin, fibronectin, collagen, polylysine, vitronectin, hyaluronic acid, hyaluronan hydrogels, silk fibroin, chitosan or a composite of any of the forementioned. In some embodiments, the cells are seeded at higher density on the 3D scaffolds than on the 2D cultures, such as threefold higher or fivefold higher or tenfold higher. In some embodiments, the cells are seeded in the presence of cell survival factor, such as an inhibitor of ROCK Rho kinase.

[00195] In some aspects, a biocompatible substrate is used to generate the tissue herein, e.g., culturing cells under a culture medium on a three dimensional biocompatible substrate. In some embodiments, the biocompatible substrate comprises a polymeric substrate. In some embodiments, the biocompatible substrate is biodegradable. In some embodiments, the polymeric substrate comprises poly(caprolactone) (PCL). In some embodiments, the polymeric substrate is selected from the group consisting of polylactic acid (PLA), poly-L-lactic acid (PLLA), poly-D-lactic acid (PDLA), polyglycolide, polyglycolic acid (PGA), polylactide-co-glycolide (PLGA), polydioxanone, polygluconate, polylactic acid-polyethylene oxide copolymers, modified cellulose, collagen, polyhydroxybutyrate, polyhydroxypriopionic acid, polyphosphoester, poly(alpha-hydroxy acid), polycarbonates, polyamides, polyanhydrides, polyamino acids, polyorthoesters, polyacetals, polycyanoacrylates, degradable urethanes, aliphatic polyester polyacrylates, polymethacrylate, acyl substituted cellulose acetates, non-degradable polyurethanes, polystyrenes, polyvinyl chloride, polyvinyl flouride, polyvinyl imidazole, chlorosulphonated polyolifins, polyethylene oxide, polyvinyl alcohol, teflon RTM, nylon silicon, poly(styrene-block-butadiene), polynorbornene, hydrogels, metallic alloys and oligo(ϵ -caprolactone)diol. In some embodiments, the biocompatible substrate comprises a synthetic polymer. According to some embodiments of the invention, the biocompatible substrate comprises a natural polymer. In some embodiments, the biodegradable substrate is selected from the group consisting of poly(caprolactone) (PCL), polyglycolic acid, poly(DL-lactic-coglycolic acid), cat gut sutures, cotton, cellulose, gelatin, dextran, alginate, fibronectin, laminin, collagen, hyaluronic acid, polyhydroxyalkanoate, poly 4 hydroxybutyrate (P4HB) and polygluconic acid (PGA).

Induced hepatocytes as a source for gene therapy

[00196] In additional embodiments, induced hepatocytes are utilized as a source for gene therapy. In some instances, the gene therapy is an *ex vivo* gene therapy. In some instances, induced hepatocytes are utilized as a therapeutic agent for gene therapy treatment of a liver-associated disease or disorder. In some instances, the gene therapy treatment is an induced hepatocyte-based gene therapy. In some instances, the induced hepatocyte-based gene therapy is utilized such as for example replacing defective or missing gene products, preventing allograft rejection, repopulating host liver, aid in generating xenogeneic hepatocytes, or tailored for patient-specific liver treatment or regeneration.

[00197] As described elsewhere herein, a liver-associated disease or disorder includes alagille syndrome, alpha 1 anti-trypsin deficiency, autoimmune hepatitis, benign liver tumors, biliary atresia, cirrhosis, cystic disease of the liver, fatty liver disease including alcohol-related liver

disease and non-alcohol fatty liver disease (NAFLD), galactosemia, gallstones, Gilbert's Syndrome, hemochromatosis, liver cysts, liver cancer, liver disease in pregnancy (e.g. acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, preeclampsia, or HELLP Syndrome (hemolysis, elevated liver tests, low platelets)), neonatal hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, porphyria, Reye's Syndrome, sarcoidosis, toxic hepatitis, type 1 glycogen storage disease, tyrosinemia, viral hepatitis A, B, C, and Wilson disease.

[00198] In some instances, induced hepatocytes are utilized as a therapeutic agent for gene therapy treatment of alagille syndrome, alpha 1 anti-trypsin deficiency, autoimmune hepatitis, benign liver tumors, biliary atresia, cirrhosis, cystic disease of the liver, fatty liver disease including alcohol-related liver disease and non-alcohol fatty liver disease (NAFLD), galactosemia, gallstones, Gilbert's Syndrome, hemochromatosis, liver cysts, liver cancer, liver disease in pregnancy (e.g. acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, preeclampsia, or HELLP Syndrome (hemolysis, elevated liver tests, low platelets)), neonatal hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, porphyria, Reye's Syndrome, sarcoidosis, toxic hepatitis, type 1 glycogen storage disease, tyrosinemia, viral hepatitis A, B, C, Wilson disease, or a combination thereof.

[00199] In some instances, genes are transferred into induced hepatocytes via viral or nonviral means. In some instances, viral means include vectors such as from murine leukemia retroviruses and lentiviruses, adenoassociated virus, T-antigen-deleted SV40 virus, neurotropic viruses such as Herpes simplex virus, episomal viruses and hybrid viruses such as adenoassociated viruses. In some instances, nonviral means include lipoplexes, polyplexes, dendrimers, inorganic nanoparticles, or hybrid vectors such as virosomes, which are a combination of liposomes with an inactivated virus such as HIV or influenza virus. In some instances, additional nonviral means include injection of naked DNA, electroporation, gene gun, sonoporation, or magnetofection. Methods of gene transfer by viral or nonviral means are well known in the art and are described for example, in Guha *et al.* "Hepatocyte-based gene therapy," *J Hepatobiliary Pancreat Surg.* 8(1):51-57 (2001).

[00200] As used herein, a gene can contain at least two nucleotides linked together. In some instances, a nucleic acid described herein can contain phosphodiester bonds, natural nucleic acids, or unnatural nucleic acids. A natural nucleic acid include both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) and is known by the one letter abbreviations A, T, G, C, and U. Exemplary unnatural nucleic acids include, without limitation, diaminopurine, isoguanine, isocytosine, 2-amino-6-(2-thienyl)purine, pyrrole-2-carbaldehyde, 2,6-

bis(ethylthiomethyl)pyridine, pyridine-2,6-dicarboxamide, 4-methylbenzimidazole, 2,3-difluorotoluene, d5SICS, and dNaM.

Diagnostic Methods

[00201] Methods for determining the expression or presence of biomarkers described *supra* are well known in the art, and can be measured, for example, by flow cytometry, immunohistochemistry, Western Blot, immunoprecipitation, magnetic bead selection, and quantification of cells expressing either of these cell surface markers. Biomarker RNA expression levels could be measured by RT-PCR, Q_t-PCR, microarray, Northern blot, or other similar technologies.

[00202] By "detecting expression" or detecting "expression levels" is intended for determining the expression level or presence of a biomarker protein or gene in the biological sample. Thus, "detecting expression" encompasses instances where a biomarker is determined not to be expressed, not to be detectably expressed, expressed at a low level, expressed at a normal level, or overexpressed.

[00203] In some embodiments, the expression or presence of a biomarker described herein is determined at a nucleic acid level, using, for example, immunohistochemistry techniques or nucleic acid-based techniques such as in situ hybridization and RT-PCR. In one embodiment, the expression or presence of one or more biomarkers is carried out by a means for nucleic acid amplification, a means for nucleic acid sequencing, a means utilizing a nucleic acid microarray (DNA and RNA), or a means for in situ hybridization using specifically labeled probes.

[00204] In other embodiments, the determining the expression or presence of a biomarker is carried out through gel electrophoresis. In one embodiment, the determination is carried out through transfer to a membrane and hybridization with a specific probe.

[00205] In other embodiments, the determining the expression or presence of a biomarker is carried out by a diagnostic imaging technique.

[00206] In still other embodiments, the determining the expression or presence of a biomarker is carried out by a detectable solid substrate. In one embodiment, the detectable solid substrate is paramagnetic nanoparticles functionalized with antibodies.

[00207] In some embodiments, the expression or presence of a biomarker is at an RNA (e.g. mRNA) level. In some embodiments, techniques that detect RNA (e.g. mRNA) level include, but are not limited to, Southern or Northern analyses, polymerase chain reaction analyses and probe arrays.

[00208] One method for the detection of mRNA levels involves contacting the isolated mRNA with a nucleic acid molecule (probe) that hybridize to the mRNA encoded by the gene being detected. The nucleic acid probe comprises of, for example, a full-length cDNA, or a portion thereof, such as an oligonucleotide of at least 7, 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to an mRNA or genomic DNA encoding a biomarker described herein. Hybridization of an mRNA with the probe indicates that the biomarker or other target protein of interest is being expressed.

[00209] In one embodiment, the mRNA is immobilized on a solid surface and contacted with a probe, for example by running the isolated mRNA on an agarose gel and transferring the mRNA from the gel to a membrane, such as nitrocellulose. In an alternative embodiment, the probe(s) are immobilized on a solid surface and the mRNA is contacted with the probe(s), for example, in a gene chip array. A skilled artisan readily adapts known mRNA detection methods for use in detecting the level of mRNA encoding the biomarkers or other proteins of interest.

[00210] An alternative method for determining the level of an mRNA of interest in a sample involves the process of nucleic acid amplification, e.g., by RT-PCR (see, for example, U.S. Pat. No. 4,683,202), ligase chain reaction (Barany (1991) Proc. Natl. Acad. Sci. USA 88:189-193), self-sustained sequence replication (Guatelli et al. (1990) Proc. Natl. Acad. Sci. USA 87:1874-1878), transcriptional amplification system (Kwoh et al. (1989) Proc. Natl. Acad. Sci. USA 86:1173-1177), Q-Beta Replicase (Lizardi et al. (1988) Bio/Technology 6:1197), rolling circle replication (U.S. Pat. No. 5,854,033) or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers. In some embodiments, biomarker expression is assessed by quantitative fluorogenic RT-PCR (i.e., the TaqMan[®] System).

[00211] Expression levels of an RNA of interest are monitored using a membrane blot (such as used in hybridization analysis such as Northern, dot, and the like), or microwells, sample tubes, gels, beads or fibers (or any solid support comprising bound nucleic acids). See U.S. Pat. Nos. 5,770,722, 5,874,219, 5,744,305, 5,677,195 and 5,445,934, which are incorporated herein by reference. The detection of expression also comprises using nucleic acid probes in solution.

[00212] In some embodiments, microarrays are used to determine expression or presence of one or more biomarkers. Nucleic acid microarrays provide one method for the simultaneous measurement of the expression levels of large numbers of genes. Each array consists of a reproducible pattern of capture probes attached to a solid support. Labeled RNA or DNA is

hybridized to complementary probes on the array and then detected by laser scanning. Hybridization intensities for each probe on the array are determined and converted to a quantitative value representing relative gene expression levels. See, U.S. Pat. Nos. 6,040,138, 5,800,992 and 6,020,135, 6,033,860, and 6,344,316, which are incorporated herein by reference. High-density oligonucleotide arrays are particularly useful for determining the gene expression profile for a large number of RNA's in a sample.

[00213] Techniques for the synthesis of these arrays using mechanical synthesis methods are described in, e.g., U.S. Pat. No. 5,384,261, incorporated herein by reference in its entirety. In some embodiments, an array is fabricated on a surface of virtually any shape or even a multiplicity of surfaces. In some embodiments, an array is a planar array surface. In some embodiments, arrays include peptides or nucleic acids on beads, gels, polymeric surfaces, fibers such as fiber optics, glass or any other appropriate substrate, see U.S. Pat. Nos. 5,770,358, 5,789,162, 5,708,153, 6,040,193 and 5,800,992, each of which is hereby incorporated in its entirety for all purposes. In some embodiments, arrays are packaged in such a manner as to allow for diagnostics or other manipulation of an all-inclusive device.

[00214] In some embodiments, the expression or presence of a biomarker described herein is determined at a protein level, using, for example, antibodies that are directed against specific biomarker proteins. These antibodies are used in various methods such as Western blot, ELISA, multiplexing technologies, immunoprecipitation, or immunohistochemistry techniques. In some embodiments, detection of biomarkers is accomplished by ELISA. In some embodiments, detection of biomarkers is accomplished by electrochemiluminescence (ECL).

[00215] Any means for specifically identifying and quantifying a biomarker in the biological sample is contemplated. Thus, in some embodiments, expression level of a biomarker protein of interest in a biological sample is detected by means of a binding protein capable of interacting specifically with that biomarker protein or a biologically active variant thereof. In some embodiments, labeled antibodies, binding portions thereof, or other binding partners are used. The word "label" when used herein refers to a detectable compound or composition that is conjugated directly or indirectly to the antibody so as to generate a "labeled" antibody. In some embodiments, the label is detectable by itself (e.g., radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, catalyzes chemical alteration of a substrate compound or composition that is detectable.

[00216] The antibodies for detection of a biomarker protein are either monoclonal or polyclonal in origin, or are synthetically or recombinantly produced. The amount of complexed protein, for example, the amount of biomarker protein associated with the binding protein, for example, an

antibody that specifically binds to the biomarker protein, is determined using standard protein detection methodologies known to those of skill in the art. A detailed review of immunological assay design, theory and protocols are found in numerous texts in the art (see, for example, Ausubel et al., eds. (1995) *Current Protocols in Molecular Biology* (Greene Publishing and Wiley-Interscience, NY)); Coligan et al., eds. (1994) *Current Protocols in Immunology* (John Wiley & Sons, Inc., New York, N.Y.).

[00217] The choice of marker used to label the antibodies will vary depending upon the application. However, the choice of the marker is readily determinable to one skilled in the art. These labeled antibodies are used in immunoassays as well as in histological applications to detect the presence of any biomarker or protein of interest. The labeled antibodies are either polyclonal or monoclonal. Further, the antibodies for use in detecting a protein of interest are labeled with a radioactive atom, an enzyme, a chromophoric or fluorescent moiety, or a colorimetric tag as described elsewhere herein. The choice of tagging label also will depend on the detection limitations desired. Enzyme assays (ELISAs) typically allow detection of a colored product formed by interaction of the enzyme-tagged complex with an enzyme substrate. Radionuclides that serve as detectable labels include, for example, I-131, I-123, I-125, Y-90, Re-188, Re-186, At-211, Cu-67, Bi-212, and Pd-109. Examples of enzymes that serve as detectable labels include, but are not limited to, horseradish peroxidase, alkaline phosphatase, beta-galactosidase, and glucose-6-phosphate dehydrogenase. Chromophoric moieties include, but are not limited to, fluorescein and rhodamine. The antibodies are conjugated to these labels by methods known in the art. For example, enzymes and chromophoric molecules are conjugated to the antibodies by means of coupling agents, such as dialdehydes, carbodiimides, dimaleimides, and the like. Alternatively, conjugation occurs through a ligand-receptor pair. Examples of suitable ligand-receptor pairs are biotin-avidin or biotin-streptavidin, and antibody-antigen.

[00218] In certain embodiments, expression or presence of one or more biomarkers or other proteins of interest within a biological sample is determined by radioimmunoassays or enzyme-linked immunoassays (ELISAs), competitive binding enzyme-linked immunoassays, dot blot (see, for example, *Promega Protocols and Applications Guide*, Promega Corporation (1991), Western blot (see, for example, Sambrook et al. (1989) *Molecular Cloning, A Laboratory Manual*, Vol. 3, Chapter 18 (Cold Spring Harbor Laboratory Press, Plainview, N.Y.)), chromatography such as high performance liquid chromatography (HPLC), or other assays known in the art. Thus, the detection assays involve steps such as, but not limited to, immunoblotting, immunodiffusion, immunoelectrophoresis, or immunoprecipitation.

Kits/Article of Manufacture

[00219] Disclosed herein, in certain embodiments, are kits and articles of manufacture for use with one or more methods and compositions described herein. Such kits include a carrier, package, or container that is compartmentalized to receive one or more containers such as vials, tubes, and the like, each of the container(s) comprising one of the separate elements to be used in a method described herein. Suitable containers include, for example, bottles, vials, syringes, and test tubes. In one embodiment, the containers are formed from a variety of materials such as glass or plastic.

[00220] The articles of manufacture provided herein contain packaging materials. Examples of pharmaceutical packaging materials include, but are not limited to, blister packs, bottles, tubes, bags, containers, bottles, and any packaging material suitable for a selected formulation and intended mode of use.

[00221] For example, the container(s) include hTS cells, optionally in a composition as disclosed herein. Such kits optionally include an identifying description or label or instructions relating to its use in the methods described herein.

[00222] A kit typically includes labels listing contents and/or instructions for use, and package inserts with instructions for use. A set of instructions will also typically be included.

[00223] In some embodiments, a label is on or associated with the container. In one embodiment, a label is on a container when letters, numbers or other characters forming the label are attached, molded or etched into the container itself; a label is associated with a container when it is present within a receptacle or carrier that also holds the container, e.g., as a package insert. In one embodiment, a label is used to indicate that the contents are to be used for a specific therapeutic application. The label also indicates directions for use of the contents, such as in the methods described herein.

EXAMPLES

[00224] These examples are provided for illustrative purposes only and not to limit the scope of the claims provided herein.

Example 1*Cell Culture and Differentiation*

[00225] Undifferentiated hTS cells were maintained in α -MEM (Gibco) supplemented with 10% (v/v) fetal bovine serum (SAFC Biosciences). Cultures were manually passaged at a 1:3–1:6 split ratio every 2–3 days. Differentiation of DE was carried out by a conditioned α -MEM

media containing 10% FBS, 1 mM 2-mercaptoethanol, 10 mM nicotinamide, and 10 ng/ml bFGF for 8 hr in 37 °C, 5 % CO₂ incubator. For hepatocytic differentiation, cultured medium was added with dexamethasone (0.1 μM, Sigma) and recombinant human oncostatin M (10 ng/ml, Excel-Biomedical Inc.) and incubated for an additional 4 days or 6 days.

[00226] The study was approved by the Institutional Review Board on Human Subjects Research and Ethics Committees, Kaohsiung Medical University Hospital. The hTS cells were obtained with informed consent.

Plasmids

[00227] MiR-124a precursor and anti-miR-124a were purchased from System Biosciences. Briefly, miR-124a precursor (60 pmol) or anti-miR-124a (60 pmol) was transfected to hTS cells in 12-well culture dishes using TransIT-LT1 transfection reagent (Mirus, Madison, WI). Total RNAs were used for quantifying miR-124a at 36 hr after transfection. Small interfering RNA (siRNA) targeting PI3K (SASI_Hs01_00233971 and SASI_Hs01_00127787), AKT1 (SASI_Hs01_00205545), and AKT2 (SASI_Hs01_00035055) were purchased from Sigma. Short hairpin RNA (shRNA) targeting CREB1 (TRCN0000007310, TRCN0000226467 and TRCN0000226468), SMAD4 (TRCN0000010321, TRCN0000010323 and TRCN0000040032), AKT3 (TRCN0000001615 and TRCN0000001616), OCT4 (TRCN0000004879 and TRCN0000004882), CDX2 (TRCN0000013683 and TRCN0000013686), and control shRNA (shGFP; TRCN0000072178, TRCN0000072179 and TRCN0000072183) were purchased from National RNAi Core platform, Academia Sinica, Taiwan. Transfection was performed with siRNA or shRNA at 2 μg plus 4 μl transfection reagent.

Western Blot and Immunoprecipitation (IP)

[00228] For immunoblotting assay, cells were harvested into RIPA lysis solution (Millipore, Billerica, MA) supplemented with protease and phosphatase inhibitors (Roche). After electrophoresis of 30 μg lysates on polyacrylamide gels, electroblotting onto PDVF membranes (Millipore) was performed. After blocked by 5% non-fat milk in PBS at room temperature (1 hr), target protein was detected by using primary antibody. All membranes were incubated with chemiluminescent (Millipore) and imaging was captured by the ChemiDoc XRS system (Bio-RAD). Antibodies used were listed in Table 1. Data were analyzed by AlphaEaseFC (version 4.0.0) system. For IP assay, Cell lysates of bFGF-treated hTS cells were collected. By incubation with protein G-agarose (Millipore) for 30 min, total protein (100 μg) was treated with specific primary antibody overnight listed in Table 1. After treating with protein G-agarose beads (2 hr), sample was washed three times with RIPA lysis buffer (Millipore), following by adding with

protein loading dye and boiled for 5 min. The sample was resolved by 8% SDS-PAGE and subjected to immunoblotting analysis.

mRNA, miRNA, and chromatin immunoprecipitation (ChIP)-qPCR Assays

[00229] For mRNA expression, RNA was isolated from hTS cells in triplicate or quintuple samples using TRIZOL reagent (Invitrogen) with DNAase I on-column digestion (Qiagen, Valencia, CA). Total RNA (500 ng) was used for reverse transcription with iScript cDNA synthesis kit (Bio-Rad). Real-time polymerase chain reaction (qPCR) was carried out in duplicate using 1/40th of the cDNA per reaction and 400 nM forward and reverse primers. Comparative real-time PCR was carried out at least triplicate using the Power SYBR® Master Mix (Applied Biosystems) with the 7500 Real-Time PCR System (Applied Biosystems). All genes were normalized to the GAPDH expression and were normalized to the expression of undifferentiated hTS cells using the $\Delta\Delta C_t$ method. Primer sequences used in this study are illustrated in Table 2.

[00230] For miRNA analysis, 25 ng of total RNA was reverse-transcribed using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems). qPCR was carried out at least triplicate using the TaqMan Universal PCR Master Mix (Applied Biosystems) with the 7500 Real-Time PCR System (Applied Biosystems) including no-template controls, using specific primers for miR-124a or *RNU6B* (Applied Biosystems). U6 snRNA (*RNU6B*; Applied Biosystems) served as an endogenous control.

[00231] For ChIP assay, hTS cell samples of indicated time in induction were fixed with a final concentration of 1% formaldehyde. After incubation at room temperature (10 min), the reaction was stopped by adding glycine (125 mM). ChIP assay was performed using a protocol associated with the ChIP assay kit (Upstate Biotechnology). After extensive washing, ChIPed DNA was eluted from the beads and analyzed by qPCR.

Luciferase Reporter Assay

[00232] To prepare the luciferase-3' UTR reporter plasmids, 3'UTR fragments from genomic DNA extract of hTS cells were amplified. The 3' UTR PCR fragment was cloned into the pGL4.51 vector (Promega, Madison, WI) downstream of the luciferase gene by using *PsiI* and *MfeI* (Thermo Scientific, Rockford, IL). Primers for 3' UTR reporter construct were listed as followings: For *CDX2* 3' UTR region: forward, 5'-aaattataagctgtttgggttggtgct-3' and reverse, 5'-aaacaattgccccataatttctgactgc-3; For *SMAD4* 3' UTR region 1: forward, 5'-aaattataactcccaaagtctgggatta-3' and reverse, 5'-aaacaattgctgcactgttcacaggagga-3; For *SMAD4* 3' UTR region 2: forward, 5'-aaattataacagttgtcccagtctgcta-3' and reverse, 5'-

aaacaattgatgactgccc aaaggtcac-3; For *GSK3 β* 3' UTR region: forward, 5'-aaattataaccacaactggggtaaaaga-3' and reverse, 5'-aaacaattgctgtggaaggggcaaagata-3.

[00233] For dual luciferase assays, firefly luciferase reporter (500 ng) or empty vector without any 3'UTR co-transfected with pGL4.74 and renilla luciferase plasmid (500 ng, Promega), and non-specific control miRNA (30 pmol) or miR-124a precursor (30 pmol; System Biosciences, Mountain View, CA) were co-transfected to hTS cells (1.5×10^4 cells in each well) using TransIT®-LT1 transfection reagent (Mirus Bio LLC, Madison, WI). After transfection (36 hr), the luciferase activity was analyzed by the dual luciferase reporter assay system (Promega) and the Centro LB 960 Microplate Luminometer (Berthold Technologies, Bad Wildbad, Germany). For evaluation, renilla luciferase value was first normalized to the firefly luciferase activity and the calculated activity of each 3'UTR reporter was further normalized to the control vector. Data represented as mean \pm SD, n = 8, p < 0.05 as statistic significance. Whole cell extracts prepared in the cell lysis buffer were subjected to immunoblotting with CDX2, SMAD4, GSK3 β , and β -actin antibodies.

Immunofluorescence Staining

[00234] Slides with cell culture was fixed for 30 min at room temperature in 95% (v/v) ethanol, washed three times in PBS and incubated with blocking buffer PBS containing 0.1% (wt/v) Triton X-100 (Sigma) and 5% (v/v) normal donkey serum (Millipore) for 60 min. Primary and secondary antibodies were diluted in blocking buffer. Primary antibody was incubated. After incubation with specific primary antibody in PBS at 4 °C (24 hr) or room temperature (2 hr), appropriate fluorescein isothiocyanate (FITC, Invitrogen) or Alexa Fluor 488, 594, and 647 (Invitrogen) or Dylight 488 and 594 (BioLegend) conjugated secondary antibody was added at room temperature (1 hr). After DAPI staining of nucleus (5 min), incubation with secondary antibody (1 hr) at room temperature, and washes, sample was mounted with 50% glycerol. Images were captured by confocal laser scanning microscopy (LSM700; Zeiss Z1 or Olympus FluoView 1000 confocal laser scanning microscope) or TissueFAXS system (TissueQnostics GmbH, Vienna, Austria). Data were analyzed by TissueQuest software.

Flow Cytometry

[00235] After transfection with non-specific shRNA or shRNAs against CDX2, OCT4, SOX2, and NANOG, cells (5×10^6 cells/ml) were incubated with specific primary antibodies for 30 min as listed in Table 1. Followed by incubation with the appropriate fluorescent dye-conjugated primary antibody at adjusted dilution for 1 hr at 4 °C, samples were washed and re-suspended in PBS. After passing through polystyrene round-bottom tube with cell strainer cap (BD Falcon),

sample was subjected for flow cytometry (FACScan, BD Biosciences, San Jose, CA). Data were analyzed with Cell-Quest software (BD Biosciences).

Electron Microscopy

[00236] For transmission electron microscopy, the hTS cell-derived hepatocytes-like cells (at day-4 after induction) were fixed in 0.1 M sodium cacodylate buffer (pH 7.4) containing 3% wt/vol formaldehyde, 1.5% (wt/vol) glutaraldehyde and 2.5% (wt/vol) sucrose at room temperature (RT) for 1 hr or at 4°C overnight. The samples were washed with 0.1 M sodium cacodylate buffer (pH 7.4) before and after osmication treatment (2 hr) at 4°C in Palade's fixative containing 1% (vol/vol) OsO₄. After treated with tannic acid, stained with 1 % uranyl acetate, and dehydrated through a graded series of ethanol solutions, sample was embedded in TABB epoxy resin (Agar Scientific Ltd.). Ultrathin sections were stained with uranyl acetate and lead citrate and analyzed by using JEM-2000 EXII Transmission electron microscope (JEOL, Tokyo).

LDL Uptake Assay

[00237] LDL uptake was performed by using LDL Uptake Cell-Based Assay Kit as manufacturer's instruction (Cayman Chem Co. Ann Arbor, MI.). Briefly, 5x10⁴ cells were seeded at coverslip in each well of a 24-well plate. hTS cells (as control) and the differentiated hepatocyte-like cells (hHLCs) were fixed after 5 µg/ml LDL-DyLight™ 549 probe treatment (4 hr, 37 °C) and then stained for LDL receptor by rabbit anti-LDL and DyLight™ 488-conjugated Goat anti-rabbit antibody. Nuclei were visualized with DAPI. The final staining was observed by fluorescence microscopy.

Oil-O-Red Test

[00238] For detection of lipid accumulation, differentiated cells were fixed with 4% paraformaldehyde (20 min) at room temperature (RT) and washed with 60% isopropanol for 5 min. After incubation at RT (20 min) with a freshly prepared 60% Oil Red O solution (0.5 g Oil Red O in 100 ml isopropanol passed through a 0.22 µm filter before using, Sigma), cells were rinsed with 60% isopropanol and counterstained with Hematoxylin I (Thermo Scientific) for microscopy.

Glycogen Storage Test

[00239] For glycogen detection, differentiated cells were fixed by 4% paraformaldehyde. Fixed samples were permeabilized with 0.4% Triton X-100. Undifferentiated control cells were incubated with Diastase (1 mg/ml in PBS; Sigma) for 1 hr at 37°C. Cells were incubated with periodic acid (0.5 g dissolved in 100 ml distilled water) for 5 min at RT, washed with distilled water, and incubated with fresh prepared Schiff's reagent (15 min) and subjected for microscopy.

Albumin and Urea Assays

[00240] The concentrations of total protein, albumin, and urea in the culture medium of hTS cells were measured before and after induction by an automatic analyzer (Hitachi 7080; Tokyo, Japan).

Statistical Analysis

[00241] All of the experiments were conducted in triplicate and repeated two times as indicated. Data obtained from Western blots, qPCR, luciferase reporter assay, and flow cytometry were calculated by Student's *t*-test. *p*-value < 0.05 was considered statistically significant.

A Cellular Process from hTS Cells to DE Lineages.

[00242] Differentiation of human pluripotent stem cells to hepatocyte-like cells, DE formation is the first step needed to be identified during the cell processes. It was found that in hTS cells, bFGF (10 ng/ml) enabled to efficiently yield DE at 8 hr induction, expressing specific biomarkers; forkhead box protein A2 (FOXA2) and SRY-box 17 (SOX17), Goosecoid (GSC), and Homeodomain protein MIXL1 by immunofluorescence microscopy (Figure 1A-1C). Subsequently, a timeline expression of the DE-associated markers was established, including transcription factors: GSC, brachyury (T), MIXL1, SOX17, and FOXA2, upon bFGF induction by immunoblotting assays (Figure 1D). It was found that levels of MIXL1, Brachyury, and GSC significantly elevated at the initial 15 min, suggesting a transition of primitive streak. These levels, however, declined after 30 min, implicating a migration from primitive streak to a nascent mesendoderm. Specifically, MIXL1 levels decreased from the peak (15 min) down to a nadir (~50% lower than the native one) at 4 hr and, henceforth, the levels returned to the original ones. This fact was supported by imaging study (Figure 1C) and TissueFAX analysis (Figure 7). These results suggested the cellular processes moving from the mesendoderm to the DE stage because: i) MIXL1 mRNA expression is absent from endoderm but confined to the mesoderm, and ii) loss of MIXL1 has an impact on the endoderm potential of the mesendoderm progenitors as MIXL1 is expressed specifically in the primitive streak. SOX17 levels upregulated to peak at 2 hr (1.5-fold) but downregulated at 8 hr; while a continually upregulated FOXA2 to the highest levels (3-fold) at 8 hr (Figure 1D). However, there was a downregulation of GSC from 30 min to 1 hr but still sustained at a slightly higher than the original levels (Figure 1D). To this end, these data suggest that bFGF (10 ng/ml) enables to induce transdifferentiation of hTS cells to DE lineages in a highly efficient manner by upregulating SOX17, FOXA2, and GSC, but downregulating MIXL1 at 8 hr induction. Wherefrom, DE gives rise to epithelial lining of the lungs, esophagus, stomach, and intestines, as well as endocrine glands such as the liver, pancreas, and thyroid.

Dexamethasone and SOX17 Driving Differentiation to Hepatic Fate by HNF4a Expression

[00243] Hepatocyte nuclear factor 4 (HNF4) is an essential transcription factors for specification of human hepatic progenitor cells. Since dexamethasone (Dexa) induces HNF4 α expression and cytokine oncostatin M (OSM) involves in the fetal liver development. It was found that by adding dexamethasone (0.1 μ M) and oncostatin M (10 ng/ml) to the conditioned culture medium at 8 hr of induction resulted in the differentiation of hepatocyte-like cells, expressing hepatic markers after 4 days by immunostainings, for example, albumin, α -fetoprotein (AFP), biliary transport protein MRP2 (ABCC2), and bile salt export pump (BSEP) (Figure 1E).

[00244] Subsequently, immunoblotting assays in time course revealed that both FOXA2 and SOX17 sustained at a higher level towards 24 hr, following a sudden declination at day-2 (Figure 1F). Interestingly, SOX17 can directly activate zinc finger protein 202 (ZFP202) that suppresses HNF4 α during endoderm differentiation. In DE stage, a significant reduction of SOX17 levels after peaking (2 hr) (Figure 1D) that probably indirectly reduced the suppressive effect on HNF4 α ; thereby, facilitated the dexamethasone-induced HNF4 α activation. As such a combinatory effect of bFGF, dexamethasone, and SOX17 withdrawal devotes the initiation of hepatic specified endoderm by HNF4 α expression. Moreover, albumin expressed after 12 hr, supporting a differentiation to hepatic endodermal lineages (Figure 1F). Consequently, active HNF4 α may control morphological and functional differentiation of hepatocytes; thereby, the entrance of hepatoblastic stage can take place at day-2 of induction. The appearance of AFP at day-3 indicated a cell process of fetal immature hepatocytes. Interestingly, a peak level of betatrophin appeared at day-3, suggesting its involvement in the regulation of nutrition and lipid metabolism. Taken together, hTS cells can be efficiently differentiated to hepatocyte-like cells within week, mimicking cellular processes of primary hepatocytes in embryogenesis. Indeed, these findings suggest that this two-step regimen enables to generate hepatocyte-like cells from hTS cells distinct from the time-consuming protocols reported previously in hES cells and iPS cells.

Regulatory Mechanisms of miRNA-124a in DE Specification.

[00245] Understanding the molecular mechanisms of how bFGF induces DE formation are essential and required for further hepatic differentiation. bFGF enabled to induce the PI3K/AKT/CREB1 signaling pathway via its receptor FGFR1 (Figure 8A-8D). Activation of CREB1 therefore allowed us to focus on the involvement of microRNAs (miRs), the small non-coding RNAs, because of two reasons: i) miR-124a enables to regulate FOXA2 in pancreatic β -cells, the hepatocyte counterpart of DE-derivation and ii) miR-124 binding to the site of *CREB1* gene is conserved in the mammalian CREB1 3'UTR. Generally, miRs play as key regulators

involved in various biological processes including the stem cell differentiation by inhibiting translation and/or to cause RNA degradation. To that, it was found that active CREB1 enabled to target at three sites of the promoter of miR-124a mRNA by ChIP-qPCR assay to promote miR-124a expression (Figure 2A). This action was supported by knockdown of CREB1 that reduced miR-124a expression (Figure 2B) and, also, a parallel correlation in expression by qPCR assay (Figure 2B). Together, these results suggest that bFGF enables to induce the PI3K/AKT/CREB1 signaling pathway and, in turn, CREB1 promoted miR-124a expression peaking at 4 hr induction during DE stage.

[00246] Notably, a correlative expression between the highest miR-14a and the lowest MIXL1 at 4 hr induction attracted us to examine whether there was a relationship between them. By sequence analysis and luciferase reporter assay, miR-124a enabled to target Smad4 messenger RNA (mSmad4) at two sites, resulting in the prevention of signal transduction protein Smad4 production evidenced by the luciferase reporter assay (Figure 2D) and immunoblotting assay (Figure 2E). Consistently, the inhibitory Smad4 of miR-124 caused a suppression of MIXL1, supported by knockdown of Smad4 (Figure 2F). These data explained the downregulation of MIXL1 in DE stage, which was attributed to the activation of bFGF-induced miR-124a. Furthermore, miR-124a also enabled to play other roles, for example, it suppressed glycogen synthase kinase 3 β (GSK3 β) mRNA by luciferase reporter assay (Figure 2G) that inhibited the production of GSK3 β (Figure 2E). This inhibitory GSK3 β resulted in the nuclear translocation of its downstream substrate β -catenin. In the nucleus, β -catenin enabled to target the promoter of *FOXA2* gene by ChIP-qPCR assay to produce FOXA2 (Figure 2H). To this end, the expression of FOXA2 highlights the cell differentiation at DE stage.

Maintenance of Self-Renewal Characteristics by OCT4

[00247] On the other hand, miR-124a also enabled to target *CDX2* mRNA (Figure 2I) to inhibit its translation that decreased CDX2 production of CDX2, a pluripotent transcription factor (Figure 2E). This was supported by the presence of co-transfected miR-124a- and CDX2 plasmids (Figure 2I). The inhibitory CDX2, however, led to an activation of pluripotent transcription factor OCT4 (Figure 2E) via the reciprocal inhibitory relationship between OCT4 and CDX2. This function was reflected by the imaging study (Figure 2J) and immunoblotting assay (Figure 2K). OCT4 activation could be inhibited by anti-miR-124a antibody, linking miR-124a and OCT4 by immunoblotting assay (Figure 2E). The gradual elevation of both pluripotent transcription factors NANOG and SOX2 towards 8 hr (Figure 2K) suggested a supportive role in the maintenance of pluripotency of DE lineages compatible with that in hES cells. Therefore, these data suggest that OCT4 mainly maintains the self-renewal characteristics of DE, supported

by other core pluripotency transcription factors NANOG and SOX2. Furthermore, the active OCT4 was capable of targeting at two sites of the promoter of *SOX17* mRNA by ChIP-qPCR assay (Figure 2L) that induced SOX17 expression peaking at 2 hr (Figure 1C). SOX17 expression represents another milestone in DE identification. Taken together, these results demonstrate in hTS cells that bFGF-dependent miR-124a induces DE formation in a highly efficient manner (8 hr) distinct from the 3-day course in hES cells. A schematic regulatory molecular mechanism illustrates the DE specification through the miR-124a signaling to upregulate FOXA2, SOX17, and OCT4 but downregulate MIXL1; wherein OCT4 plays a main role in the maintenance of self-renewal of DE lineages (Figure 2L).

Genetic Profiles Correspond with the Stage-Specific Phenotypes in Hepatic Development

[00248] To subsequently direct DE differentiation into hepatic lineages, dexamethasone and oncostatin M were added after completion of DE stage at 8 hr. Given the advantages of qRT-PCR assay, the dynamic expression of hepatic development-associated 31 genes in a time course profile was explored to characterize mRNA fingerprint that could be used to follow the differentiation process. In all, the genetic profiles of each gene revealed a similar pattern with 4-5 peaks during 6-day induction. Based on the cellular processes of hepatic development in mouse model, the hTS cells treated with bFGF and the cocktail of dexamethasone and oncostatin M were classified based on their genetic expression profiles into four stages of cellular processes: primitive streak to DE (< 8 hr), hepatic specified endoderm lineages (8 hr to day-1), hepatoblasts (day 2-4), and fetal and adult hepatocyte-like cells (day \geq day 4) (Figure 9A-9F).

[00249] Therefore, these results revealed that i) at the stage of primitive streak to DE, four genes expressed predominantly (>10- to 1,000-fold), include CXCR4, FOXA2, SOX17, and HHEX; ii) at the hepatic specified endoderm, six genes expressed predominantly (between 10- and 100-fold), including SOX17 for liver bud formation and lipid metabolism, thyroxin- and retinol-binding protein TTR, proteins carrier albumin (ALB), tyrosine catabolism enzyme TAT, SERPINA1, and bile acid biosynthesis enzyme CYP7A1; iii) at the hepatoblastic stage, there were 6 genes expressed predominantly (between 10- and 100-fold), including TTR, ALB, TAT, CYP7A1, SERPINA1, and bile salts excretion pump BSEP; and iv) at the fetal and adult hepatocyte-like cell stage, there were 11 genes expressed prominently (>100-fold), including HHEX, BSEP, TTR, ALB, TAT, SERPINA1, glucose homeostasis enzyme G6PC, hepatobiliary excretion transporter MRP2 (ABCC2), immune and normal macrophage regulator C/EBP β , and several hepatic gene regulators such as HNF4 α and HNF1 α . Furthermore, expression of α -fetoprotein (AFP) appeared at fetal stage (day-4 and day-5), but decreased after day-5 of adult hepatocyte-like cell stage (Figure 6).

Hepatic Plate-Like Architecture Exhibits Signatures of Hepatocytes

[00250] In liver, hepatic plate system constitutes a unique tissue structure, composed of bile ducts and blood vessels surrounded by a sheath that is continuous with Glisson's capsule. To characterize the morphologic changes of hTS cell-derived hepatocyte-like cells during differentiation, it was found that cellular morphology changed from the initial fibroblast-like to a longer spindle feature in accompany with a trend to form lobular shape, showing numerous polygonal cells localized at the central areas at day-2 and day-3 (Figures 3A). After day-4, however, cells might aggregate to form a plate-like mass and this phenomenon depended on the initial cell number cultured. The cell mass was then subjected to further examinations.

[00251] Histologically, most of the cellular arrangement appeared to be one cell or two cells thick eosinophilic cytoplasm to form a plate-like tissue; however, cells might aggregate together to form a cell mass (Figure 3A). Immunohistochemically, these cells exhibited immunofluorescence stainings for Albumin, AFP, Betatrophin, HNF4 α , APOF, CPS1, ADH1, and CYP2B6 in the cytoplasmic compartment; while a subset of cell membrane markers, including CXCR4, CX32, MRP2, and BSEP, making the cell in polygonal shape similar to the primary hepatocytes (Figure 3B). Electron microscopy displayed ultrastructures similar to the primary hepatocyte, for example, large cytoplasm to nucleus ratio, plenty of mitochondria, well-organized endoplasmic reticulum, desmosome junction, intact golgi apparatus, and specifically, the enlarged lumen of the canaliculus and the junctional complexes (Figure 3C). Moreover, immunocytofluorescence imaging revealed a colocalization of AFP and Albumin as well as ABCC2 (MRP2) and BSEP (Figure 1E). To this end, it was demonstrated that these hepatocyte-like cells possess hepatic characteristics of either cellular components or infrastructures that resemble to the primary hepatocytes.

Hepatocyte-Like Cells Function as Primary Hepatocytes in vitro and in vivo

[00252] The liver is the most important organ responsible for many specific functions in metabolisms such as albumin synthesis, ureagenesis, glycogenesis, and detoxification. To examine whether these hepatocyte-like cells are able to function similar to the primary hepatocytes, the secreting capability of albumin and urea in the cells were investigated. Culture medium at day-4 induction was harvested and subjected to the ELISA analysis. The results revealed that both albumin and urea levels were significantly increased, suggesting their capabilities to produce secreting albumin and urea in the culture medium (Figure 4A). Next, glycogen storage capacity test revealed a positive periodic acid-Schiff (PAS) staining after diastase digestion treatment in either cellular phase or hepatic plate-like tissue (Figure 4B). This action was further confirmed by the PAS fluorescence emission for both immunocytochemistry

and immunohistochemistry (Figure 4B). In addition, LDL uptake assay revealed that the ability of LDL uptake of cells initiated at the immature hepatocytes of day-4 induction (Figure 4C). Oil-O-Red staining revealed the presence of lipid droplets, suggesting somehow the degree of adipogenesis (Figure 4D). Furthermore, it was examined whether the hepatocyte-like cells possess the capacity of drug metabolism and detoxification *in vitro* by using cytochromes P450 (CYPs) enzymes as target by qPCR analysis. The results revealed that the hepatocyte-like cells significantly expressed activities of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4, and CYP7A1 in response to metabolize specific drugs (Figure 5A-5I), suggesting that these hepatocyte-like cells can be used for drug screening and discovery similar to primary hepatocytes. For example, a liver enzyme-inducer rifampin can promote CYP3A4 activity to increase the metabolic rate of drug and inhibition of CYP3A4 is a major cause of drug-drug interactions (DDI), which have been widely used in the clinical settings. Furthermore, it has been shown that phloracetophenone (2,4,6-trihydroxyacetophenone,THA) promotes both CYP7A1 activity and mRNA expression to reduce both plasma cholesterol and triglyceride in hypercholesterolemic hamsters and THA antagonized the inhibitory regulation of chenodeoxycholic acid (CDCA) on CYP7A1 mRNA expression. To that, it was shown that in the hepatocyte-like cells, rifampin-induced CYP3A4 was able to be reduced by its inhibitor itraconazole (Figure 5H), while THA induced elevation of CYP7A1 mRNA was reduced by CDCA (Figure 5I). From the pharmacological point of view, for example, bile acid binding resins are indicated for the treatment of elevated plasma low-density lipoprotein cholesterol concentrations, however, resin therapy is hazardous. Therefore, new drugs have been designed by approaching the regulation of CYP7A1 to reduce plasma cholesterol and be based on the confirmation of CYP7A1 position as a focus for innovative pharmacological intervention.

Basic FGF induced activation of PI3K/AKT/CREB1 signaling pathway in hTS cells

[00253] The hTS cells were treated with bFGF (10 ng/ml) in the conditioned medium, and it was shown that FGF receptor (FGFR) inhibitor PD166866 could block the bFGF-induced activation of phosphatidylinositol 3-kinase (PI3K) by immunoblotting assay (Figure 8A), suggesting that the inhibitory effect was through the FGFR at the cell membrane. As a result, the downstream effector AKT was phosphorylated evidenced by using PI3K siRNA (Figure 8B). To clarify which protein kinase B (AKT) subunit was activated, specific siRNA against three AKT subunits: AKT1, AKT2, and AKT3 were examined by immunoblotting assay. The result showed that only AKT1 phosphorylated and activated its downstream effector cAMP response element-binding protein 1 (CREB1) (Figure 8C). This function was further confirmed by

immunoprecipitation (IP) assay (Figure 8D). Taken together, this indicates that bFGF induces activation of the PI3K/AKT1/CREB1 signaling pathway at 4 hr induction.

Example 2

EXPERIMENTAL PROCEDURES

Cell Culture and Differentiation

[00254] This study was approved by the Institutional Review Board on Human Subjects Research and Ethics Committees (KMUHIRB-20140071). The hTS cells were obtained with informed consent as described previously (Lee et al., 2012, PLoS ONE 7, e52491) and maintained in α -MEM (Gibco) medium supplemented with 10% (v/v) fetal bovine serum (FBS; SAFC Biosciences) at 37 °C in humidified air containing 5% CO₂. For DE differentiation, cells were carried out by a conditioned α -MEM media containing 10% FBS, 2-mercaptoethanol (1 mM), nicotinamide (10 mM), and bFGF (10 ng/ml) for 8 hr, according to the empirical studies (data not shown). For hepatocyte differentiation after DE formation at 8 hr, cell culture was changed to medium containing bFGF (10 ng/ml), dexamethasone (0.1 μ M, Sigma), recombinant human oncostatin M (10 ng/ml, Excel-Biomedical Inc.), BMP4 (20 ng/ml), and HGF (5 ng/ml). Cells were harvested at 4-7 days for assay as indicated. Determination of stage-specific differentiation of lineages depends on the hepatic cell-associated markers in liver development.

Animal Study

[00255] Adult male Sprague–Dawley rats (300–350 g) were housed in a 12 hr light/12 hr dark cycle with *ad libitum* access to food and water. Experimental studies were approved by Institutional Animal Ethical Committee (IAEC) of Kaohsiung Medical University (IACUC-96009). For experiments, rats were anesthetized with chloral hydrate 25% (500 mg/kg) via intraperitoneal injection. Rats were divided into two groups: the sham operation as control (n = 8) and the other as study group (n = 8). Intravenous blood (0.5 ml) was obtained as baseline before experiment and both groups were injected intraperitoneally with CCl₄ (1 ml/kg: 1:1 v/v in corn oil) after 12 hr. Immediately, study group was injected by hTS cell-derived hepatocytes (1x10⁶ cells/200 μ l culture medium) from the tail vein and sham group was given PBS solution only. Serum sample was taken at baseline, cell injection point, 24 hr, 48 hr, and 72 hr and subjected for liver function tests, namely, aspartate aminotransferase (AST or formerly called SGOT), alanine aminotransferase (ALT or formerly called SGPT), and alkaline phosphatase (ALP), serum bilirubin. All rats were sacrificed at day 4 to obtained liver and lung organs for histopathological studies.

mRNA, miRNA, Chromatin Immunoprecipitation (ChIP)-qPCR, and mRNA Microarray

[00256] Methods were performed as described previously (Lee et al., 2012, PLoS ONE 7, e52491). For mRNA expression, RNA was isolated from hTS cells in triplicate or quintuple samples using TRIZOL reagent (Invitrogen) with DNAase I on-column digestion (Qiagen, Valencia, CA) according to manufacturer's instruction. Total RNA (500 ng) was used for reverse transcription with iScript cDNA synthesis kit (Bio-Rad). Real-time polymerase chain reaction (qPCR) carried out in duplicate using 1/40th of the cDNA per reaction and 400 nM forward and reverse primers. Comparative real-time PCR was carried out at least triplicate using the Power SYBR® Master Mix (Applied Biosystems) with the 7500 Real-Time PCR System (Applied Biosystems). All genes were normalized to the GAPDH expression and were normalized to the expression of undifferentiated hTS cells using the $\Delta\Delta C_t$ method unless stated otherwise. Primer sequences used in this study can be found in Table 5.

[00257] For miRNA analysis, 25 ng of total RNA was reverse-transcribed using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems). qPCR was carried out at least triplicate using the TaqMan Universal PCR Master Mix (Applied Biosystems) with the 7500 Real-Time PCR System (Applied Biosystems) including no-template controls, using specific primers for miR-124a or *RNU6B* (Applied Biosystems). U6 snRNA (*RNU6B*; Applied Biosystems) served as an endogenous control.

[00258] For ChIP assay, hTS cell samples of indicated time in induction were fixed with a final concentration of 1% formaldehyde. After incubation at room temperature (10 min), the reaction was stopped by adding glycine (125 mM). ChIP assay was performed using a protocol associated with the ChIP assay kit (Upstate Biotechnology). After extensive washing, ChIPed DNA was eluted from the beads and analyzed by qPCR.

Luciferase Reporter Assay

[00259] To prepare the luciferase-3' UTR reporter plasmids, amplified were 3'UTR fragments from genomic DNA extract of hTS cells. The 3' UTR PCR fragment was cloned into the pGL4.51 vector (Promega, Madison, WI) downstream of the luciferase gene by using *PsiI* and *MfeI* (Thermo Scientific, Rockford, IL). Primers for 3' UTR reporter construct were listed as followings:

[00260] For *Cdx2* 3' UTR region:

forward, 5'-aaattataagctgtttgggttgggtct-3' and

reverse, 5'-aaacaattgccccataatttctgactgc-3';

[00261] For *Smad4* 3' UTR region 1:

forward, 5'-aaattataactcccaaagtctgggatta-3' and

reverse, 5'-aaacaattgctgcactgttcacaggagga-3';

[00262] For *Smad4* 3' UTR region 2:

forward, 5'-aaattataacagttgtcccagtgctgcta-3' and

reverse, 5'-aaacaattgatgacttgcccaaagggtcac-3';

[00263] For *GSK3 β* 3' UTR region:

forward, 5'-aaattataaccacaactgggtaaaaga-3' and

reverse, 5'-aaacaattgctgtggaaggggcaaagata-3.

[00264] For dual luciferase assays, firefly luciferase reporter (500 ng) or empty vector without any 3'UTR co-transfected with pGL4.74 and renilla luciferase plasmid (500 ng, Promega), and non-specific control miRNA (30 pmol) or miR-124a precursor (30 pmol; System Biosciences, Mountain View, CA) were co-transfected to hTS cells (1.5×10^4 cells in each well) using TransIT®-LT1 transfection reagent (Mirus Bio LLC, Madison, WI). After transfection (36 hr), the luciferase activity was analyzed by the dual luciferase reporter assay system (Promega) and the Centro LB 960 Microplate Luminometer (Berthold Technologies, Bad Wildbad, Germany). For evaluation, renilla luciferase value was first normalized to the firefly luciferase activity and the calculated activity of each 3'UTR reporter was further normalized to the control vector. Data represented as mean \pm SD, n = 8, p < 0.05 as statistic significance. Whole cell extracts prepared in the cell lysis buffer were subjected to immunoblotting with Cdx2, Smad4, GSK3 β , and β -actin antibodies.

Plasmids

[00265] MiR-124a precursor and anti-miR-124a were purchased from System Biosciences. Briefly, miR-124a precursor (60 pmol) or anti-miR-124a (60 pmol) was transfected to hTS cells in 12-well culture dishes using TransIT-LT1 transfection reagent (Mirus, Madison, WI). Total RNAs were used for quantifying miR-124a at 36 hr after transfection. Small interfering RNA (siRNA) targeting PI3K (SASI_Hs01_00233971 and SASI_Hs01_00127787), Akt1 (SASI_Hs01_00205545), and Akt2 (SASI_Hs01_00035055) were purchased from Sigma. Short hairpin RNA (shRNA) targeting CREB1 (TRCN0000007310, TRCN0000226467 and TRCN0000226468), Smad4 (TRCN0000010321, TRCN0000010323 and TRCN0000040032), Akt3 (TRCN0000001615 and TRCN0000001616), Oct4 (TRCN0000004879 and TRCN0000004882), Cdx2 (TRCN0000013683 and TRCN0000013686), and control shRNA (shGFP; TRCN0000072178, TRCN0000072179 and TRCN0000072183) were purchased from National RNAi Core platform, Academia Sinica, Taiwan. Transfection was performed with siRNA or shRNA at 2 μ g plus 4 μ l transfection reagent.

LDL Uptake Assay

[00266] LDL uptake was performed by using LDL Uptake Cell-Based Assay Kit as manufacturer's instruction (Cayman Chem Co. Ann Arbor, MI.). Briefly, 5×10^4 cells were seeded at coverslip in each well of a 24-well plate. hTS cells (as control) and the differentiated hepatocyte-like cells (hHLCs) were fixed after 5 $\mu\text{g}/\text{ml}$ LDL-DyLight™ 549 probe treatment (4 hr, 37 °C) and then stained for LDL receptor by rabbit anti-LDL and DyLight™ 488-conjugated Goat anti-rabbit antibody. Nuclei were visualized with DAPI. The final staining was observed by fluorescence microscopy. .

Oil-O-Red Test

[00267] For detection of lipid accumulation, differentiated cells were fixed with 4% paraformaldehyde (20 min) at RT and washed with 60% isopropanol for 5 min. After incubation at RT (20 min) with a freshly prepared 60% Oil Red O solution (0.5 g Oil Red O in 100 ml isopropanol passed through a 0.22 μm filter before using, Sigma), cells were rinsed with 60% isopropanol and counterstained with Hematoxylin I (Thermo Scientific) for microscopy.

Glycogen Storage Test

[00268] For glycogen detection, differentiated cells were fixed by 4% paraformaldehyde. Fixed samples were permeabilized with 0.4% Triton X-100. Undifferentiated control cells were incubated with Diastase (1 mg/ml in PBS; Sigma) for 1 hr at 37°C. Cells were incubated with periodic acid (0.5 g dissolved in 100 ml distilled water) for 5 min at RT, washed with distilled water, and incubated with fresh prepared Schiff's reagent (15 min) and subjected for microscopy.

Biochemical Parameter Tests

[00269] All biochemical parameters of liver function including albumin, urea, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were measured by using auto-analyzer (Hitachi 7080, Japan).

Functional Cytochrome p450 Assay

[00270] To test the activity of CYP enzyme induction in hTS cell-derived hepatocyte-like cells, cells were treated with reagents for 24 hr, for example, for CYP1A2 test, used were rifampicin (25 μM)/ rifampicin + ciprofloxacin (1 μM); for CYP2B6 test by phenobarbital (100 μM)/ phenobarbital + clopidogrel (25 μM), for CYP3A4 by rifampicin (25 μM)/ rifampicin + itraconazole (25 μM), for CYP7A1 by 2,4,6-trihydroxyacetophenone (THA, 1 μM)/ THA + CDCA (25 μM), for CYP2C8 and CYP2C9 by rifampicin (25 μM)/ rifampicin + gemfibrozil (25 μM) and for CYP2C19 by rifampicin (25 μM)/ rifampicin + ticlopidine (25 μM). Huh-7 cells were used as positive control.

Immunocytochemistry and Immunohistochemistry

[00271] Methods were performed as described previously (Lee et al., 2012, PLoS ONE 7, e52491). Briefly, slides with cell culture was fixed for 30 min at room temperature in 95% (v/v) ethanol, washed three times in PBS and incubated with blocking buffer PBS containing 0.1% (wt/v) Triton X-100 (Sigma) and 5% (v/v) normal donkey serum (Millipore) for 60 min. Primary and secondary antibodies were diluted in blocking buffer. Primary antibody was incubated. After incubation with specific primary antibody in PBS at 4 °C (24 hr) or room temperature (2 hr), appropriate fluorescein isothiocyanate (FITC, Invitrogen) or Alexa Fluor 488, 594, and 647 (Invitrogen) or Dylight 488 and 594 (BioLegend) conjugated secondary antibody was added at room temperature (1 hr). After DAPI staining of nucleus (5 min), incubation with secondary antibody (1 hr) at room temperature, and washes, sample was mounted with 50% glycerol. Images were captured by confocal laser scanning microscopy (LSM700; Zeiss Z1 or Olympus FluoView 1000 confocal laser scanning microscope) or TissueFAXS system (TissueQnostics GmbH, Vienna, Austria). Data were analyzed by TissueQuest software.

Electron Microscopy

[00272] For transmission electron microscopy, methods were performed as described previously (Lee et al., 2012, PLoS ONE 7, e52491). Briefly, the hTS cell-derived hepatocytes-like cells (at day-4 induction) were fixed in 0.1 M sodium cacodylate buffer (pH 7.4) containing 3% wt/vol formaldehyde, 1.5% (wt/vol) glutaraldehyde and 2.5% (wt/vol) sucrose at RT for 1 hr or at 4°C overnight. The samples were washed with 0.1 M sodium cacodylate buffer (pH 7.4) before and after osmication treatment (2 hr) at 4°C in Palade's fixative containing 1% (vol/vol) OsO₄. After treated with tannic acid, stained with 1 % uranyl acetate, and dehydrated through a graded series of ethanol solutions, sample was embedded in TABB epoxy resin (Agar Scientific Ltd.). Ultrathin sections were stained with uranyl acetate and lead citrate and analyzed by using JEM-2000 EXII Transmission electron microscope (JEOL, Tokyo).

Immunoblotting and Immunoprecipitation (IP)

[00273] Methods were performed as described previously (Lee et al., 2012, PLoS ONE 7, e52491). For immunoblotting assay, cells were harvested into RIPA lysis solution (Millipore, Billerica, MA) supplemented with protease and phosphatase inhibitors (Roche). After electrophoresis of 30 µg lysates on polyacrylamide gels, electroblotting onto PDVF membranes (Millipore) was performed. After blocked by 5% non-fat milk in PBS at room temperature (1 hr), target protein was detected by using primary antibody. All membranes were incubated with chemiluminescent (Millipore) and imaging was captured by the ChemiDoc XRS system (Bio-RAD). Antibodies used were listed in Table 4. Data were analyzed by AlphaEaseFC (version

4.0.0) system. For IP assay, Cell lysates of bFGF-treated hTS cells were collected. By incubation with protein G-agarose (Millipore) for 30 min, total protein (100 μ g) was treated with specific primary antibody overnight listed in Table 4. After treating with protein G-agarose beads (2 hr), sample was washed three times with RIPA lysis buffer (Millipore), following by adding with protein loading dye and boiled for 5 min. The sample was resolved by 8% SDS-PAGE and subjected to immunoblotting analysis.

Sample Preparation for 2-Dimensional Gel Electrophoresis (2-DE)

[00274] Two samples were obtained: cell culture medium (5-days, as study group) and pure culture medium (as control group). Samples were prepared as described previously (Chou et al., 2015). Briefly, samples (0.1 ml) were incubated with 1 ml ice-cold acetone containing 11% trichloroacetic acid (TCA, w/v) and 20 mM DTT for 30 min at -20°C . After centrifugation (12,000 rpm, 10 min, 4°C), the protein pellet was washed twice with 1 ml cold acetone containing 20 mM DTT, followed by air-dry to remove the acetone. Then, appropriate rehydration buffer (7M urea, 2M thiourea, 2% CHAPS, 0.5% IPG buffer, 20 mM DTT) was added and the concentrated sample was measured by the Bradford method. For 2-DE analysis, a total of 150 μ g protein was incubated with buffer containing 5M urea, 2M thiourea, 3% w/v CHAPS, 1% immobilized pH gradient (IPG) with a nonlinear pH of 3–10, 100 mM DeStreak reagent, and a trace of bromophenol blue. After a series of treating processes, the sample was cup-loaded near the anode of the IPG strips using the Ettan IPGphor cup-loading (Amersham Biosciences) and protein focusing was achieved using the IEF parameters according to the manufacturer's protocol. After first dimensional electrophoresis, isoelectric focusing IPG strips was shaken in a conditioned equilibration buffer containing 1% w/v DTT (15 min), and followed by the same solution containing 2.5% w/v iodoacetamide (15 min). The strip was transferred on top of the 12 % SDS–polyacrylamide gel (PAGE). The second dimension separation was performed by a constant 75 V (30 min) and 100 V (16 hr). The 2-DE gel was silver-stained and detected with the Typhoon 9410 scanner (Amersham Biosciences) The spots were compared and quantified by using the Image Master 2D Platinum system. (Amersham Biosciences).

Electrospray Ionization–Quadrupole-Time of Flight Tandem Mass Spectrometry (ESI–Q–TOF–MS/MS) for Protein Identification and Quantitation

[00275] To identify the 2D gel protein observed, the samples were digested by trypsin, followed by subjecting to the nanoflow liquid chromatography and Waters-Micromass ESI–Q–TOF for protein identification (Waters, Manchester, UK) as described previously (Chou et al., 2015). To obtain the corresponding peak lists, the MS/MS spectra of individual fragments of each of the

precursors were processed by MassLynx 4.0 software (Manchester, UK) and the peak list files were uploaded to an in-house Mascot server for protein identification.

Statistical Analysis

[00276] All of the experiments were conducted in triplicate and repeated two times as indicated. Data obtained from Western blots, qPCR, luciferase reporter assay, and flow cytometry were calculated by Student's *t*-test. In animal study, paired ANOVA test was used statistically. *p*-value < 0.05 was considered statistically significant.

RESULTS

1) bFGF Alone Induces DE Differentiation in hTS Cells

[00277] The path from stem cells to hepatic lineages comprises of a progressive series of cellular processes, particularly including the required and essential step in DE formation. hTS cells were treated with bFGF (10 ng/ml) initially and measured the levels of DE-associated markers over time by immunoblotting assay. The results showed that at the initial 15 min of induction, transcription factors such as goosecoid (Gsc), Brachyury (T), homeodomain protein Mixl1 (Mixl1), SRY-box 17 (Sox17), forkhead box protein A2 (Foxa2, also known as Hnf3 β), and the primitive endoderm marker Sox7 were significantly upregulated, peaking in between 30 min and 1 hr (Figure 10A). These data implicated a fast transition from hTS cells to the nascent mesendoderm mediating primitive streak stage compatible with the liver development in early embryogenesis. Henceforth, Sox17 levels continually elevated to 4 hr and declined; whilst Foxa2 and Brachyury elevated to 8 hr but Sox7 expression became nascent after 15 min of induction. Notably, intensity of Mixl1 downregulated from the peak (15 min) to a nadir at 4 hr (~50% lower than the native one) and returned to the original levels at 8 hr measured by TissueFAX analysis (Figure 10AS). Their changes in expression were also demonstrated by immunofluorescence imaging (Figure 10B). These results indicate that bFGF alone enables to rapidly differentiate hTS cells to DE stage through primitive streak and mesendoderm mimicking the embryonic liver development.

2) PI3K/Akt/CREB1 Signaling Pathway Promotes MiR-124a Expression

[00278] bFGF enabled to induce the PI3K/Akt/CREB1 signaling pathway via its receptor FGFR1 in hTS cells. hTS cells were treated with bFGF (10 ng/ml) in the conditioned medium. FGF receptor (FGFR) inhibitor PD166866 could block the bFGF-induced activation of phosphatidylinositol 3-kinase (PI3K) by immunoblotting assay (Figure 10BS), suggesting that the inhibitory effect was through the FGFR at the cell membrane. As a result, the downstream effector AKT was phosphorylated evidenced by using PI3K siRNA (Figure 10CS). To clarify which protein kinase B (AKT) subunit was activated, specific siRNA against three AKT

subunits: AKT1, AKT2, and AKT3 were examined by immunoblotting assay. The result showed that only AKT1 phosphorylated and activated its downstream effector cAMP response element-binding protein 1 (CREB1) (Figure 10DS). This function was further confirmed by immunoprecipitation (IP) assay (Figure 10ES). Taken together, this indicates that bFGF induces activation of the PI3K/AKT1/CREB1 signaling pathway at 4 hr induction.

[00279] microRNA (miR)-124, a small non-coding RNA, is involved in the *Foxa2* expression in pancreatic β -cells, a derivative of ventral foregut endoderm. Subsequently, in the nucleus, the activated CREB1 directly targeted at three sites of the promoter of *miR-124a* to induce miR-124a expression at 4 hr induction by ChIP-qPCR assay (Figure 10C) and knockdown of CREB1 reduced its expression (Figure 10FS). Expression of CREB1 and miR-124 over time appeared in a parallel correlation by qPCR analysis (Figure 10D). These results indicate that bFGF-induced PI3K/Akt/CREB1 signaling pathway enables to spatiotemporally upregulate miR-124a at the early differentiation of hTS cells.

3) *MiR-124a Directs DE Specification*

[00280] Several genes relevant to hepatogenesis were screened and constructed the luciferase reporter assays, by which several signal transduction proteins were measured, including mothers against decapentaplegic homolog 4 (*Smad4*) (Figure 11A), glycogen synthase kinase 3 β (GSK3 β) (Figure 11B), and homeobox transcription factor *Cdx2* (Figure 11C). Inhibitory functions of miR-124a include: i) to target at the promoter of *Smad4* messenger RNA (*Smad4* mRNA) to prevent *Smad4* production (Figure 11A, lower). Consequently, the inhibitory *Smad4* caused suppression of *Mix11*, which was verified by knockdown of *Smad4* (Figure 11AS). This mechanism explained the downregulation of *Mix11* in the DE stage (Figure 10A) and the migratory cell fate transition during gastrulation; ii) to target at the promoter of GSK3 β mRNA to inhibit its translation (Figure 11B, lower), thereby, resulting in the nuclear translocation of downstream substrate cadherin-associated protein β -1 (β -catenin). In the nucleus, β -catenin targeted the promoter of *Foxa2* gene to produce *Foxa2* (Figure 11D), highlighting the differentiation at the stage of DE. Interestingly, this increased *Foxa2* in turn induced *c19orf80* gene transcription, encoding betatrophin protein expression (Figure 11E). Betatrophin is a hormone produced in liver, controls pancreatic β cell proliferation; iii) to target at the caudal-related homeobox transcripts *Cdx2* mRNA to inhibit its translation to the pluripotent transcription factor *Cdx2* (Figure 11C, lower). All these molecular events occurred at 4 hr induction, which was confirmed by using miR-124a and anti-miR-124a antibody by immunoblotting assay (Figure 11F).

[00281] Subsequently, the decreased Cdx2 promoted upregulation of pluripotent transcription factor Oct4 by immunofluorescence imaging study (Figure 11G). Overexpression of Oct4 was further verified by knockdown of miR-124a using anti-miR-124a antibody by immunoblotting assay (Figure 11F). This reciprocal inhibitory relationship between Cdx2 and Oct4 is evidenced by immunoblotting assay (Figure 11BS, upper). Furthermore, observed was the significantly gradual elevation of pluripotency transcription factor Nanog at 8 hr induction (Figure 2BS, lower). These results suggested that Oct4 played the main role in maintaining the pluripotent characteristics of DE lineages; while Nanog might play as a supportive role consistent with that in hES cells. Importantly, the activated Oct4 in turn targeted at the promoter of *Sox17* gene by ChIP-qPCR assay (Figure 11H) that promoted *Sox17* expression (Figure 10A). Expression of *Sox17* represented another milestone in the DE differentiation. Together, Figure 11I is a schematic illustration to describe the regulatory molecular mechanisms, by which bFGF induction initiated DE formation mediating miR-124a in hTS cells.

4) Generation of Hepatocyte-Like Cells in 3-D Tissue Structure

[00282] Subsequently, cells were cultured with a combination of bFGF (10 ng/ml), dexamethasone (Dexa; 0.1 μ M), oncostatin M (OSM; 10 ng/ml), bone morphogenetic protein 4 (BMP4; 20 ng/ml), and hepatic growth factor (HGF; 5 ng/ml) after DE formation (8 hr). Unexpectedly, cellular morphology might exhibit as dispersed fibroblast-like cells or gradually aggregate to form a crescent cell mass, depending on seeding density in culture (Figure 12A, insert and Figure 12AS). Histologic examination of the cell mass revealed two distinct peripheral and central compartments, constructing a 3-dimensional (3D) tissue structure. In the peripheral part, numerous clustered small cells distributed irregularly among the extracellular matrix (ECM) beyond the basement membrane. Cells had condensed nuclei, frequently eccentric located, and abundant granular and vacuoles in the eosinophilic cytoplasm similar to the embryonic stem/progenitor cells (Figure 12AS). In the central part, many independent columnar ECMs, by cell linings at both sides, distributed from the basal towards the central areas (Figure 12A). These cells contained abundant eosinophilic cytoplasm and dispersed chromatin in the single round nucleus with one or two prominent nucleoli mimicking the phenotypic hepatocytes. Several binucleate cells could be seen. This feature is similar to that known as hepatic plates in human liver.

[00283] Immunocytochemically, these hepatocyte-like cells exhibited specific marker(s) of: i) human cytoplasmic marker stem 121TM for human cells, mast/stem cell growth factor receptor *C-kit* for liver intrinsic stem cells, CK19 for cholangiocytes, and CK18 for hepatocytes (Figure 12B); and ii) albumin (ALB), α -fetoprotein (AFP), Betatrophin, ADH1,

APOF, CPS1, GATA4, CYP1A1, and CYP2B6 in the cytoplasm for hepatocytes immunohistochemically (Figure 12C, and Figure 12CS). Whilst a subset of surface markers including ASGR1, CXCR4, BSEP, MRP2, and Cx32 constructed a polygonal cell shape similar to the primary human hepatocyte (Figure 12C). Furthermore, electron microscopy revealed a similar ultrastructure to primary hepatocyte, including a large cytoplasm to nucleus ratio, plenty of mitochondria, well-organized endoplasmic reticulum, tight junction, numerous lipid vacuoles, glycogen storage, enlarged lumen of the bile canaliculus with junctional complexes, and multiplex ECMs (Figure 12D).

5) TGF β 1 Contributes to the Formation of Fibronectin and Collagen IV Scaffold in Hepatic ECMs

Among 9 newly upregulated, secreted proteins in the cell-cultured medium, protein (no. 413) became an attractive target because it significantly predicted, by 46% of peptide sequences matched, to be the transforming growth factor- β (TGF- β)-induced protein ig-h3 precursor (TGF β 1) by Mascot MS/MS ions search system (ESI-QUAD-TOF, Bruker Impact HD, Matrix Science, USA) (Figure 13A, red arrow; Figure 13AS). TGF β 1 is a major fibrogenic, multifunctional cytokine, acting as both autocrine and paracrine manner to enhance fibronectin and collagen formation in hepatic stellate cells (HSCs). Accordingly, to identify the presence of TGF β 1, immunohistochemistry was used to demonstrate the coexpression of immunoreactive TGF β 1, fibronectin, and collagen IV in the ECMs by immunohistochemistry (Figure 13B). These results suggest that TGF β 1, fibronectin, and collagen IV constitute, at least partly, the scaffold of ECMs in the 3-D tissue structure of hepatocyte-like cells that may support proliferation and differentiation of hepatocytes in the hepatic plates.

6) Transcriptional Expression Characterizes the Stage-Specific Hepatic Differentiation

[00284] Forty two hepatic development-associated genes were analyzed, suggesting that differentiating cells might share an overlapping pattern in gene expressions during cellular processes. As mentioned, the transition from pluripotent hTS cells to primitive streak (15 to 30 min) and mesendoderm (< 1 hr), expressing an elevation of GSC, Brachyury (T), and Sox7 along with a gradual increase of Mixl1, Foxa2 and Sox17 was observed (Figure 10A). Sox7 is primarily expressed in the primitive streak, visceral endoderm, and parietal endoderm but not DE (Kanai-Azuma et al., 2002). At the DE stage (1 to 8 hr), persistence of high transcriptional expressions sustained, including CXCR4, Foxa2, Sox17, HHEX, and Sox7, and declined thereafter (Table 3). As cell process entered the hepatic endoderm stage (8 hr to 1 day), a core group of endoderm transcription factors including *Sox17* and *Foxa2*, in turn, regulated a cascade of genes committing cells to the endoderm lineage. Shortly after hepatic specification, the

epithelium begins to express genes associated with liver bud genes including *Albumin*, *AFP*, and *Hnf4a*. A large number of hepatoblast-associated gene expressions emerged to commit cell differentiation to bipotential hepatoblasts (day-2 to day-4). Wherefrom hepatoblasts expressed specific genes in association with fetal hepatocytes (like *AFP*), adult hepatocytes (like *ALB* and *Hnf4a*), and biliary epithelial cells (like *cytokeratin-19*), allowing the differentiation to reach the fetal/adult hepatocytic stage (>day-4). Together, these progressive transcriptional expressions are consistent with the cellular processes in liver development as listed in Table 3.

7) Hepatocyte-Like Cells Exhibit Liver Functions

[00285] Preservation of liver functions is essential requirement in the pluripotent stem cell-derived hepatocytes. To that, cell culture medium was collected and subjected to the enzyme-linked immunosorbent assay (ELISA). The results demonstrated the elevated levels of albumin, NHCl_4 -induced urea, and CCl_4 -induced GOT, GPT, and ALP in the medium after induction (Figure 14A). LDL uptake assay revealed that these cells contained ability of LDL uptake (Figure 14B). Oil-O-Red staining revealed the presence of lipid droplets, suggesting the capacity in adipogenesis (Figure 14C). Furthermore, glycogen storage test revealed a positive periodic acid-Schiff (PAS) staining, which was supported by diastase digestion and PAS fluorescence emission test in either cytology or histology (Figure 14D). Next, qPCR analysis revealed the capacity of cytochromes P450 (CYPs) enzymes in response to a variety of metabolize specific drugs, including CYP3A4, CYP7A1, CYP2B6, CYP1A2, CYP2C8, CYP2C9, CYP2D6, and CYP2E1 (Figure 14E). Functionally, for example, the refampin-induced CYP3A4 mRNA was reduced by its inhibitor itraconazole; while the 2,4,6-trihydroxyacetophenone (THA)-induced cholesterol 7α -hydroxylase (CYP7A1) mRNA was reduced by chenodeoxycholic acid (CDCA). These results suggest the capability in oxidation of xenobiotics as well as the bile acid and cholesterol metabolism, respectively.

8) Functional Hepatocyte-Like Cells Posses Characteristic of Stem Cell Homing

[00286] Animal study was designed to mimic the clinical scenario in acute hepatic failure, by which intraperitoneal infusion of carbon tetrachloride (CCl_4) was given in Sprague Dawley rats, followed by intravenous injection (tail vein) of the hTS cell-derived hepatocyte-like cells. The goals were to examine whether these xenografts can be survival by homing in the rat's liver and what role of these cells play. Serum samples were collected at 0, 1, 2, 4, and 7 days to measure AST and ALT levels. Rats were sacrificed at 2, 4, and 7 days to get the liver samples for histopathological studies. Biochemical study revealed that serum AST and ALT levels appeared to be significantly higher in the cell therapy group (CCl_4 + cells) than the control group

(CCl₄ only) over time (Figure 15A). To elucidate this ambiguous observation, the liver tissues were inspected histopathologically.

[00287] Using human cytoplasmic marker stem-121TM (Stem Cell Technologies, Inc. WA) as an indicator, a positive immunoreactive stem-121 expression in hTS cells was identified (Figure 15B), followed by the confirmation of presence of stem-121-positive hepatocyte-like cells in the liver tissues 4-day after implantation (Figure 15C). This observation indicated that intravenous administration of the hepatocyte-like cells enabled to be homing to the liver tissues. Interestingly, these stem-121^{positive} hepatocytes underwent degeneration as well immunohistochemically (Figure 15C). This fact explains a much higher elevation of AST and ALT levels in the cell therapy group than the only CCl₄-treated group because of an additional effect of CCl₄ (24 hr half-live in blood) which caused degeneration of the implanted hepatocyte-like cells. The intravenous infusion of hTS cell-derived hepatocyte-like cells can reach to and reside in the CCl₄ injury liver tissues.

9) Hepatocyte-Like Cells Possess Immune Privilege by Expressing HLA-G and TGFβ1 and Recruiting Capacity of CD4⁺Foxp3⁺ Treg Cells

[00288] Implanted hepatocyte-like cells expressed human leukocyte antigen G (HLA-G) because there was a coexpression of stem-121 and HLA-G in the hepatic tissues at 4-days post-implantation immunohistochemically (Figure 15D), suggesting a characteristic of immune privilege. HLA-G, membrane-bound or soluble, strongly acts on different immune cell types (NK, T, B, monocytes/dendritic cells) to inhibit both innate and adaptive immunity through the interaction with inhibitory receptors that are expressed at the surface of immune cells.

[00289] Furthermore, hepatocyte-like cells were able to secrete TGFβ1 into the ECMs (Figure 13B). TGFβ1 is a critical regulator of thymic T cell development and a crucial player in peripheral T cell homeostasis, tolerance to self antigens, and T cell differentiation during the immune response. Meanwhile, CD4⁺Foxp3⁺ T regulatory (Treg) cells were present in the hepatic sinusoids immunocytochemically (Figure 15E), suggesting the recruitment of the Treg cells to the liver in response to the implanted cells. Active immune suppression by cytokine TGFβ1 or CD4⁺Foxp3⁺ Treg cells plays a pivotal mechanism of peripheral T cell tolerance. The implanted hepatocyte-like cells possess immune privilege by expressing HLA-G and TGFβ1, and recruiting CD4⁺Foxp3⁺ Treg cells to the liver to control peripheral T cell tolerance.

Table 1. Antibodies used, e.g., in Example 1.

Target	Manufacturer	Code no.	WB	Flow	IF
FGFR1	Abcam	ab10646	1/400		1/200
MIXL1	Abcam	ab57854	1/1000		1/200
SMAD4	Santa Cruz	sc-7966	1/200		

	Biotechnology				
CDX2	Abcam Cell signaling BD Pharmingen	Ab76541 3977s 560395	1/1000 1/1000	1/40 1/40	1/200
OCT4	Abcam Millpore BD Pharmingen	Ab19857 MAB4419 560794 (Cy 5.5)	5 µg/ml 2 µg/ml	1/40	1 µg/ml 1/200
NANOG	Chemicon Cell signaling BD Pharmingen	AB9220 3580s 560791	1/1000 1/1000	1/40	1/200 1/200
SOX2	Epitomics Abcam BD Pharmingen	2683s Ab59776 560291 (PE)	1/1000 1/1000	1/40	1/200
C-peptide	Abcam Santa Cruz Biotechnology	Ab14181 Sc-51647	1/100 1/100		1/50 1/50
β-actin	Santa Cruz Biotechnology	Sc-130065	1/2000		
Somatostatin	Santa Cruz Biotechnology	Sc-55565	1/200		1/100
Glut2	Chemicon	AB1342			1/100
Glucagon	Santa Cruz Biotechnology	Sc-13091	1/200		1/100
Insulin	Santa Cruz Biotechnology	sc-7839	1/100		1/50
Ngn3	Santa Cruz Biotechnology	sc-25654	1/200		1/100
Amylase	Santa Cruz Biotechnology	sc-12821	1/200		1/100
Pancreatic polypeptide	Chemicon	sc-80494			1/100
PDX1	BD Pharmingen Cell signaling	562160 5679	1/2000 1/1000		1/200 1/200
PI3K	Cell signaling	4249s	1/1000		
p-AKT(Ser473)	Cell signaling	4058	1/1000		
AKT	Cell signaling	4685	1/1000		
CREB1	Cell signaling	9197	1/1000		
p-CREB1(Ser1330)	Cell signaling	9191	1/1000		
β-Catenin	Cell signaling Epitomics	9587 1247-1	1/1000 1/2000		
GSK3β	Cell signaling	9315	1/1000		
p-GSK3β(Ser9)	Cell signaling	9336	1/500		
GSK-3α/β (Tyr-279/Tyr-216)	ECM Biosciences	GM1321	1/500		
GSC	Abcam	ab117871	1/500		1/100
Brachyury	Abcam	Ab20680	1/1000		1/200
SOX17	Origene	TA502483	1/200		1/100
FOXA2	Abcam	Ab40874			
HNF1b	Abcam	ab59118	1/1000		1/200
SOX9	Abcam	ab26414	1 µg/ml		1/200
PTF1a	Abcam	ab57257	1/500		1/200
NKX6.1	Abcam	ab90716	1 µg/ml		5 µg/ml
GATA4	Abcam	ab84593	1/1000		1/200
NKX2.2	Abcam	Ab79916	1/1000		1/200
FOXA2	Abcam	Ab40874	1/1000		1/200
SOX17	R&D systems	AF1924	1/1000		1/200
CXCR4	Abcam	Ab124824	1/1000		1/200
HNF4a	Santa Cruz Biotechnology	Sc374229	1/200	1/100	1/100
Albumin	Calbiochem	126584	1/500	1/100	1/100

AFP	Millipore	Mabd78	1/1000	1/100	1/200
BSEP	Santa Cruz Biotechnology	Sc74500	1/200	1/100	1/100
MRP2	Santa Cruz Biotechnology	Sc5570	1/200	1/100	1/100
Betatrophin	Acris Antibodies GmbH	H00055908- B01P	1/500	1/100	1/100

Table 2. Primers used, e.g., in Example 1

Target gene	Gene Name	Forward	Reverse	NCBI accession numbers
T	Brachyury	acctgggtactccaatccta	actgactggagctggtaggt	NM_00127048 4.1
SOX7	Sex determining region Y (SRY)-box 7	cgaagcgaggcgacc	ccacgacttcccagcatct	NM_031439.3
CXCR4	C-X-C chemokine receptor type 4	gaaaccctcagcgtctcagt	agtagtgggctaagggcaca	NM_00100854 0.1
FOXA2	Forkhead box protein A2	ctggctggttgtgtggctg	ggaggagtagccctcgg	NM_021784.4
SOX17	SRY-box 17	gatagccagtgacgaccag	acgacttgcccagcatcttg	NM_022454.3
AFP	Alpha-1-fetoprotein	cagccactgttgccaactc	ggccaacaccagggttact	NM_001134.2
ALB	Albumin	aagccttgggtgtgattgcc	gcacagcagtcagccatttc	NM_000477.5
HNF1a	Hepatocyte nuclear factor 1- alpha	caccaagcaggtcttcacctc	tctcgatgacgctgtggttg	NM_000545.5
HNF4a	Hepatocyte nuclear factor 4- alpha	tgacgatgggcaatgacacg	agcccggaagcatttctga	NM_178850.2
HNF6	Hepatocyte nuclear factor 6	gcttagcagcatgcaaaagga	ctgacagtgtcagctccaa	NM_004498.2
TTR	transthyretin	gcctctgggaaaaccagtga	atcccatccctcgtcctca	NM_000371.3
KRT8	Keratin 8	ggacctgcaggaagggatct	tctggtgaccgtaactgcg	NM_00125628 2.1
KRT18	Keratin 18	acatccgggccaatgatgac	tccaagctggccttcagattt	NM_199187.1
KRT19	Keratin 19	agctgagcatgaaagctgcct	gatcttctgtccctcgagca	NM_002276.4
SERPINA1	Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1	tccgataactgggtgacct	agacggcattgtcgattcact	NM_000295.4
TAT	Tyrosine aminotransferase	gatgagcagcaaaggcaacc	acagtagggtccccaatgga	NM_000353.2
G6PC	Glucose-6-phosphatase	tcaacctgctttaagtggatt	gtatacacctgctgtgccat	NM_000151.3

ADH1C	Alcohol dehydrogenase 1C (class I), gamma polypeptide	gctgcaggaatctgtcgttc	ccccgaggattgcctagatcat	NM_000669.4
APOF	Apolipoprotein F	aatgactggactgtgtgggta	caggacaaggggtctgagga	NM_001638.2
C/EBPa	CCAAT-enhancer-binding protein alpha	taactccccatggagtccg	atgtcgatggacgtctcgtg	NM_004364.4
C/EBPb	CCAAT-enhancer-binding protein beta	actttagcagtcagagccg	gatttaaaggcaggcggcg	NM_005194.3
CPS1	Carbamoyl-phosphate synthase 1, mitochondrial	aggcccatgccacaaatca	agcaacagaggatggatggc	NM_00112263 3.2
PCK2	Phosphoenolpyruvate carboxykinase 2, mitochondrial	acagtgaaggctgactccg	ccgcacataccaggttcca	NM_00101807 3.2
TDO2	Tryptophan 2,3-dioxygenase	tggaactacctgcatttga	tcggtgatccgagaacaa	NM_005651.3
GYS2	Glycogen synthase 2 (liver)	ccaagagaagctaccaaagcc	tgctccaactttattggcac	NM_021957.3
HHEX	Hexosaminidase A (alpha polypeptide)	cccctgggcaaaccttact	tctctccatttagcgcgtc	NM_002729.4
PROX1	Prospero homeobox 1	agcaaatgactttgaggtcca	ctctttaggcagttcgggg	NM_00127061 6.1
CX32	Connexin 32	gctcccaaggtgtgaatga	actaggatgagctgcaggga	NM_000166.5
BSEP	Bile salt export pump	tattcacagggctgttgct	agaagccaacttaaccca	NM_003742.2
MRP2	Multidrug resistance-associated protein 2	gtgtttccacagagcggcta	ccaggtcacatctcggact	NM_000392.4
CYP1A2	Cytochrome P450 1A2	aacaagggacacaacgtgaat	ggaagagaacaagggctgagt	NM_000761.4
CYP2B6	Cytochrome P450 2B6	atggggcactgaaaagactga	agaggcggggactgaatgac	NM_000767.4
CYP3A4	Cytochrome P450 3A4	ccttacatacacacctttgga agt	agctcaatgcatgtacagaatccc cggta	NM_017460.5
CYP2C8	Cytochrome P450 2C8	tatgtctctgtttaccgt	tcaactctccacaaggcagt	NM_00119885 5.1
CYP2C9	Cytochrome P450 2C9	ttcatgcctttctcagcagg	ttgcacagtgaacatagga	NM_000769.2
CYP2C19	Cytochrome P450 2C19	cgaggccagagatacatc	tgcatgtagcacagaagtg	NM_000771.3
CYP2D6	Cytochrome P450 2D6	ctaagggaacgacactcatcac	ctcaccaggaagcaagacac	NM_000106.5
CYP2E1	Cytochrome P450 2E1	acagagaccaccagcacaact	atgagcggggaatgacacaga	NM_000773.3
CYP3A5	Cytochrome P450 3A5	gaagaaaagtcgcctcaac	aagaagtcttgcgtgtcta	NM_0007 77.4
CYP7A1	Cytochrome P450 7A1	tgctactctgcgaaggcat	tccgtgagggaaattcaaggc	NM_000780.3

UGT	UDP glucuronosyltransferase	ccctatttttcaaaaatgtctt	attgatcccaagagaaaaccac	NM_019077.2
Betatrophin	Chromosome 19 Open Reading Frame 80 (Angiopoietin-Like Protein 8, Hepatocellular Carcinoma-Associated Gene TD26, Lipasin,)	acatctccctccccagactc	tgctctgtgctcagaagtgg	NM_018687.6
		ctgtcggctgaggggttccat	gagtctggggagggagatgt	
<i>miR124-2</i> ChIP		tctcggctctttggttca	tctgccttcagcacaagagg	NC_000008.11
		gcggctctttggttcaagg	ctgccttcagcacaagagga	
<i>miR124-3</i> ChIP		cccgcagttctcaaggacac	agaaggaggccaggcaagtc	NC_000020.11
<i>SOX17</i> ChIP		ttgtagattgctctctctctcc	gtgaagccttggetagggg	NC_000008.10
<i>FOXA2</i> ChIP		cccattgattcctggat	ttggaggctgagattgtc	NC_000020.10
<i>Betatrophin</i> ChIP		gtcagccctccctgactgat	catgtggattccagcctgc	NC_000019.9

Table 3. Transcriptional gene profiles throughout hepatic differentiation

Function \ Stage	Gene	DE (8 hr)	Hepatic endoderm (8 hr to 1 D)	Hepatoblast 2 D	Hepatoblast 4 D	Hepatocy- like cells (> 4D)
DE	<i>CXCR4</i>	+++	+	+	+	NA
	<i>Foxa2</i>	++++	+	++	+	
	<i>Sox17</i>	++++	++	+	+	
	<i>HHEX</i>	++	+	-	+++	
	<i>Brachyury (T)</i>	++++	+	-	-	
	<i>Sox7</i>	++++	++	-	+	NA
Tyrosine catabolism	<i>TAT</i>	NA	++	-	-	-
Fetal α -fetoprotein precursor	<i>AFP</i>	NA	+	-	++++	+++
Proteins carrier synthesized in the liver	<i>ALB</i>	NA	+	+	++++	++++
Gluconeogenesis	<i>PCK2</i>	NA	+	+	++	+++
Pancreatic β -cell promoter, Lipid regulator	<i>Betatrophin</i>	NA	+	+	++	+++
Serine protease inhibitor	<i>SERPINA1</i>	NA	+	-	++	+++
Bile acid biosynthesis	<i>CYP7A1</i>	NA	+	+	+	+++

Drug and steroid metabolism (phase I)	<i>CYP2B6</i>	NA	+	-	++	+++
Drug and steroid metabolism (phase I)	<i>CYP3A4</i>	NA	+	+	++	+++
Ethanol catabolism (phase I)	<i>ADH1C</i>	NA	+	+	++	++
Liver glucagon synthase	<i>GYS2</i>	NA	+	+	++	++
	<i>PEPCK</i>	NA	+	-	++	-
Hepatic transcriptional activator	<i>Hnf6</i>	NA	+	+	+	++
Secretion of bile salts	<i>BSEP</i>	NA	+	-	+	++
Cholesterol transport regulator	<i>APOF</i>	NA	+	-	-	++
Hepatic gap junction	<i>Cx32 (GJB1)</i>	NA	+	-	+	++
Regulator of several hepatic genes	<i>Hnf4a</i>	NA	+	-	+	+
Adipocyte differentiation	<i>C/EBPβ</i>	NA	+	+	-	+
Thyroxin- and retinol-binding protein	<i>TTR</i>	NA	+	-	-	+
Enzyme of urea cycle	<i>CPS1</i>	NA	+	-	+	+
Enzyme of glucose homeostasis	<i>G6PC</i>	NA	-	-	+++	+++
Regulator of several hepatic genes	<i>Hnf1a</i>	NA	-	-	++	+++
IL-6-mediated barrier protection	<i>CK18</i>	NA	-	-	++	++
IL-6-mediated barrier protection	<i>CK8</i>	NA	-	-	++	++
Hepatocyte migration	<i>PROX1</i>	NA	+	-	+	+++
Organization of bile duct	<i>CK19</i>	NA	-	-	+	++
Hepatobiliary excretion	<i>MRP2 /ABCC2</i>	NA	+	-	-	+
Tryptophan metabolism	<i>TDO2</i>	NA	+	++	-	+

Denotation: NA, not available; (-) indicating expression <2-fold, (+) >2-fold, (++) >10-fold, (+++) >100-fold, and (++++>) >1,000-fold.

Table 4. Antibodies used, e.g., in Example 2

Target	Manufacturer	Code no.	WB	Flow	IF/IHC
Stem121	StemCells	AB-121-U-050			1/1000
Mixl1	Abcam	ab57854	1/1000		1/200
Smad4	Santa Cruz Biotechnology	sc-7966	1/200		
Cdx2	Abcam Cell signaling BD Pharmingen	Ab76541 3977s 560395	1/1000 1/1000	1/40 1/40	1/200
Oct4	Abcam Millipore BD Pharmingen	Ab19857 MAB4419 560794 (Cy 5.5)	5 µg/ml 2 µg/ml	1/40	1 µg/ml 1/200
c-Kit	Santa Cruz Biotechnology	Sc19983			1/400
CK18	Abcam	Ab32118		1/100	1/200
CK19	Cell signaling	4558			1/200
β-actin	Santa Cruz Biotechnology	Sc-130065	1/2000		
ADH	Santa Cruz Biotechnology	Sc137078			1/200
CPS1	Abcam	Ab110303			1/200
ASGR1	Thermo Fisher Scientific	MAB0244		1/100	1/200
Cx32	Santa Cruz Biotechnology	Sc7258			1/100
ApoF	Santa Cruz Biotechnology	Sc107409			1/400
CYP1A1	Santa Cruz Biotechnology	Sc25304			1/100
CYP2B6	Santa Cruz Biotechnology	Sc62204			1/100
HLA-G	Abcam	Ab4570			1/200
CD4	eBioscience	14-0040-85			1/400
Foxp3	Abcam	Ab22510			1/400
HNF4A	Santa Cruz Biotechnology	Sc374229	1/200		1/100
α-tubulin	GeneTex	GTX112141	1/1000		
CREB1	Cell signaling	9197	1/1000		
p- CREB1(S er1330)	Cell signaling	9191	1/1000		
GSK3β	Cell signaling	9315	1/1000		
TGFβ1	Santa Cruz Biotechnology	Sc146			1/500
COL4	Santa Cruz Biotechnology	Sc59814			1/500

FN1	Santa Cruz Biotechnology	Sc6952			1/500
GSC	Abcam	ab117871	1/500		1/100
Brachyury	Abcam	Ab20680	1/1000		1/200
Sox17	Origene R&D	TA502483 MAB1927	1/1000		1/100
Sox7	Santa Cruz Biotechnology	Sc20093	1/200		
Foxa2	Abcam	Ab40874	1/1000		1/200
GATA4	Abcam	ab84593	1/1000		1/200
CXCR4	Abcam	Ab124824	1/1000		1/200
Hnf4a	Santa Cruz Biotechnology	Sc374229	1/200	1/100	1/100
Albumin	Calbiochem	126584	1/500	1/100	1/100
AFP	Millipore	Mabd78	1/1000	1/100	1/200
BSEP	Santa Cruz Biotechnology	Sc74500	1/200	1/100	1/100
MRP2	Santa Cruz Biotechnology	Sc5570	1/200	1/100	1/100
Betatrophin	Acris Antibodies GmbH	H00055908- B01P	1/500	1/100	1/100

Table 5. Primers used, e.g., in Example 2

Target gene	Forward	Reverse	
Brachyury	acctgggtactcccaatccta	actgactggagctggtaggt	
Sox7	cgaagcgaggcgaccc	ccacgactttcccagcatct	
Cxcr4	gaaacctcagcgtctcagt	agtagtgggctaagggcaca	
Foxa2	ctggtcgtttgttggtg	ggaggagtagccctcgg	
Sox17	gatacgccagtgcgaccag	acgacttgcccagcatcttg	
AFP	cagccacttgttgccaactc	ggccaacaccagggttact	
Albumin	aagccttggtgtgattgcc	gcacagcagtcagccatttc	
Hnfla	caccaagcaggtcttcacctc	tctcgatgacgctgtggttg	
Hnf4a	tgacgatgggcaatgacacg	agcccggagcatttcttga	
Hnf6	gcttagcagcatgaaaagga	ctgacagtgtcagctccaa	
Ttr	gcctctgggaaaaccagtga	atcccatccctcgtcctca	
KRT8	ggacctgcaggaagggatct	tctggtgaccgtaactgcg	
KRT18	acatccgggccaatgac	tccaagctggcctcagattt	
KRT19	agctgagcatgaaagctgcct	gatcttctgtccctcgagca	
Serpina1	tccgataactggggtgacct	agacggcattgtcgattcact	
Tat	gatgagcagcaaaaggcaacc	acagtagggtcccaatgga	
G6p	tcaacctcgtctttaagtggatt	gtatacactgctgtgcccat	
Adh1C	gctgcaggaatctgtcgttc	ccccgaggattgctagatcat	
ApoF	aatgactggactgtgtgggta	caggacaaggggtctgagga	
C/EBPa	taactccccatggagtcgg	atgtcgatggacgtctcgtg	
C/EBPb	actttagcgagtcagagccg	gatttaaaggcaggcggcg	
Cps1	aggcccatgccacaaatca	agcaacagaggatggatggc	
Pck2	acagtgaaggtcgactccg	ccgcacataccagggttcca	

Tdo2	tggaactacctgcatttga	tcggtgcatccgagaaaca	
Gys2	ccaagagaagctaccaagcc	tgctccaactttattggtcac	
Hex	cccctgggcaaactctact	tctctccatttagcgctc	
Prox1	agcaaatgactttgaggtcca	ctctttaggcagttcgggg	
Cx32	gctcccaaggtgtgaatga	actaggatgagctgcaggga	
BSEP	tattcacagggtcgftggct	Agaagccaactctaacgcca	
MRP2	gtgttccacagagcggcta	Ccaggttcacatctcggact	
CYP1A2	aacaagggacacaacgctgaat	ggaagagaaacaagggctgagt	
CYP2B6	atggggcactgaaaaagactga	agaggcggggacactgaatgac	
CYP3A4	ccttacacatacacaccttggaaagt	agctcaatgcatgtacagaatccccggta	
CYP2C8	tatggtcctgtgttcaccgt	tcaactcctccacaaggcagt	
CYP2C9	ttcatgcctttctcagcagg	ttgcacagtgaaacatagga	
CYP2C19	cgaggtccagagatacatc	tgtcatgtagcacagaagtg	
CYP2D6	ctaagggaaacgacactcatcac	ctcaccaggaaagcaaagacac	
CYP2E1	acagagaccaccagcacaact	atgagcggggaatgacacaga	
CYP3A5	gaagaaaagtcgcctcaac	aagaagtccttgcgtgtcta	
CYP7A1	tgctacttctgcaaggcat	tccgtgaggggaattcaaggc	
UGT	ccctatttttcaaaaatgtctt	attgatcccaagagaaaaccac	
Betatrophin	acatctccctcccagactc	tgctctgtgctcagaagtgg	
	ctgtcggctgagggttccat	gagtctggggagggagatgt	
<i>miR124-2</i> ChIP	tctgcggctctttggttca	tctgccttcagcacaagagg	
	gcggtctttggttcaagg	ctgccttcagcacaagagga	
<i>miR124-3</i> ChIP	cccgcagttctcaaggacac	agaagggagccaggcaagtc	
<i>Sox17</i> ChIP	ttgtagattgctctctctctcc	gtgaagccttggtagggg	
<i>Foxa2</i> ChIP	cccatcattgattcctggat	ttgggaggctgagattgtc	
<i>betatrophin</i> ChIP	gtcagccctccctgactgat	catgtggatttccagcctgc	-2.5 kb

[00290] The examples and embodiments described herein are for illustrative purposes only and various modifications or changes suggested to persons skilled in the art are to be included within the spirit and purview of this application and scope of the appended claims.

CLAIMS**WHAT IS CLAIMED IS:**

1. A method of inducing a trophoblast stem (TS) cell to differentiate into an induced hepatocyte *in vitro*, comprising:
 - contacting the trophoblast stem cell with a conditioned medium to induce differentiation of the trophoblast stem cell into an induced hepatocyte, wherein the conditioned medium comprises a fibroblast growth factor (FGF), a steroid, and a cytokine.
2. The method of claim 1, further comprising contacting the trophoblast stem cell with the FGF prior to addition of the steroid and the cytokine to the conditioned medium.
3. The method of claim 2, wherein the trophoblast stem cell is contacted with the FGF for at least 2 hours, at least 4 hours, at least 6 hours, 8 hours, at least 12 hours, at least 16 hours, at least 20 hours, or at least 24 hours prior to addition of the steroid and the cytokine to the conditioned medium.
4. The method of any preceding claim, further comprising incubating the trophoblast stem cell for at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, or at least 7 days.
5. The method of any preceding claim, wherein the induced hepatocyte is a hepatic progenitor cell.
6. The method of any preceding claim, wherein the differentiation comprises one or more of four stages: primitive streak to definitive endoderm (DE) stage, hepatic specified endoderm stage, hepatoblastic stage, and the fetal and adult hepatocyte cell stage.
7. The method of claim 6, wherein one or more biomarkers selected from the group consisting of CXCR4, FOXA2, SOX17, HHEX, TTR, ALB, TAT, CYP7A1, BSEP, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , HNF4 α , and any combination thereof express in one or more of the four stages.
8. The method of claim 6 or 7, wherein one or more biomarkers selected from the group consisting of CXCR4, FOXA2, SOX17, HHEX, and any combination thereof, express at the primitive streak to DE stage.
9. The method of claim 8, wherein an expression level of CXCR4, FOXA2, SOX17, and/or HHEX increases at the primitive streak to DE stage, relative to that before the primitive streak to DE stage.

10. The method of claim 9, wherein the increased expression level is an increased level of gene expression.
11. The method of claim 9 or 10, wherein the expression level of CXCR4, FOXA2, SOX17 and/or HHEX increases by about 1 fold and about 10,000 fold higher than that before the primitive streak to DE stage.
12. The method of claim 9 or 10, wherein the expression level of CXCR4, FOXA2, SOX17 and/or HHEX increases by about 10 fold and about 1000 fold higher than that before the primitive streak to DE stage.
13. The method of any one of claims 6-12, wherein one or more biomarkers selected from the group consisting of SOX17, TTR, ALB, TAT, SERPINA1, CYP7A1, and any combination thereof express in the hepatic specified endoderm stage.
14. The method of claim 13, wherein an expression level of SOX17, TTR, ALB, TAT, SERPINA1, and/or CYP7A1 increases at the hepatic specified endoderm stage, relative to that before the hepatic specified endoderm stage.
15. The method of claim 14, wherein the increased expression level is an increased level of gene expression.
16. The method of claim 14 or 15, wherein the expression level of SOX17, TTR, ALB, TAT, SERPINA1, and/or CYP7A1 increases by about 1 fold and about 1000 fold higher than that before the hepatic specified endoderm stage.
17. The method of claim 14 or 15, wherein the expression level of SOX17, TTR, ALB, TAT, SERPINA1, and/or CYP7A1 increases by about 10 fold and about 100 fold higher than that before the hepatic specified endoderm stage.
18. The method of any one of claims 5-17, wherein one or more biomarkers selected from the group consisting of TTR, ALB, TAT, CYP7A1, SERPINA1, BSEP, and any combination thereof express at the hepatoblastic stage.
19. The method of claim 18, wherein an expression level of TTR, ALB, TAT, CYP7A1, SERPINA1, and/or BSEP increases at the hepatoblastic stage, relative to that before the hepatoblastic stage.
20. The method of claim 19, wherein the increased expression level is an increased level of gene expression.
21. The method of claim 19 or 20, wherein the expression level of TTR, ALB, TAT, CYP7A1, SERPINA1, and/or BSEP increases by about 1 fold and about 1000 fold higher than that before the hepatoblastic stage.

22. The method of claim 19 or 20, wherein the expression level of TTR, ALB, TAT, CYP7A1, SERPINA1, and/or BSEP increases by about 10 fold and about 100 fold higher than that before the hepatoblastic stage.
23. The method of any one of claims 6-22, wherein one or more biomarkers selected from the group consisting of HHEX, BSEP, TTR, ALB, TAT, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , HNF4 α , and any combination thereof express at the fetal and adult hepatocyte-like cell stage.
24. The method of claim 23, wherein an expression level of HHEX, BSEP, TTR, ALB, TAT, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , and/or HNF4 α increases at the fetal and adult hepatocyte-like cell stage, relative to that before the fetal and adult hepatocyte-like cell stage.
25. The method of claim 24, wherein the increased expression level is an increased level of gene expression.
26. The method of claim 24 or 25, wherein the expression level of HHEX, BSEP, TTR, ALB, TAT, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , and/or HNF4 α increases by about 10 fold and about 1000 fold higher than that before the fetal and adult hepatocyte cell stage.
27. The method of claim 24 or 25, wherein the expression level of HHEX, BSEP, TTR, ALB, TAT, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , and/or HNF4 α increases by at least 100 fold higher than that before the fetal and adult hepatocyte cell stage.
28. The method of any preceding claim, wherein the TS cell is a human TS cell.
29. The method of any preceding claim, wherein the steroid is dexamethasone.
30. The method of any preceding claim, wherein the cytokine is oncostatin M.
31. The method of claim 30, wherein the oncostatin M is a human oncostatin M.
32. The method of claim 31, wherein the human oncostatin M is a recombinant human oncostatin M.
33. The method of any preceding claim, wherein the conditioned medium further comprises a bone morphogenetic protein (BMP).
34. The method of claim 33, wherein the BMP is present in a concentration of about 1-100 ng/ml.
35. The method of claim 33, wherein the BMP is present in a concentration of about 1-50 ng/ml.
36. The method of claim 33, wherein the BMP is present in a concentration of about 20 ng/ml.

37. The method of any one of claims 33-36, wherein the BMP is BMP1, BMP2, BMP3, BMP4, BMP5, BMP6, BMP7, BMP8a, BMP8b, BMP10, or BMP15.
38. The method of claim 37, wherein the BMP is BMP4.
39. The method of any preceding claim, wherein the conditioned medium further comprises a hepatic growth factor (HGF).
40. The method of claim 39, wherein the HGF is present in a concentration of about 0.1-50 ng/ml.
41. The method of claim 39, wherein the HGF is present in a concentration of about 0.1-25 ng/ml.
42. The method of claim 39, wherein the HGF is present in a concentration of about 5 ng/ml.
43. The method of any preceding claim, wherein the induced hepatocyte is immune privileged.
44. The method of any preceding claim, wherein the induced hepatocyte expresses TGF β 1.
45. The method of any preceding claim, wherein the induced hepatocyte expresses TGF β 1, fibronectin, and collagen IV in extracellular matrix (ECM).
46. The method of any preceding claim, wherein the induced hepatocyte expresses HLA-G.
47. The method of any preceding claim, wherein the induced hepatocyte expresses HLA-G and stem-121.
48. The method of any preceding claim, wherein the induced hepatocytes recruit CD4⁺Foxp3⁺ Treg cells.
49. The method of any preceding claim, wherein the induced hepatocytes form tissue of a 3-dimensional structure.
50. The method of any preceding claim, wherein the induced hepatocytes cluster or aggregate.
51. The method of any preceding claim, wherein the induced hepatocytes form a crescent cell mass.
52. The method of any preceding claim, wherein the induced hepatocytes comprise a peripheral compartment and a central compartment.
53. The method of claim 52, wherein the induced hepatocytes distribute irregularly along ECM beyond basement membrane in the peripheral compartment.
54. The method of claim 52 or 53, wherein the induced hepatocytes distribute from basal towards central areas in the central compartment.
55. The method of any preceding claim, wherein the induced hepatocyte expresses one or more markers selected from the group consisting of TGF β 1, HLA-G, stem 121, C-kit,

- CK19, CK18, ALB, α -AFP, betatrophin, ADH1, APOF, CPS1, GATA4, CYP1A1, CYP2B6, ASGR1, CXCR4, BSEP, MRP2, Cx32, and any combination thereof.
56. The method of claim 55, wherein the induced hepatocyte expresses one or more markers selected from the group consisting of TGF β 1, HLA-G, stem 121, C-kit, betatrophin, ADH1, APOF, CPS1, CYP2B6, ASGR1, CXCR4, Cx32, and any combination thereof.
57. The method of claim 56, wherein the induced hepatocyte expresses one or more markers selected from the group consisting of CPS1, CYP2B6, and a combination thereof.
58. An induced hepatocyte produced by the method of any preceding claim.
59. An isolated induced hepatocyte derived from a trophoblast stem cell, wherein the hepatocyte expresses one or more biomarkers selected from the group consisting of human leukocyte antigen G (HLA-G), transforming growth factor beta 1 (TGF β 1), cluster of differentiation 4 (CD4), forkhead box P3 (Foxp3), human cytoplasmic marker stem 121 (stem 121), mast/stem cell growth factor receptor C-kit (C-kit), betatrophin, apolipoprotein F (APOF), alcohol dehydrogenase-1 (ADH1), carbamoyl-phosphate synthase 1 (CPS1), GATA transcription factor 4 (GATA4), cytochrome P450 family 1 subfamily A polypeptide 1 (CYP1A1), cytochrome P450 2B6 (CYP2B6), asialoglycoprotein receptor 1 (ASGR1), C-X-C chemokine receptor type 4 (CXCR4), bile salt export pump (BSEP), multi-drug resistance protein-2 (MRP2), connexin 32 (CX32), forkhead box protein A2 (FOXA2), SRY-box 17 (SOX17), hexosaminidase A alpha polypeptide (HEXA), hematopoietically expressed homeobox (HHEX), transthyretin (TTR), albumin (ALB), tyrosine aminotransferase (TAT), cytochrome P450 7A1 (CYP7A1), glucose-6-phosphatase (G6PC), serpin peptidase inhibitor clade A (alpha-1 antiproteinase, antitrypsin) member 1 (SERPINA1), ATP-binding cassette subfamily C (ABCC2), CCAAT-enhancer-binding protein beta (C/EBP β), hepatocyte nuclear factor 1-alpha (HNF1 α), hepatocyte nuclear factor 4-alpha (HNF4 α), alpha-1-fetoprotein (AFP), cytokeratin 8 (CK8), phosphoenolpyruvate carboxykinase 2 mitochondrial (PCK2), glycogen synthase 2 (GYS2), hepatocyte nuclear factor 6 (HNF6), alcohol dehydrogenase 1C (class I) gamma polypeptide (ADH1C), cytochrome P450 3A4 (CYP3A4), prospero homeobox 1 (PROX1), tryptophan 2,3-dioxygenase (TDO2), cytokeratin 18 (CK18), and cytokeratin 19 (CK19).
60. The hepatocyte of any preceding claim, wherein the hepatocyte is a hepatic progenitor cell.

61. The hepatocyte of any preceding claim, wherein the hepatocyte is at one of four stages: primitive streak to definitive endoderm (DE) stage, hepatic specified endoderm stage, hepatoblastic stage, and the fetal and adult hepatocyte cell stage.
62. The hepatocyte of claim 61, wherein one or more biomarkers selected from the group consisting of CXCR4, FOXA2, SOX17, HHEX, TTR, ALB, TAT, CYP7A1, BSEP, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , HNF4 α , and any combination thereof express in one or more of the four stages.
63. The hepatocyte of claim 61 or 62, wherein one or more biomarkers selected from the group consisting of CXCR4, FOXA2, SOX17, HHEX, and any combination thereof, express at the primitive streak to DE stage.
64. The hepatocyte of claim 63, wherein an expression level of CXCR4, FOXA2, SOX17, and/or HHEX increases at the primitive streak to DE stage, relative to that before the primitive streak to DE stage.
65. The hepatocyte of claim 64, wherein the increased expression level is an increased level of gene expression.
66. The hepatocyte of claim 64 or 65, wherein the expression level of CXCR4, FOXA2, SOX17 and/or HHEX increases by about 1 fold and about 10,000 fold higher than that before the primitive streak to DE stage.
67. The hepatocyte of claim 64 or 65, wherein the expression level of CXCR4, FOXA2, SOX17 and/or HHEX increases by about 10 fold and about 1000 fold higher than that before the primitive streak to DE stage.
68. The hepatocyte of any one of claims 60-67, wherein one or more biomarkers selected from the group consisting of SOX17, TTR, ALB, TAT, SERPINA1, CYP7A1, and any combination thereof express in the hepatic specified endoderm stage.
69. The hepatocyte of claim 68, wherein an expression level of SOX17, TTR, ALB, TAT, SERPINA1, and/or CYP7A1 increases at the hepatic specified endoderm stage, relative to that before the hepatic specified endoderm stage.
70. The hepatocyte of claim 69, wherein the increased expression level is an increased level of gene expression.
71. The hepatocyte of claim 69 or 70, wherein the expression level of SOX17, TTR, ALB, TAT, SERPINA1, and/or CYP7A1 increases by about 1 fold and about 1000 fold higher than that before the hepatic specified endoderm stage.

72. The hepatocyte of claim 69 or 70, wherein the expression level of SOX17, TTR, ALB, TAT, SERPINA1, and/or CYP7A1 increases by about 10 fold and about 100 fold higher than that before the hepatic specified endoderm stage.
73. The hepatocyte of any one of claims 60-72, wherein one or more biomarkers selected from the group consisting of TTR, ALB, TAT, CYP7A1, SERPINA1, bile salts excretion pump (BSEP), and any combination thereof express at the hepatoblastic stage.
74. The hepatocyte of claim 73, wherein an expression level of TTR, ALB, TAT, CYP7A1, SERPINA1, and/or BSEP increases at the hepatoblastic stage, relative to that before the hepatoblastic stage.
75. The hepatocyte of claim 74, wherein the increased expression level is an increased level of gene expression.
76. The hepatocyte of claim 74 or 75, wherein the expression level of TTR, ALB, TAT, CYP7A1, SERPINA1, and/or BSEP increases by about 1 fold and about 1000 fold higher than that before the hepatoblastic stage.
77. The hepatocyte of claim 74 or 75, wherein the expression level of TTR, ALB, TAT, CYP7A1, SERPINA1, and/or BSEP increases by about 10 fold and about 100 fold higher than that before the hepatoblastic stage.
78. The hepatocyte of any one of claims 60-77, wherein one or more biomarkers selected from the group consisting of HHEX, BSEP, TTR, ALB, TAT, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , HNF4 α , and any combination thereof express at the fetal and adult hepatocyte-like cell stage.
79. The hepatocyte of claim 78, wherein an expression level of HHEX, BSEP, TTR, ALB, TAT, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , and/or HNF4 α increases at the fetal and adult hepatocyte-like cell stage, relative to that before the fetal and adult hepatocyte-like cell stage.
80. The hepatocyte of claim 79, wherein the increased expression level is an increased level of gene expression.
81. The hepatocyte of claim 79 or 80, wherein the expression level of HHEX, BSEP, TTR, ALB, TAT, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , and/or HNF4 α increases by about 10 fold and about 1000 fold higher than that before the fetal and adult hepatocyte cell stage.
82. The hepatocyte of claim 79 or 80, wherein the expression level of HHEX, BSEP, TTR, ALB, TAT, SERPINA1, G6PC, ABCC2, C/EBP β , HNF1 α , and/or HNF4 α increases by at least 100 fold higher than that before the fetal and adult hepatocyte cell stage.

83. The hepatocyte of any one of claims 59-82, wherein the trophoblast stem cell is a human trophoblast stem cell.
84. The hepatocyte of any preceding claim, wherein the hepatocyte is immune privileged.
85. The hepatocyte of any preceding claim, wherein the hepatocyte expresses TGF β 1.
86. The hepatocyte of any preceding claim, wherein the hepatocyte expresses TGF β 1, fibronectin, and collagen IV in extracellular matrix (ECM).
87. The hepatocyte of any preceding claim, wherein the hepatocyte expresses HLA-G.
88. The hepatocyte of any preceding claim, wherein the hepatocyte expresses HLA-G and stem-121.
89. The hepatocyte of any preceding claim, wherein the hepatocyte recruits CD4⁺Foxp3⁺ Treg cells.
90. The hepatocyte of any preceding claim, wherein the hepatocytes form tissue of a 3-dimensional structure.
91. The hepatocyte of any preceding claim, wherein the hepatocytes cluster or aggregate.
92. The hepatocyte of any preceding claim, wherein the hepatocytes form a crescent cell mass.
93. The hepatocyte of any preceding claim, wherein the hepatocytes comprise a peripheral compartment and a central compartment.
94. The hepatocyte of claim 93, wherein the hepatocytes distribute irregularly along ECM beyond basement membrane in the peripheral compartment.
95. The hepatocyte of claim 93 or 94, wherein the hepatocytes distribute from basal towards central areas in the central compartment.
96. The hepatocyte of any preceding claim, wherein the hepatocyte expresses one or more markers selected from the group consisting of TGF β 1, HLA-G, stem 121, C-kit, CK19, CK18, ALB, α -AFP, betatrophin, ADH1, APOF, CPS1, GATA4, CYP1A1, CYP2B6, ASGR1, CXCR4, BSEP, MRP2, Cx32, and any combination thereof.
97. The hepatocyte of claim 96, wherein the hepatocyte expresses one or more markers selected from the group consisting of TGF β 1, HLA-G, stem 121, C-kit, betatrophin, ADH1, APOF, CPS1, CYP2B6, ASGR1, CXCR4, Cx32, and any combination thereof.
98. The hepatocyte of claim 97, wherein the hepatocyte expresses one or more markers selected from the group consisting of CPS1, CYP2B6, and a combination thereof.
99. The hepatocyte of claim 96, wherein the hepatocyte expresses one or more markers selected from the group consisting of stem 121, C-kit, CK19, CK18, and any combination thereof.

100. The hepatocyte of claim 96, wherein the hepatocyte expresses one or more markers selected from the group consisting of ALB, AFP, betatrophin, ADH1, APOF, CPS1, GATA4, CYP1A1, CYP2B6, and any combination thereof.
101. The hepatocyte of claim 96, wherein the hepatocyte expresses one or more markers selected from the group consisting of ASGR1, CXCR4, BSEP, MRP2, Cx32, and any combination thereof.
102. A method of screening a therapeutic compound for use in treatment or prevention of a condition, comprising:
 - a) contacting the isolated hepatocyte of any one of claims 55-101 with the therapeutic compound; and
 - b) detecting an expression level of a biomarker in the isolated hepatocyte.
103. The method of claim 102, wherein the expression level of a biomarker in the isolated hepatocyte increases as compared to an equivalent isolated hepatocyte not contacted with the therapeutic compound.
104. The method of claim 102, wherein the expression level of a biomarker in the isolated hepatocyte decreases as compared to an equivalent isolated hepatocyte not contacted with the therapeutic compound.
105. The method of any one of claims 102-104, wherein the expression level is a gene expression level.
106. The method of any one of claims 102-105, wherein the biomarker comprises CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4, or CYP7A1.
107. The method of any one of claims 102-106, wherein the therapeutic compound is a small molecule drug, a peptide, or a protein.
108. The method of any one of claims 102-106, wherein the therapeutic compound is a synthetic chemical drug.
109. The method of any one of claims 102-108, wherein the condition is a liver failure.
110. The method of any one of claims 102-109, wherein the condition is a liver-associated disease or disorder.
111. The method of claim 110, wherein the liver-associated disease or disorder comprises alagille syndrome, alpha 1 anti-trypsin deficiency, autoimmune hepatitis, benign liver tumors, biliary atresia, cirrhosis, cystic disease of the liver, fatty liver disease including alcohol-related liver disease and non-alcohol fatty liver disease (NAFLD), galactosemia, gallstones, Gilbert's Syndrome, hemochromatosis, liver cysts, liver cancer, liver disease in pregnancy (optionally acute fatty liver of pregnancy, intrahepatic cholestasis of

- pregnancy, preeclampsia, or HELLP Syndrome (hemolysis, elevated liver tests, low platelets)), neonatal hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, porphyria, Reye's Syndrome, sarcoidosis, toxic hepatitis, type 1 glycogen storage disease, tyrosinemia, viral hepatitis, Wilson disease, or any combination thereof.
112. A composition comprising the isolated hepatocyte of any one of claims 55-101.
 113. A pharmaceutical composition comprising the isolated hepatocyte of any of claims 55-101.
 114. A method of treating a condition in a subject, comprising administering to a subject a pharmaceutical composition that comprises the isolated hepatocyte of any one of claims 55-101, in an amount effective for the hepatocytes to engraft to the subject.
 115. The method of claim 114, wherein the hepatocytes are administered in a pharmaceutically acceptable carrier.
 116. The method of claim 114, wherein the pharmaceutically acceptable carrier comprises a phosphate buffer saline.
 117. The method of any one of claims 114-116, wherein the hepatocytes are administered in a suspension containing about 10×10^6 to about 40×10^6 cells per ml.
 118. The method of any one of claims 114-117, wherein the hepatocytes are administered in a volume of about 10 ml to about 150 ml.
 119. The method of any one of claims 114-118, wherein the subject is a human.
 120. The method of any one of claims 114-119, wherein the administering comprises an injection.
 121. The method of claim 120, wherein the injection is an intravenous injection.
 122. The method of claim 120, wherein the injection is administered at a hepatic vein.
 123. The method of claim 120, wherein the injection is administered at a hepatic artery.
 124. The method of any one of claims 114-123, wherein the condition is a liver-associated disease or disorder.
 125. The method of claim 124, wherein the condition is a liver failure.
 126. The method of claim 124, wherein the liver-associated disease or disorder comprises alagille syndrome, alpha 1 anti-trypsin deficiency, autoimmune hepatitis, benign liver tumors, biliary atresia, cirrhosis, cystic disease of the liver, fatty liver disease including alcohol-related liver disease and non-alcohol fatty liver disease (NAFLD), galactosemia, gallstones, Gilbert's Syndrome, hemochromatosis, liver cysts, liver cancer, liver disease in pregnancy (optionally, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, preeclampsia, or HELLP Syndrome (hemolysis, elevated liver tests, low


- platelets)), neonatal hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, porphyria, Reye's Syndrome, sarcoidosis, toxic hepatitis, type 1 glycogen storage disease, tyrosinemia, viral hepatitis, Wilson disease, or any combination thereof.
127. Use of a composition comprising the isolated hepatocyte of any one of claims 55-101 for the production of therapeutic proteins.
 128. The use of claim 127, wherein the therapeutic proteins comprise major plasma proteins such as human serum albumin, soluble plasma fibronectin, α -fetoprotein, C-reactive protein, and several globulins; proteins involved in hemostasis and fibrinolysis such as coagulation factors involved in the coagulation cascade, α 2-macroglobulin, α 1-antitrypsin, antithrombin III, protein S, protein C, plasminogen, α 2-antiplasmin, and complement component 3; carrier proteins such as albumin, ceruloplasmin, transcortin, haptoglobin, hemopexin, IGF binding protein, major urinary proteins, retinol binding protein, sex hormone-binding globulin, transthyretin, transferrin, and Vitamin D-binding protein; hormones such as insulin-like growth factor 1, thrombopoietin, hepcidin, and betatrophin; prohormones such as angiotensinogen; or apolipoproteins.
 129. Use of a composition comprising the hepatocyte of any one of claims 55-101 for liver regeneration.
 130. The use of claim 129, wherein the liver regeneration is an *ex vivo* liver regeneration.
 131. The use of claim 130, wherein the *ex vivo* liver regeneration is a bioprinting method.
 132. The use of claim 131, wherein the bioprinting method is a 3 dimensional bioprinting method.
 133. Use of a composition comprising the hepatocyte of any one of claims 55-101 for bioprinting.
 134. The use of claim 133, wherein the bioprinting is a 3 dimensional bioprinting.
 135. Use of the hepatocyte of any one of claims 55-101 for tissue scaffold generation.
 136. The use of claim 135, wherein the tissue scaffold is a 3 dimensional tissue scaffold.
 137. Use of a composition comprising the hepatocyte of any one of claims 55-101 for gene therapy.
 138. The use of claim 137, wherein the gene therapy is an *ex vivo* gene therapy.
 139. An artificial tissue generated from the hepatocytes of any one of claims 55-101.
 140. The tissue of claim 139, wherein the tissue is three-dimensional.
 141. The tissue of claim 139 or 140, wherein the tissue is vascularized.
 142. An artificial organ generated from the hepatocytes of any one of claims 55-101.

143. The hepatocyte, tissue, or organ of any preceding claim, wherein the hepatocyte, tissue, or organ produces AFP, ALB, alpha-1-antitrypsin, glucose, or glycogen.
144. The hepatocyte, tissue, or organ of any preceding claim, wherein the hepatocyte, tissue, or organ metabolizes a lipid, cholesterol, or carbohydrate.
145. The hepatocyte, tissue, or organ of any preceding claim, wherein the hepatocyte, tissue, or organ metabolizes a pharmaceutical drug or toxic substance.
146. The hepatocyte, tissue, or organ of any preceding claim, wherein the hepatocyte, tissue, or organ uptakes ammonia or bile acid.

FIG. 1A
(first column)


FIG. 1B
(middle column)

FIG. 1C
(right column)




2 / 45

FIG. 1D




3 / 45

FIG. 1E




4 / 45

FIG. 1F



5 / 45

FIG. 2A



6 / 45

FIG. 2B








FIG. 2C



7 / 45

FIG. 2D



8 / 45

FIG. 2E




FIG. 2F







FIG. 2G





10 / 45

FIG. 2H




11 / 45

FIG. 2I



13 / 45

FIG. 2K



14 / 45

FIG. 2L




FIG. 2M






FIG. 3A




16 / 45

FIG. 3B



17 / 45

FIG. 3C



18 / 45

FIG. 4A





FIG. 4B



19 / 45

FIG. 4C

Oil-red-O





FIG. 4D



20 / 45

FIG. 5A

CYP1A2





FIG. 5B

CYP2B6



21 / 45

FIG. 5C
CYP2C8





FIG. 5D
CYP2C9



22 / 45

FIG. 5E

CYP2C19





FIG. 5F

CYP2D6



23 / 45

FIG. 5G
CYP2E1




FIG. 5H
CYP3A4





FIG. 5I
CYP7A1




25 / 45
FIG. 6

Function \ Stage	Gene	Primitive cells (< 8 hr)	Hepatic endoderm lineages (8 hr to day-1)	Hepatoblasts (day 2-4)	Fetal and adult hepatocyte-like cells (\geq day-4)
	CXCR4	+++	+		+
	FOXA2	++++	+		+
	SOX17	++++	++		+
	HHEX	++	+	+	+++
Secretion of bile salts	BSEP		+	++	++++
Thyroxin- and retinol-binding protein	TTR		++	++	+++
Proteins carrier synthesized in the liver	ALB		++	++	+++
Tyrosine catabolism	TAT		++	++	+++
Serine protease inhibitor	SERPINA1		++	++	+++
Bile acid biosynthesis	CYP7A1		++	++	++
Enzyme of glucose homeostasis	G6PC		+	+	+++
Hepatobiliary excretion	ABCC2		+	+	+++
Adipocyte differentiation	C/EBP β		+	+	+++
Regulator of several hepatic genes	HNF1 α		+	+	+++
Regulator of several hepatic genes	HNF4 α		+	+	+++
Fetal α -fetoprotein precursor	AFP		+	+	++ *
IL-6-mediated barrier protection	CK8		+	+	++
Gluconeogenesis	PCK2		+	+	++
Drug and steroid metabolism (phase I)	CYP2B6		+	+	++
Liver glucagon synthase	GYS2		+	+	++
Hepatic transcriptional activator	HNF6		+	+	+
Enzyme of urea cycle	CPS1		+	+	+
Ethanol catabolism (phase I)	ADH1C		+		+
Hepatic gap junction	CX32		+		+
Drug and steroid metabolism (phase I)	CYP3A4		+		+
Hepatocyte migration	PROX1		+		?
Tryptophan metabolism	TDO2		+	+	
Cholesterol transport regulator	APOF		+	+	
IL-6-mediated barrier protection	CK18			+	
Organization of bile duct	CK19			+	+
Pancreatic β -cell promoter, Lipid regulator	Betatrophin			+	+

Denotation: blank indicating expression <2-fold, +: >2-fold, ++: >10-fold, +++: >100-fold, and ++++: >1,000-fold * : only at fetal and post-natal stages

FIG. 7



27 / 45

FIG. 8A





FIG. 8B



28 / 45

FIG. 8C





FIG. 8D



29 / 45

FIG. 9A





FIG. 9B



30 / 45

FIG. 9C





FIG. 9D



31 / 45

FIG. 9E




FIG. 9F




FIG. 10A








FIG. 10B





34 / 45

FIG. 10BS




FIG. 10CS




FIG. 10DS




FIG. 10ES




FIG. 10FS




FIG. 11A





FIG. 11C





FIG. 11B





FIG. 11D




FIG. 11E




FIG. 11F




FIG. 11G




FIG. 11H




FIG. 11I




FIG. 11AS




FIG. 11BS




FIG. 12A




FIG. 12B




FIG. 12C




FIG. 12D




FIG. 12AS




FIG. 12BS




FIG. 13A





FIG. 13B



41 / 45

FIG. 13AS

Fixed modifications: Carboxymethyl (C)
 Variable modifications: Oxidation (M)
 Cleavage by Trypsin: cuts C-term side of KR unless next residue is P
 Sequence Coverage: 46%

Matched peptides shown in **BOLD**

1 MALFVRLAL ALALALGPAA TLAGPAKSPY QLVLQHSRLR GRQHGPNVCA
 51 VQKVIGTNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPGEKGCFAA
 101 LPLSNLYETL GVVGSTTTQL YDRTEKLRP EMEGPGSFTI FAPSNEAWAS
 151 LPAEVLDSL V SNVNIELLNA LRYHMGVRRV LTDELKHGMT LTSMYQNSNI
 201 QIHHPNGIV TVNCARLLKA DHHATNGVVH LIDKVISTIT NNIQQIIEIE
 251 DTFETLRAAV AASGLNTMLE GNGQYTLLAP TNEAFEKIPS ETLNRILGDP
 301 EALRDLLNNH ILKSAMCAEA IVAGLSVETL EGTTLVVGCS GDMLTINGKA
 351 IISNKDILAT NGVINHYIDEL LIPDSAKTLF ELAAESDVST AIDLFRQAGL
 401 GNHLSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDQLASKYLY
 451 HGQTLETGG KKLRFVYRN SLCIENSCIA AHDKRGRYGT LFTMDRVLTF
 501 PMGTVMVVK GDNRFSLVA AIQSAGLTET LNREGVYTVF APTNEAFRAL
 551 PPRERSRLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGDKLEVS
 601 LKNNVSVNK EPVAEPDIMA TNGVVHVITN VLQPPANRPQ ERGDELADSA
 651 LEIFKQASAF SRASQSVRL APVYQKLLER MKH

42 / 45

FIG. 14A




FIG. 14B




FIG. 14C




FIG. 14D




FIG. 14E




FIG. 15A




FIG. 15B




FIG. 15C




FIG. 15D




FIG. 15E





FIG. 15F



A. CLASSIFICATION OF SUBJECT MATTER

C12N 5/0735 (2010.01) A61K 35/545 (2015.01) A61K 35/407 (2015.01)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Databases: EPODOC, WPIAP, TXTE, MEDLINE, CAPLUS, FSTA, CABA, BIOSIS, EMBASE, GOOGLE SCHOLAR, PUBMED. Searched for keywords: TROPHOBLAST, SYNCYTIOTROPHOBLAST, CYTOTROPHOBLAST, STEM CELL, PROGENITOR, PRECURSOR, HEPATOCYTE, HEPATOBLAST, LIVER CELL, CYP2B6, ALB, CYP7A1, GP6C, SERPINA1, HNF1alpha, AFP, CK8, PCK2 and GYS2 and like terms.

Databases: THE LENS, AUSPAT, PUBMED, GOOGLE SCHOLAR. Searched for applicant and inventor names.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Documents are listed in the continuation of Box C		

 Further documents are listed in the continuation of Box C See patent family annex

* Special categories of cited documents:		
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search
15 March 2016Date of mailing of the international search report
15 March 2016

Name and mailing address of the ISA/AU

AUSTRALIAN PATENT OFFICE
PO BOX 200, WODEN ACT 2606, AUSTRALIA
Email address: pct@ipaaustralia.gov.au

Authorised officer

Kelly Hitchens
AUSTRALIAN PATENT OFFICE
(ISO 9001 Quality Certified Service)
Telephone No. +61262223604

INTERNATIONAL SEARCH REPORT		International application No.
C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		PCT/US2015/062674
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2012/104731 A2 (KATHOLIEKE UNIVERSITEIT LEUVEN) 09 August 2012 Abstract, claims 10 and 12, 010, 019, 070-071, 077, 090	
X	KUCKENBERG, P., ET AL., 'Lineage conversion of murine extraembryonic trophoblast stem cells to pluripotent stem cells', Molecular and Cellular Biology, 2011, vol. 31, no. 8, pages 1748-56. Abstract, Figures 3-4, Page 1749 column 2 paragraph 6	58-146
X	WO 2014/085493 A1 (LEE, ET AL.) 05 June 2014 Abstract, Claims 1-8, 72, 85, 87-89 and 116, Figures 1, 3K and 8	58-146
X	ROELANDT, P., ET AL., 'Human embryonic and rat adult stem cells with primitive endoderm-like phenotype can be fated to definitive endoderm, and finally hepatocyte-like cells', PloS One, 2010, vol. 5, no. 8, article e12101. Abstract, Figures 2-5 and S1, Table S1, Page 1 column 1	58-146
X	SCHWARTZ, R., ET AL., 'Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells', The Journal of Clinical Investigation, 2002, vol. 109, no. 10, pages 1291-302 Abstract, Table 1, Figures 1-6 and 8, Page 1294 column 1 paragraph 2 – column 2 paragraph 2, Page 1301 column 2 paragraph 1	58-146
X	US 2013/0259836 A1 (LEE, ET AL.) 03 October 2013 Abstract, Figures 2-5, 0056-0068, Embodiment 2	58-146
X	WO 2008/002662 A2 (THE UNIVERISTY OF KANSAS) 03 January 2008 Example 1, Page 29 lines 27 – page 33 line 6, Page 43 line 25 – page 44 line 10, claim 26	58-146
X	CHOI, S., ET AL., 'Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells', Hepatology, 2013, vol. 57, no. 6, pages 2458-68. Abstract, Figures 1-2 and 4, Page 2460 column 1 paragraphs 2-4	58-146
X	LIU, H., ET AL., 'In vivo liver regeneration potential of human induced pluripotent stem cells from diverse origins', Science Translational Medicine, 2011, vol. 3, no. 82, article 82ra39. Abstract, Figures 1-3 and S4, Table 3	58-146
X	WO 2013/189521 A1 (WACLAWCZYK, ET AL.) 27 December 2013 Abstract, Figures 1, 3-10 and 12, Claims 12-13, 15-19, 0083, 0013-0018	58-146
X	TEE, J., ET AL., 'Immunogenicity and immunomodulatory properties of hepatocyte-like cells derived from human amniotic epithelial cells', Current Stem Cell Research & Therapy, 2013, vol. 8, no. 1, pages 91-9. Abstract, Figures 1 and 3	58-146

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2015/062674

This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
WO 2012/104731 A2	09 August 2012	WO 2012104731 A2	09 Aug 2012
		EP 2670842 A2	11 Dec 2013
		US 2014057313 A1	27 Feb 2014
WO 2014/085493 A1	05 June 2014	WO 2014085493 A1	05 Jun 2014
		AU 2013352307 A1	04 Jun 2015
		CA 2891542 A1	05 Jun 2014
		CN 105102611 A	25 Nov 2015
		EP 2925860 A1	07 Oct 2015
		GB 2523696 A	02 Sep 2015
		US 2014170118 A1	19 Jun 2014
US 2013/0259836 A1	03 October 2013	US 2013259836 A1	03 Oct 2013
		TW 201339303 A	01 Oct 2013
		TW I449789 B	21 Aug 2014
WO 2008/002662 A2	03 January 2008	WO 2008002662 A2	03 Jan 2008
		AU 2007265359 A1	03 Jan 2008
		BR PI0713965 A2	27 Nov 2012
		CA 2690985 A1	03 Jan 2008
		CN 101627112 A	13 Jan 2010
		CR 10584 A	12 May 2009
		EP 2079829 A2	22 Jul 2009
		JP 2009542215 A	03 Dec 2009
		KR 20090038439 A	20 Apr 2009
		MX 2009000023 A	06 Apr 2009
		RU 2009102643 A	10 Aug 2010
		TW 200810769 A	01 Mar 2008
		US 2008019949 A1	24 Jan 2008

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

Form PCT/ISA/210 (Family Annex)(July 2009)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2015/062674

This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
WO 2013/189521 A1	27 December 2013	WO 2013189521 A1	27 Dec 2013
		WO 2013190013 A1	27 Dec 2013

End of Annex

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

Form PCT/ISA/210 (Family Annex)(July 2009)